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ABSTRACT 
Combining vaccination against leukaemia-derived antigens and treatment with 
tyrosine kinase inhibitors (TKI) in chronic phase CML is potentially a promising 
strategy to eradicate a reservoir of TKI resistant leukaemic cells. Previous studies 
have documented conflicting effects of TKIs on the immune response. I aimed to 
determine the in vivo immunomodulatory effects of TKIs on T and B-cell immune 
responses to antigens in patients with CML on TKIs. 
I first demonstrated that that the B-cell response to H1N1 influenza vaccine was 
significantly better in patients with CML compared to patients with other 
haematological malignancies. 
I then performed a more comprehensive analysis of T and B cell responses to a 
viral (seasonal influenza) and bacterial (pneumococcus) vaccine. I did not find a 
significant quantitative or qualitative difference in T cell responses to influenza 
vaccine in patients with CML on TKI compared to controls. However, I 
demonstrated that CML patients on TKIs have impaired IgM responses to 
pneumococcal vaccine, associated with lower frequencies of IgM memory B cells. 
Moreover, treatment with imatinib was associated with a significant reduction in IgM 
memory B cells. In vitro co-incubation of B-cells with plasma from CML patients on 
TKI or directly with imatinib, dasatinib or nilotinib, induced a dose-dependent 
inhibition of Bruton's tyrosine kinase, a tyrosine kinase essential for B cell signalling 
and survival. These data suggest that the loss of memory B-cell subsets and 
impaired humoral immune responses may be driven by the off-target kinase 
inhibitory activity of TKIs. 
I further explored the implications of Philadelphia positive (Ph+) lymphopoiesis on B 
cell function. I found that nearly 50% of CML patients at diagnosis have evidence of 
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Ph+ B lymphopoiesis. Interestingly, the presence of Ph+ B cells predicted for worse 
prognosis, suggesting the involvement for a more committed progenitor with 
biphenotypic self-renewal capacity. 
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CHAPTER 1 INTRODUCTION 
 
I.1 CHRONIC MYELOID LEUKAEMIA 
Chronic Myeloid Leukaemia (CML) is a clonal myeloproliferative neoplasms 
originating from a single pluripotent hematopoietic stem cells in which cells of the 
myeloid lineage undergo inappropriate clonal expansion caused by a molecular 
lesion. The characteristic genetic abnormality of CML, the Philadelphia 
chromosome, results from a reciprocal translocation of genetic material on the long 
arms of one chromosome 9 and one chromosome 22 (Figure I.1). The molecular 
consequence of this translocation is the generation of a gene encoding the fusion 
protein BCR-ABL1, a constitutively activated tyrosine kinase (Figure I.2). 
 
Figure I.1: The t(9;22) translocation and resulting mRNA and oncoprotein (Goldman & Melo, 
2003) 
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Figure I.2: Physiologic regulation by the normal ABL protein and deregulation by BCR-ABL 
of key cellular processes(Goldman & Melo, 2003) 
 
This leads to eventual replacement of all myeloid tissue by normally differentiating 
leukaemia cells. The disease typically progresses through three distinct phases - 
chronic phase, accelerated phase, and blast crisis - during which the leukaemic 
clone progressively loses its ability to differentiate(Faderl et al, 1999). Definitions of 
CML chronic phase (CP), accelerated phase, and blast crisis are summarised in 
Table I.1. 
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TABLE I.1: Definitions of chronic, accelerated and blastic phase 
Kantarjian criteria (Kantarjian et al, 1988) 
Chronic phase 
•none of the criteria for accelerated phase or blastic phase 
Accelerated phase (one of the following) 
15-29% blasts in peripheral blood or bone marrow 
>30% blasts plus promyelocytes in peripheral blood or bone marrow 
>20% basophils in peripheral blood or bone marrow 
Platelets < 100 × 109/L unrelated to therapy 
Blastic phase (one of the following) 
Blasts in peripheral blood or bone marrow ≥30% 
Presence of extramedullary blastic disease 
WHO criteria 
Accelerated phase 
Blasts 10-19% in bone marrow or peripheral blood 
Peripheral blood basophils ≥ 20% 
Persistent thrombocytopenia (<100 × 109/L) unrelated to therapy, or 
persistent thrombocytosis (>1,000 × 109/L) unresponsive to therapy 
Increasing spleen size and increasing WBC count unresponsive to therapy 
Cytogenetic evidence of clonal evolution 
Severe bone marrow fibrosis 
Megakaryocytic proliferation? 
Blastic phase 
Blasts in peripheral blood or bone marrow ≥20% 
Presence of extramedullary blastic disease 
Large foci or clusters of blasts in the bone marrow biopsy 
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The worldwide annual incidence of CML is 1 to 1.5 cases per 100,000 population 
and accounts for 15% to 20% of leukaemia cases in adults. Although the disease 
may occur at any age, the median age at presentation is between 50 and 60 years. 
A higher incidence of CML is noted among persons with heavy radiation exposure, 
and those who have received therapeutic irradiation for malignancy (e.g. 
lymphoma, breast cancer) have a small but significantly increased risk. There is no 
recognized familial influence, and no causal association between CML and 
industrial chemicals or alkylating agents has been demonstrated. 
 
The t(9;22)(q34;q11) translocation juxtaposes the 3’ segment of the c-ABL 
oncogene (normally encoding the Abelson Tyrosine kinase) from the long arm of 
chromosome 9 to the 5’ part of the breakpoint cluster region (BCR) gene on the 
long arm of chromosome 22, resulting in one shortened chromosome 22 (22q–) 
(the Ph chromosome, (Rowley, 1973)) and one elongated chromosome 9 (9q+) 
(Figure I.1). 
 
 At diagnosis, the Philadelphia chromosome (Ph) is present in approximately 95% 
of CML cases. The remaining cases have either variant translocations involving a 
third and, sometimes, fourth chromosome or cryptic translocations. In these cases, 
routine cytogenetic analysis is unable to detect the Ph chromosome, and the 
diagnosis relies on demonstration of the fusion transcript by either fluorescence in 
situ hybridization (FISH) or real time quantitative polymerase chain reaction (RQ-
PCR). The molecular consequence of t(9;22)(q34;q11) translocation is the 
generation of a gene that is expressed as a BCR-ABL1 RNA transcript translated 
into a 210-kd protein known as p210BCR-ABL. The p210BCR-ABL oncoprotein 
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functions as a constitutively active tyrosine kinase that can phosphorylate a number 
of cytoplasmic substrates with other activities leading to alterations in cell 
proliferation, differentiation, adhesion, and survival (Goldman & Melo, 2003;O'Hare 
et al, 2012). 
The leukaemic clone in CML has a tendency to acquire additional oncogenic 
mutations over time, usually associated with progression to accelerated phases of 
disease or resistance to tyrosine kinase inhibitors (TKIs). At the chromosomal level, 
changes include amplification of t(9;22), trisomy 8, trisomy 19, and abnormalities of 
chromosome 17. At the molecular level, mutations in the kinase domain of BCR-
ABL account for about 50% of imatinib resistance in patients with CML in chronic 
phase and 80% of advanced phases cases (O'Hare et al, 2012). 
In vitro studies and studies in animal models have established that BCR-ABL gene 
alone is sufficient to cause CML, and that the enhanced tyrosine kinase activity of 
the p210BCR-ABL oncoprotein is required for its oncogenic activity (Heisterkamp et 
al, 1990;Daley et al, 1990;Kelliher et al, 1990;Lugo et al, 1990;Goldman & Melo, 
2003). 
 
I.2 TREATMENT OPTIONS IN CML 
 
I.2.1  Tyrosine kinase inhibitors 
Imatinib mesylate (imatinib, Gleevec, Novartis) is a an Abl kinase inhibitor (Druker 
et al, 1996), first used in 1998 to treat patients who were judged to have disease 
refractory to treatment with IFN-α or who could not tolerate IFN-α (Savage & 
Antman, 2002). Imatinib has produced impressive results in treatment of patients 
with CML in chronic phase, and the median survival for previously untreated 
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patients is now likely to be in excess of 10 years. Initial treatment with tyrosine 
kinase inhibitor (TKI) has become the gold standard for patients who present in 
chronic phase, and a complete cytogenetic response (CCyR, Table I.2) is 
considered as the minimum acceptable response, since it translates into improved 
transformation-free survival (TFS). Around 70% of patients achieve CCyR after 
frontline treatment with imatinib (de Lavallade H. et al, 2008;Druker et al, 2006), 
and the 8-year probability of being in continuing CCyR while still on imatinib or on 
second line treatment with second generation TKI is at 77% (Marin et al, 2012). 
 
TABLE I.2: Conventional definitions of cytogenetic responses to treatment for 
chronic myeloid leukemia 
Ph-positive marrow metaphases (%)  Designation 
0 Complete cytogenetic response (CCR) 
1-35 Partial cytogenetic response (PCyR) 
36-95 Minor cytogenetic response 
>95 None 
Percentages cited above are based on a minimum of 20 analyzable metaphases. 
Complete and partial responses are often grouped together as 'Major cytogenetic 
responses' (MCyR). 
 
 
Imatinib has also proved active in patients with accelerated phase (AP) and blastic 
phase (BP) disease, but in most of these cases the benefits have been transient. 
Although 70% of imatinib-treated patients with CP CML achieve a CCyR, the 
majority of patients have persisting molecular disease as assessed by q-PCR for 
BCR-ABL transcripts and 60% of them will relapse following imatinib withdrawal 
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(Mahon et al, 2010). Functional leukaemic CD34+ progenitor cells have been 
identified in such patients in CCyR, suggesting the presence of a reservoir of 
leukaemic primary quiescent CML stem cells that are insensitive to imatinib and 
persist and accumulate following imatinib exposure (Graham et al, 2002) 
suggesting that imatinib is more cytostatic than pro-apoptotic in this subpopulation. 
In vivo studies in CML patients have demonstrated persistence of BCR-ABL 
positive progenitors despite continuing responses to imatinib therapy (Bhatia et al, 
2003). This suggests that imatinib does not eliminate malignant primitive 
progenitors in CML patients and these cells provide a reservoir for disease relapse.  
 
I.2.2  Second generation TKI, dasatinib,nilotinib and bosutinib 
These drugs have been shown to induce responses in patients who have failed to 
achieve a cytogenetic response on imatinib (primary resistance) or have lost the 
response or progressed to advanced phase (secondary resistance) on imatinib 
therapy. Approximately 50% of patients who fail to obtain a cytogenetic response 
on imatinib achieve a CCyR on second line therapy, although the durability of these 
responses has not yet been established. Second generation TKI dasatinib (Sprycel; 
Bristol-Myers Squibb) and nilotinib (Tasigna; Novartis) have also been used as first 
line treatment in CML. In a randomised trial higher rates of CCyR have been 
reported in patients treated with first line nilotinib compared to imatinib (80% vs 
65% at 12 months) with significantly lower rate of transformation to AP or BP with 
nilotinib (2.1%-3.2% vs 6.7%, respectively) (Kantarjian et al, 2011). However the 
benefit of each drug has been considered in isolation, not accounting for the effect 
of subsequent therapy. To date the only proven cure for CML remains allogeneic 
haematopoietic stem cell transplantation. 
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I.3 THE ROLE OF IMMUNOTHERAPY IN CML 
 
1.3.1  Immunomodulatory drugs 
Interferon-alfa (IFN-α) (Silver et al, 1999) is an immunomodulatory agent, shown to 
prolong overall survival. The drug may cause a wide range of side effects, 
especially in older persons, but it induces complete or nearly complete cytogenetic 
responses in 10-30% of patients and probably prolongs survival to a greater extent 
than hydroxyurea (1997). IFNα enhances the functional activity of T cells, as well 
as macrophages and NK cells, and induces dendritic cell (DC) differentiation of 
CML mononuclear cells. DC serve as antigen-presenting cells for CML-specific 
peptides (Kanodia et al, 2010). On the other hand treatment with IFNα increases 
the expression of tumor-associated antigens and major histocompatibility complex 
antigens. It induces Proteinase 3 expression by mononuclear cells, and increased 
Proteinase 3 expression levels in CML cells has been shown to be associated with 
a favourable prognosis for patients. Nearly all CML patients who respond to IFNα 
therapy have cytotoxic T-cells (CTLs) specific for PR1 (an HLA2.1-restricted 
peptide derived from Proteinase 3). Kanodia and colleagues have reported that the 
numbers of PR1-CTLs are increased in CML patients who remain in CCyR after 
IFNα therapy is discontinued (Kanodia et al, 2010). In line with those findings 
Burchert and colleagues have shown that treatment IFNα enables discontinuation 
of imatinib in CML patients, in relation with the induction of antileukaemic PR1-
CTLs (Burchert et al, 2010).  
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1.3.2  Stem cell transplantation (SCT) 
Allogeneic haematopoietic stem cell transplantation (allo-SCT) and donor 
lymphocyte infusions (DLI) offer the possibility of cure for CML and amply 
demonstrate the potential of immunotherapy in this disease and in other 
malignancies. However, allo-SCT is associated with an appreciable risk of 
morbidity and mortality and is only available to a minority of patients. 
 
1.3.3  Immunotherapy 
The immunological graft-versus-leukaemia (GVL) effect seen after allo-SCT 
suggests that stimulating the patient’s own T cell responses to CML with a vaccine 
might retard disease progression and even achieve complete molecular response. 
In recent years, several classes of human leukaemia-associated antigens (LAA) 
that may be targets of the GVL effect have been identified and investigated for 
exploitation of immunotherapy (Bocchia et al, 2005;Rojas et al, 2007). 
 
I.4 TYROSINE KYNASE INHIBITORS AND THEIR IMMUNOMODULATORY 
EFFECTS ON T-CELL 
 
I.4.1  Tyrosine Kinases and T-cell receptor (TCR) activation 
A number of tyrosine kinases (TK) play a critical role in TCR primary transduction 
pathways, such as Abl, Src family kinases (SFK) Lck and Fyn, Zap-70 and Tec. 
The proximal signalling events of T cell activation through the TCR complex 
includes the following steps (depicted in Figure I.3): after engagement of the TCR 
with peptide–MHC and recruitment of the CD4/CD8 co-receptor, the Src tyrosine 
kinases Lck and Fyn are activated and recruited to the TCR. Of note Lck and Fyn 
32 
 
have been shown to play a role at every stage of T-cell development (Palacios & 
Weiss, 2004). Activated Lck and Fyn then phosphorylate the tyrosine residues 
within the immunoreceptor tyrosine-based activation motifs (ITAM) of the TCR 
complex which leads to ZAP-70 recruitment followed by LAT and SLP-76 
phosphorylation. SLP-76 and LAT induce activation of secondary signal 
transduction pathways. Co-stimulatory signals mediated by ligation of CD28, ICOS 
and adhesion molecules are also necessary for complete T-cell activation, and 
signalling through CD28 has been shown to involve tyrosine phosphorylation by 
Lck and/or Fyn (Acuto & Michel, 2003). 
The tyrosine kinase Abl also plays a significant role in the TCR signalling pathway 
as shown by Zipfel and colleagues (Zipfel et al, 2004): Following TCR engagement, 
c-Abl is activated through phosphorylation by Lck and subsequently activates ZAP-
70. 
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Figure I.3: T-cell activation via the CD3-TCR complex, (Seggewiss et al, 2008) 
TKI (boxed) may interfere with this signalling cascade by blocking specific tyrosine kinases as 
shown. Primary TK inhibitor actions are shown in bold, with secondary inhibition shown in italics. 
 
 
 
  
- PI3/Akt/MAPkinase
- ERK
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I.4.2  Immunomodulatory effect of tyrosine kinase inhibitors on T-cells 
 
Over the last few years, a number of studies have documented seemingly 
contradictory effects of the TKI imatinib on the immune response, ranging from 
impaired antigen-specific T-cell responses (Mumprecht et al, 2006;Seggewiss et al, 
2005;Cwynarski et al, 2004) to enhanced stimulation of tolerant CD4+ T-cells 
(Wang et al, 2005) or enhanced active immunotherapy against BCR-ABL-
expressing tumours (Larmonier et al, 2008). However, to date few studies have 
been performed to assess the potential immunomodulatory effects of the second-
generation tyrosine inhibitors dasatinib and little data are available for nilotinib. It is 
possible that these three increasingly used agents differ in their effects on the 
immune response and as such may have differing implications for patient 
management. Information on any positive or negative effects of these drugs on the 
immune system will have significant implications for long-term immune surveillance 
against infectious agents and leukaemia. Such data will be clinically very useful as 
it may help in the choice of drug for therapy, especially for patients susceptible to 
haematological complications such as lymphopaenia or neutropaenia and as such 
at increased risk of infectious complications.  
 
Furthermore a better understanding of potential immunomodulatory effects of TKIs 
is of particular importance in the design of immunotherapeutic strategies, especially 
in view of fact that dasatinib was first developed as a potential immunosuppressive 
drug. Indeed in vitro data support a global immunosuppressive role for dasatinib, 
including suppression of NK cell cytotoxicity (Blake et al, 2008b), inhibition of T-cell 
activation and proliferation (Schade et al, 2008), suppression of CD4+CD25+ 
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regulatory T cells (Fei et al, 2009), and antigen-specific proliferation of murine and 
human T cells(Fraser et al, 2009a;Weichsel et al, 2008). 
Seminal work by Rix and colleagues using chemical proteomic profiles of imatinib, 
dasatinib and nilotinib identified a number of kinases including major regulators of 
T-cell and B-cell signalling pathways that are substrates of off-target inhibition by 
TKI, as shown in Figure I.4 (Rix et al, 2007). 
 
Figure I.4: A list of target kinases inhibited by dasatinib, nilotinib and imatinib (Rix et al, 
2007) 
Unique peptides no: number of all unique peptides observed for a particular protein. The listed 
sequence coverage (SC) is based on these unique peptides. IPI-ID indicates IPI protein database 
entries to which identified peptides were assigned; SC, sequence coverage; and —, no entry. 
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Indeed a number of tyrosine kinases which play a critical role in TCR primary 
transduction pathways are potentially targeted by the TKIs imatinib, nilotinib 
dasatinib and bosutinib (Bosulif, Pfizer). Figure I.3 shows where TKI interfere with 
the TCR signalling cascade by blocking specific tyrosine kinases. 
 
Imatinib 
Cwynarski and colleagues were the first to demonstrate that imatinib inhibits PHA-
induced proliferation of normal peripheral blood mononuclear cells (PBMCs) and 
CD3/CD28-induced T-cell stimulation at pharmacological concentrations (5 to 7.5 
μM) of imatinib (Cwynarski et al, 2004). Dose-dependent inhibition of the 
proliferative response of purified CD8+ and CD4+ T cells to anti-CD3/CD28 was 
also observed and associated with reduction in IFN-gamma production, while 
inhibition of T-cell proliferation was reversible after removal of the drug from the 
cultures. Seggewiss and colleagues further investigated the effect of imatinib on 
TCR-mediated activation. In line with the results from Cwynarski and colleagues 
they showed that proliferation of activated T-cells in response to stimulation with 
anti-CD3 antibody was almost completely inhibited by imatinib. Furthermore 
antigen-triggered expansion of CD8+ T cells in response to cytomegalovirus (CMV) 
and Epstein-Barr virus (EBV) peptides was significantly reduced. Finally imatinib 
reduced tyrosine phosphorylation of ZAP70 and LAT in response to activation 
through the TCR; while in an in vitro tyrosine kinase assay they showed Lck 
inhibition by imatinib. This finding was later confirmed by the work from Lee and 
colleagues (Lee et al, 2010) who demonstrated that imatinib inhibits Lck 
phosphorylation during human T-cell activation, although at relatively higher 
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concentrations of imatinib (25 μM). 
Further to the work by Seggewiss and colleagues, Mumprecht and colleagues 
showed in a murine model that imatinib selectively impairs expansion of 
lymphocytic choriomeningitis virus (LCMV)-memory cytotoxic T-cell (CTL) without 
affecting the control of primary infections (Mumprecht et al, 2006). Furthermore, 
imatinib delayed the onset of CTL-induced diabetes in mice. These observations 
suggest a reduced secondary expansion of antigen-specific memory CTL in the 
presence of imatinib, resulting in impaired protection against reinfection. 
 
In another murine model Wang and colleagues described imatinib-induced 
enhancement of APC function that overcame tumor-induced T-cell tolerance: in 
vitro treatment of APCs with imatinib enhanced the activation of naive antigen-
specific T-cells and restored the responsiveness of tolerant T-cells from tumour-
bearing hosts (Wang et al, 2005). Furthermore, in vivo treatment with imatinib not 
only prevented the induction of tolerance in tumour-specific CD4+ T-cells, 
preserving their responsiveness to a subsequent immunization, but also resulted in 
enhanced vaccine efficacy. Further to this study Larmonier and colleagues 
investigated the influence of imatinib on CD4+CD25+FoxP3+ regulatory T-cells 
(Treg) (Larmonier et al, 2008). They found that imatinib impaired Treg 
immunosuppressive function and FoxP3 expression associated with a reduction of 
STAT3 and STAT5 activation, two transcription factors which are required for 
FoxP3 up-regulation in Tregs. Importantly CD28-induced Lck activation is critical 
for STAT3 induction in FoxP3+ Tregs. As Lck has been shown to be a possible 
target of imatinib (Seggewiss et al, 2005) the authors showed that imatinib inhibited 
phosphorylation of ZAP70 and LAT, both located immediately downstream Lck in 
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the signal transduction cascade. These observations provide a possible molecular 
basis for the attenuation of Treg suppressive activity by imatinib, although in 
contrast to the well-characterized intracellular events leading to conventional T-cell 
activation, the signalling pathways regulating Treg activity remain more elusive. 
Furthermore, in a murine model, imatinib treatment for 7 days decreased Treg 
frequency and impaired their immunosuppressive function in vivo. Imatinib 
significantly enhanced antitumor immune responses to dendritic cell-based 
immunization against lymphoma, providing the proof of principle that imatinib can 
be successfully incorporated in immunotherapy protocols. In line with this murine 
model, Bocchia and colleagues reported that CML patients undergoing prolonged 
imatinib therapy mount similar CD4+ T-cell responses against a poorly 
immunogenic tumour peptide Ag, BCR-ABL, as observed in patients treated with 
IFN-α (Bocchia et al, 2006). 
 
However imatinib has also been shown to have both positive and negative effects 
on the function and differentiation of antigen-presenting cells in several in vitro 
studies and in animal models (Appel et al, 2004;Taieb et al, 2004;Mohty et al, 
2004). 
 
Dasatinib 
Dasatinib was first developed as a potential immunosuppressive drug. Indeed its 
tyrosine kinase activity includes a broader range of protein kinases than imatinib 
such as the SFKs Lck and Fyn, both of which play an important role in TCR 
primary signal transduction pathways as shown in Figure I.3 (Section I.4.1). 
Schade and colleagues were the first to explore the inhibitory effect of dasatinib on 
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T-cells through its impact on TCR downstream pathway (Schade et al, 2008). They 
showed that dasatinib inhibits the TCR-mediated signal transduction in vitro, while 
signal transduction and proliferative responses via IL-2 remained essentially 
unperturbed: dasatinib was shown to inhibit TCR secondary signal pathway pERK 
but not the IL2 downstream pathway JAK-STAT (see Figure I.5), thus suggesting 
that dasatinib displays specificity for TCR signalling. 
 
Figure I.5: Downstream pathways of TCR and IL2 receptor (Verdeil et al, 2006) 
 
 
Moreover they showed that dasatinib inhibitis cellular proliferation, proinflammatory 
cytokine production, and in vivo T-cell responses. Interestingly dasatinib-mediated 
inhibition did not induce apoptosis as the effect was reversible. The potent 
inhibitory effect of low concentrations of dasatinib on Lck was further studied by 
Lee and colleagues who showed this effect both in cell line and in human T cells 
(Lee et al, 2010). In a similar work, Blake and colleagues confirmed the finding that 
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dasatinib blocks the function of normal human T-cells in vitro, including 
proliferation, activation and cytokine production through Lck inhibition. Their 
findings were in keeping with work from other groups showing suppression of 
antigen-specific T-cell proliferation both in murine and human studies (Fraser et al, 
2009a;Weichsel et al, 2008). Weichsel and colleagues compared the effect of 
dasatinib and the promiscuous TK inhibitor staurosporine on T-cells and showed 
that naive T-cells were more sensitive to dasatinib than memory T-cells; in addition 
virus specific CD8+ T-cells responses were suppressed by dasatinib in a dose-
dependent manner (Weichsel et al, 2008). 
The effect of dasatinib on Tregs was studied by Fei and colleagues who suggested 
that dasatinib inhibits proliferation of Tregs in a dose-dependent manner, 
associated with reduced IL-10 production and inhibition of Treg suppressive 
capacity. Further in vitro data also supported an immunosuppressive role for 
dasatinib on NK cells showing suppression of NK cell cytotoxicity (Blake et al, 
2008b). 
 
Nilotinib 
Similarly, nilotinib has also been shown to inhibit the proliferation and function of 
CD8+ T-cell in vitro (Chen et al, 2008) while no effect was seen on Tregs at clinical 
relevant doses (Fei et al, 2009). 
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I.5 TYROSINE KINASE INHIBITORS AND THEIR IMMUNOMODULATORY 
EFFECTS ON B-CELLS 
 
I.5.1  Tyrosine kinases and B-cell receptor (BCR) signalling pathway 
A number of TKIs could also potentially inhibit the B-cell receptor (BCR) 
downstream signalling pathways through the inhibition of tyrosine kinases such as 
Lyn, Syk, or Btk all involved in the BCR signalling cascade as shown in Figure I.6).  
 
Figure I.6: BCR signalling upon antigen binding in B lymphocytes (Hendriks, 2011) 
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Indeed off-target inhibition of Lyn, Syk and Btk by dasatinib has been shown by the 
work of Rix and colleagues (summarised in Figure I.4, (Rix et al, 2007)). Hantschel 
and colleagues further confirmed Btk as a major target of dasatinib-induced kinase 
inhibtion (Hantschel et al, 2007). 
Using proteomics analysis, Breitkopf and colleagues have reported Btk and Syk as 
potential imatinib targets, suggesting that imatinib could also potentially inhibit the 
BCR downstream pathways (Atwell et al, 2004;Breitkopf et al, 2010). 
 
Btk is a crucial regulator for B-cell development and differentiation, and its 
expression is believed to be a prerequisite for B-cell proliferation and survival. Btk-
deficient B lymphocytes fail to reach the mature state and are likely to undergo 
premature death. In humans, mutations in the Btk gene cause X-linked 
agammaglobulinaemia which is an immunodeficiency disease characterized by an 
almost complete absence of circulating B cells and an inability to generate 
immunoglobulins of all classes. Therefore patients with mutations in the Btk gene 
fail to mount humoral immune responses. A schematic model of Btk regulation is 
shown in Figure I.7: Upon BCR stimulation, phosphatidylinositol-3-kinase (PI3K) is 
activated which results in the production of the phosphoinositide, 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 generation leads to 
recruitment of several intracellular signalling proteins including Btk. Once present 
at the cytoplasmic surface of the plasma membrane, Btk is phosphorylated on its 
tyrosine 551 (Y551) in the activation loop, followed by the subsequent 
autophosphorylation of Y223 in the SH3 domain which leads to its fully activated 
conformation. Functionally competent Btk executes downstream signalling duties, 
such as phosphorylation of phospholipaseCγ2 (PLCγ2). 
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Figure I.7: Model for activation of BCR signalling (Mohamed et al, 2009) 
 
 
I.5.2  Putative effect of TKIs on B cells (murine models) 
To date only two studies have examined the impact of TKIs on B cells, although 
hypogammaglobulinaemia has been reported in CML patients treated with imatinib 
(Steegmann et al, 2003). Indeed Steegman and colleagues reported that IgG and 
IgM hypogammaglobulinaemia developed in 28%, and 22% of CML patients 
treated with imatinib respectively. 
 
In a murine model of autoimmune arthritis, Paniagua and colleagues reported that 
imatinib prevents and treats murine collagen-induced arthritis, partly through B-cell 
inhibition (Paniagua et al, 2006). They showed that mouse B cell proliferation 
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induced by anti-IgM was inhibited by imatinib as well as IgM production by LPS-
stimulated B cells. 
 
More recently Kawamata and colleagues reported in a murine study that imatinib 
may directly impair class switch recombination following B cell activation through 
downregulation of activation-induced cytidine deaminase (AID) known to be 
essential for class switch recombination (CSR) and somatic hypermutation 
(Kawamata et al, 2012). They first showed that following stimulation with IL-4 and 
LPS for 72 hours, imatinib decreased the proportion of IgG1-positive B-cells dose-
dependently after, associated with AID suppression. In an in vivo murine model 
they found that AID expression, which is induced in germinal centre-activated B-
cells, was barely detectable in the spleens of imatinib-treated mice but was strongly 
positive in the spleens of nontreated mice, while ectopic expression of AID rescued 
impairment of CSR in vitro. Finally, they found that expression of E2A, a key 
transcription factor for AID induction, was markedly suppressed by imatinib, 
therefore suggesting a possible mechanism for AID inhibiton. They did not 
investigate the role of Btk or Syk inhibition by imatinib as a possible contributing 
factor to CSR impairment. 
 
In summary, although there is growing evidence that TKIs inhibit kinases important 
for BCR downstream signalling and for B-cell development, differentiation and 
proliferation, there are currently no data  to relate this to the 
hypogammaglobulinaemia seen in CML patients on TKI. 
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I.5.3  B-cell development and B cell subsets 
B-cell development occurs in both the bone marrow and peripheral lymphoid 
tissues such as the spleen. In the bone marrow, development progresses through 
the pro-B-cell, pre-B-cell and immature-B-cell stages (Figure I.8). 
Figure I.8: Stages of B cell development (Cambier et al, 2007) 
 
During B cell maturation and differentiation, rearrangements at the immunoglobulin 
locus result in the generation and surface expression of the pre-B-cell receptor 
(pre-BCR, which is comprised of an Igμ heavy chain and surrogate light chains) 
and finally a mature BCR (comprised of rearranged heavy- and light-chain genes) 
that is capable of binding antigen. At this immature stage of development, B cells 
undergo a selection process to prevent any further development of self-reactive 
cells. Both receptor editing and clonal deletion have a role at this stage. Cells 
successfully completing this checkpoint leave the bone marrow as transitional B 
cells, eventually maturing into mature follicular B cells (or marginal-zone B cells). 
BCR signalling appears to be an important determinant in the transition from T1/T2 
to mature B cells. Many mutations that affect BCR signalling pathways also 
interfere with transition to mature B cells. In the absence of Btk, BLNK or PLCγ2 
BCR signalling is insufficient to induce T1/T2 cells to differentiate into mature B 
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cells. 
Transitional B cells represent 2.2 to 7% of circulating human B cells and are 
defined by high expression of CD24, CD38. They also are IgM+ and are negative 
for CD27, a marker for memory B cells. As they progress through maturation they 
express decreasing levels of IgM and CD10. Further maturation of transitional B 
cells occurs in the spleen to naive B cells bearing functional BCR which can 
proliferate upon BCR engagement. Naive B cells represent 40 to 60% of total B 
cells and express CD24int, CD38int, CD21 and are negative for CD27 and CD10. 
Following an immune response, antigen-specific B cells develop into either plasma 
(antibody-secreting) cells or memory B cells. 
Memory B cells are antigen experienced cells, that secret Immunoglobulin under 
stimulation, persist in the absence of the immunizing agents and respond rapidly 
during a secondary response. CD27+ memory B cells consist of two major groups, 
the IgM memory B cell (IgM+IgD+CD27+) and the isotype switched memory B cells 
(IgM-IgD-CD27+), which are the final product of a successful T-cell dependent 
germinal centre reaction. 
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I.6 VACCINE STRATEGIES IN CML AND MYELOID LEUKAEMIAS 
 
I.6.1  Leukaemia-associated antigens 
In recent years, several classes of human leukaemia associated antigens (LAA) 
that can be used as targets of immunotherapy have been identified, including minor 
histocompatibility antigens such as HA-1 (Mutis et al, 1999), neoantigens created 
by chromosomal translocations such as BCR-ABL (Clark & Christmas, 2001), 
overexpressed self-antigens such as Wilms tumour (WT1) (Gao et al, 2000), 
proteinase 3 (PR1) (Molldrem et al, 1997), and cancer testis antigens such as 
Preferentially Expressed Antigen of Melanoma (PRAME) (Ikeda et al, 1997). A 
number of studies including from our group, have previously demonstrated that low 
frequencies of T cells recognising self-antigens overexpressed by leukaemia cells 
such as WT1, PR1 and PRAME exist in healthy individuals and patients with 
leukaemia (Rezvani et al, 2003;Rezvani et al, 2005;Rezvani et al, 2009). These 
responses were found to be significantly higher in leukaemia patients compared to 
healthy donors but the greatest responses occurred after SCT with most patients 
responding to multiple antigens. These LAA specific CD8+ T cells were found to be 
of memory phenotype, suggesting ongoing in vivo antigenic stimulation. These 
findings formed the basis for design of clinical protocols led by Dr. Rezvani to test 
WT1 and PR1 peptides as leukaemia vaccines at the National Institutes of Health, 
Bethesda, USA. Patients with myeloid malignancies received a single 
subcutaneous injection of PR1 and WT1 peptides. The combination of peptide 
vaccines was safe with minimal toxicity. CD8+ T-cell responses against PR1 or 
WT1 were associated with a significant but transient reduction in minimal residual 
disease (MRD) as assessed by WT1 gene expression, suggesting a vaccine-
48 
 
induced anti-leukaemia response(Rezvani et al, 2008). 
 
I.6.2 BCR–ABL vaccine 
Four fusion variants of the BCR–ABL protein are known. Of these, the p210 b3a2 
variant appears the most promising target for vaccination with immunogenic HLA 
class I and II binding peptides (Bocchia et al, 1996;ten Bosch et al, 1999;Mannering 
et al, 1997;Pawelec et al, 1996;Clark & Christmas, 2001). A number of studies 
have shown that b3a2 peptides can induce peptide-specific T cells and that CML 
cells can present BCR–ABL peptides, but in vitro expanded BCR–ABL specific T 
cells have not been reproducibly shown to be cytotoxic against CML. The most 
convincing results come from studies by Clark et al., who were able to generate 
HLA-restricted CTL responses to CML cells using an HLA A-3 binding BCR-ABL 
peptide (Clark et al, 2001). 
 
Pinilla-lbarz and colleagues, at the Memorial Sloane Kettering Institute, were the 
first to develop a BCR–ABL vaccine composed of a pool of six peptide fragments. A 
safety study showed that the vaccine and QS-21 adjuvant were well tolerated and 
could elicit T cell immune responses to BCR–ABL, although no direct evidence of 
cytotoxicity was shown (Pinilla-Ibarz et al, 2000). They then performed a phase II 
study where 14 CML patients in chronic phase received five doses of the vaccine 
and adjuvant (Cathcart et al, 2004). All patients developed delayed-type 
hypersensitivity or CD4+ proliferative responses to the peptides. IFN-γ-producing 
CD4 and CD8 T cells developed in 11 and 4 patients, respectively. Reduction in 
marrow Ph chromosomes occurred in four patients, but three of these continued 
other treatments with IFN-α or imatinib. Three patients in molecular relapse after 
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SCT had transient molecular remissions, but two had also been treated with donor 
lymphocyte infusions. These results, while promising, did not demonstrate 
convincingly the efficacy of the vaccine. In a subsequent trial using a similar 
peptide combination, Bocchia et al. studied 16 b3a2 variant CML patients with 
stable residual disease for at least 6 months, after a minimum of 12 months 
treatment with imatinib or 24 months with IFN-α (Bocchia et al, 2005). Patients 
received six vaccinations and were assessed for immunological and disease 
response. It is important to note that patients continued their conventional treatment 
during and after vaccination. Of 10 patients on imatinib, nine had stable cytogenetic 
disease – of whom seven were in major cytogenetic response- and one was in 
complete cytogenetic remission (CCyR) for a median of 10 months. Five achieved 
complete cytogenetic remission, with a negative polymerase chain reaction (PCR) 
for BCR–ABL in three. Of six patients stable for a median of 17 months on IFN-α 
treatment with 13% median Ph+ chromosomes in the marrow, five showed 
reductions in the percentage of Ph+ chromosomes, with two reaching complete 
cytogenetic remission. Five of five patients showed specific responses to the 
peptide with IFN-γ production, 13 of 14 had proliferative responses and delayed-
type hypersensitivity to the peptides was seen in 11 patients. Following this pilot 
study, a phase 2 multicenter study was conducted in 57 chronic phase CML 
patients who had achieved a CCyR on at least 18 months of IM treatment. The 
interim analysis presented at the Annual Meeting of the American Society of 
Hematology (ASH) in 2009 reported that 67% of 43 evaluable patients had a 
significant in vitro b3a2-peptide-specific CD4+ T cell proliferation (Bocchia et al, 
2009). Fourteen of 29 evaluable patients who reached the 9th month evaluation 
had at least a 0.5 log reduction in the BCR-ABL transcript levels.  
50 
 
A similar phase I/II study from the UK using BCR-ABL peptides, linked to the pan 
DR epitope PADRE, reported no molecular benefit in five patients not in major 
cytogenetic response (MCyR) at baseline. However, of the 14 patients in MCyR at 
baseline, 13 developed at least 1 log fall in BCR-ABL transcripts, although this 
occurred several months after completing vaccination (Rojas et al, 2007). 
 
These studies support the immunogenicity and safety of BCR-ABL peptide 
vaccination in patients with CML. Although it is possible that clinical responses to 
BCR–ABL peptide vaccination may be induced in patients with CML with low levels 
of stable disease, the rather modest results raise concerns that the method of 
vaccine administration or the immune status of the treated patients may be 
suboptimal, or that BCR–ABL does not induce sufficiently powerful cytolytic T cell 
responses to CML. Furthermore, the benefit of this approach will remain uncertain 
without a randomized arm to take into account any effect of imatinib itself on BCR-
ABL reduction. 
 
Recently Maslak and colleagues conducted a pilot vaccine study in 13 patients with 
CML on imatinib with stable complete or major cytogenic response with residual 
molecular disease (Maslak et al, 2008). Patients with the b3a2 or with the b2a2 
breakpoint were vaccinated with a heteroclitic class I peptide that bind with high 
affinity to HLA-0201 and a class II peptide. Vaccination induced a CD8+ T cell 
response that cross-reacted with native junctional peptides, overcoming the poor 
immunogenicity of the peptides. However the trial failed to demonstrate a relevant 
clinical activity, even in the setting of MRD, and underscores the difficulty of making 
any conclusions on the reduction of BCR-ABL transcripts in the setting of current 
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treatments with tyrosine kinase inhibitors. 
 
I.6.3 WT-1 vaccine trials 
Preclinical studies suggest that Wilms tumour antigen (WT1) is highly immunogenic 
in man and an interesting vaccine candidate for haematological malignancies and 
cancer in general. Oka et al. reported the outcome of a phase I clinical study of 
WT1 peptide-based immunotherapy in patients with breast or lung cancer, MDS or 
AML (Oka et al, 2004;Morita et al, 2006). Patients received an HLA-A24 restricted, 
9-mer WT1 peptide in Montanide adjuvant at 2-weekly intervals in a dose 
escalation study. The vaccine was well tolerated and 18 of 26 patients received 
three or more vaccinations. The only notable side effect was profound leucopaenia 
in two MDS patients reversed by steroid treatment, which concomitantly abrogated 
the WT1 T cell response. Twelve of the 20 evaluable patients had clinical 
responses, including reductions in blood or marrow leukaemic blasts, tumour size 
or tumour markers. Increases in WT1-specific CTL frequency correlated with a 
clinical response. 
 
Scheibenbogen and colleagues used a WT1-126 peptide vaccine in combination 
with KLH and GM-CSF as adjuvants in 17 patients with AML and 2 patients with 
high risk MDS. Patients received a median of 11 vaccinations (Keilholz et al, 2009). 
WT1-specific T cell responses were detected in 8 of 18 patients in the peripheral 
blood and 8/17 in the bone marrow by tetramer analysis. Clinical responses were 
seen in 6 of 10 patients, including four stable disease (SDs) with more than 50% 
blast reduction and two with haematological improvement. An additional four 
patients had clinical benefit after initial progression, including one complete 
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remission and three SDs. WT1 transcripts as molecular disease marker decreased 
in 35% of patients. These promising results indicate that WT1 vaccination can 
induce functional CTL responses which may be associated with clinical 
improvement in some patients. 
 
A recent pilot study was undertaken to assess the immunogenicity of a polyvalent 
WT1 peptide vaccine previously described to have higher binding and 
immunogenicity, containing 1 WT1-derived peptide to stimulate CD8+ T-cell 
responses, 2 WT1 peptides to stimulate CD4+ responses and one modified peptide 
that could stimulate both CD4 and CD8 T cells (Maslak et al, 2010). Ten AML 
patients in CR but with molecular evidence of WT1 transcript received six 
vaccinations plus immune adjuvants over 12 weeks. Of the nine evaluable patients, 
seven completed six vaccinations and WT1-specific T-cell responses were noted in 
7 of 8 patients. Three patients who were HLA-A0201-positive showed significant 
increases in the frequency of WT-1-tetramer-positive CD8 T cells. At the time of 
publication, the median disease-free survival for the group had not been reached. 
Although the small number of patients and lack of a control group limit this trial, the 
results are intriguing enough to warrant further study.  
 
Research into cellular vaccines was re-enthused with techniques to generate DCs 
from AML and CML cells. Such DC vaccines have the potential to optimally 
stimulate T cell responses to the leukaemia. A Phase I/II trial investigating the 
effects of vaccination with autologous monocyte-derived DCs transfected with WT1 
mRNA in 10 patients with AML was recently reported (Van, V et al, 2010). 
Successful vaccine production was obtained in all patients from a single 
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aphaeresis procedure; mRNA-loaded DC vaccines were administered at biweekly 
intervals and were well tolerated. Two patients in partial remission after 
chemotherapy were brought into complete remission after vaccination. In these two 
patients and three other patients who were in complete remission, the AML-
associated tumour marker returned to normal after vaccination, compatible with the 
induction of molecular remission. Interestingly, following the first round of DNA 
vaccination, WT1 mRNA expression increased on different occasions, compatible 
with molecular relapse. This was reversed by additional rounds of DC vaccination, 
further supporting the anti-leukaemia effect of the vaccine. Clinical responses were 
correlated with vaccine-associated increases in WT1-specific CD8 T cell 
frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated 
levels of activated natural killer cells post-vaccination. These promising data 
support the development of WT1 mRNA-electroporated autologous DC in AML. 
 
I.6.4 PR1 vaccine trials 
PR1 is a nine-amino-acid HLA-A*0201 restricted peptide derived from proteinase 3 
(PR3), shown to elicit myeloid-leukaemia-specific CTL responses that selectively 
kill leukaemic CD34+cells (Molldrem et al, 1997;Molldrem et al, 1996). PR1-specific 
CD8 T cells with a memory phenotype occur at low frequencies in healthy 
individuals and at higher frequencies in patients with leukaemia, suggesting that it 
should be feasible to boost these immune responses with vaccination (Rezvani et 
al, 2003;Rezvani et al, 2007). To explore the therapeutic potential of boosting 
immunity to PR1, Molldrem and colleagues began a pilot study of PR1 peptide 
vaccination in patients with myeloid malignancies. Highly encouraging preliminary 
data from this study were first presented at ASH in 2004 and an update presented 
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at ASH in 2007 (Qazilbash et al, 2004). A total of 66 HLA-A0201 patients with AML 
(42), CML (13) or MDS (11) were treated with PR1 peptide vaccine. Fifty three had 
active disease and 13 were in remission on entering the trial. The first 54 patients 
received three vaccinations, and the last 12 patients received 6 vaccinations. 
Patients received one of three dose levels: 0.25, 0.5 or 1.0 mg per vaccination 
every 3 weeks, together with Montanide adjuvant and GM-CSF. The vaccine was 
well-tolerated. Of the 53 with active disease, 25 (47%) had an immune response. 
Clinical responses ranging from improvements in blood counts to complete 
cytogenetic remission were observed in 9 out of 25 responders (36%), compared 
with 3 of the 28 non-responders (10%). Importantly, immune response to the PR1 
vaccine was associated with an 8.7 month event-free survival (EFS) compared with 
2.4 months for non-responders (p = 0.03), with a trend towards longer OS 
(Qazilbash et al, 2007a). Among the 13 patients in remission at the start of the trial, 
four remained in remission for a median time of 30.5 months. Analysis of the 
effectiveness of this approach in a subgroup of 20 patients with myeloid leukaemia 
vaccinated following SCT showed a PR1 response to the vaccine in 11/20 (55%) 
patients. Nine of 11 (82%) patients with a PR1 response compared to 1 of 9 (11%) 
patients who failed to mount an immunological response to the vaccine had clinical 
responses (P = 0.005). Importantly, a significant PR1 response to the vaccine was 
associated with significantly better clinical response and longer EFS (Qazilbash et 
al, 2007b). Although the full results of this study are yet to be published, these 
promising data have led to the initiation of a phase III, multicentre study of PR1 
peptide vaccination in myeloid malignancies. 
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I.6.5 Trial of combination PR1 and WT1 peptide vaccines 
 
A recent  Phase I safety study from the National Institutes of Health (Bethesda, 
USA), reported the results of peptide vaccination with a combination of PR1 and 
WT1-126 in 8 HLA-A*0201+ patients with low risk myeloid malignancies (Rezvani 
et al, 2008). Five patients with AML in complete remission (1 following a second 
unrelated donor SCT), 2 patients with MDS (refractory anaemia and refractory 
anaemia with ring sideroblasts) and 1 patient with CML in chronic phase (BCR-ABL 
negative on imatinib) were recruited. Patients received a single subcutaneous 
injection of PR1 (0.5 mg) and WT1-126 (0.2 mg) peptides in Montanide adjuvant, 
administered concomitantly with GM-CSF (Sargramostim). Patients were reviewed 
weekly to monitor toxicity and immunological responses. Toxicity was limited to 
grade 1-2. CD8 T-cell responses against PR1 were detected in 7/8 and against 
WT1-126 in 5/8 vaccinated patients. Vaccine-induced T cell responses were 
detected as early as 1-2 weeks post-vaccination in most patients, however these 
responses were short-lived. Post-vaccination, the emergence of PR1 or WT1-
specific CD8 T cells was associated with a significant but transient reduction in 
MRD as assessed by WT1 gene expression, suggesting a vaccine-induced anti-
leukaemia response.  These results suggested that the maintenance of sustained 
or at least repetitive response may require frequent boost injections. This led to the 
initiation of a phase 2 study of biweekly injections of PR1 and WT1 peptide 
vaccines in patients with myeloid malignancies. Again, the combination of PR1 and 
WT1 peptide vaccines was found to be immunogenic in all patients. However, 
repeated vaccination led to selective deletion of high avidity vaccine-induced T cells 
and additional boosting did not increase the frequency of PR-1 or WT-1-specific 
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CD8 T-cells further. In four of six patients the vaccine-induced T-cell response was 
lost after the fourth dose and in all patients after the sixth dose of vaccine (Rezvani 
et al, 2011). Therefore, whilst these results support the immunogenicity of PR1 and 
WT1 peptide vaccination, novel approaches will be needed to induce long-term 
immune responses against these leukaemia antigens. 
 
I.6.6 RHAMM vaccine trial 
 
The receptor for hyaluronic acid mediated motility (RHAMM) is an immunogenic 
antigen that is strongly expressed in several haematological malignancies and has 
been shown to induce humoral and cellular immune responses (Greiner et al, 
2002). A phase I/II study investigated the safety and immunogenicity of vaccination 
using the HLA-A2-restricted RHAMM/CD168-R3-peptide in 10 patients with AML, 
MDS and multiple myeloma (Schmitt et al, 2008). Vaccination with 300 µg of R3 
peptide induced immunological responses in 5/10 patients. Clinical responses were 
observed in 3 patients; 1 patient with AML and 1 with MDS had a significant 
reduction in blasts in the bone marrow and one patient with MDS no longer 
required erythrocyte transfusions after four doses of vaccine. The study was 
therefore extended and further patients were vaccinated with the increased dose of 
1000 µg R3 peptide (Greiner et al, 2010). Nine patients were vaccinated, of whom 
4 had positive immunological responses. However, higher doses of peptide did not 
improve the frequency and intensity of immune responses in this trial. 
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I.6.7 Other approaches 
 
The paracrine production of GM-CSF by irradiated tumour cells has been shown to 
promote the local recruitment of DCs to the vaccine site, which capture liberated 
tumour antigen and traffic to draining lymph nodes to activate tumour-specific CD4 
and CD8 T cells. K562/GM-CSF, a CML cell line genetically engineered to produce 
GM-CSF, expresses a number of CML-associated antigens and has the potential 
to generate or augment CML-specific immune responses. A pilot study was 
conducted at Johns Hopkins Medical Institute (Baltimore, USA), to determine 
whether K562/GM-CSF immunotherapy (GVAX) could improve molecular 
responses in patients with chronic phase CML on imatinib. Patients with CML-CP 
who have achieved at least a major cytogenetic response, but remained with 
measurable disease despite 1 or more years of imatinib therapy were recruited 
(Smith et al, 2010). Nineteen patients received four K562/GM-CSF vaccinations 
every 3 weeks. Mean PCR measurements of BCR-ABL for the group declined 
significantly following the vaccines. Thirteen patients had a progressive decline in 
disease burden, including seven who became PCR undetectable.  
 
In a phase 2 study, the same group explored the efficacy of the GVAX platform 
accompanied by infusion of immunotherapy-primed lymphocytes after autologous 
stem cell transplantation (ASCT) in haematological malignancies. The vaccine 
consisted of autologous leukaemia cells admixed with GM-CSF-secreting K562 
cells. After a single pretransplantation dose of vaccine, the "primed" lymphocytes 
were collected and reinfused with the stem cell graft as post remission therapy 
following autologous stem cell transplantation for AML (Borrello et al, 2009). Fifty-
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four subjects were enrolled; of whom 46 achieved a CR, and 28 received a total of 
nine vaccinations at 3-weekly intervals post-ASCT. For all patients who achieved 
CR, the 3-year relapse-free survival (RFS) rate was 47.4% and overall survival was 
57.4% compared to 61.8% and 73.4% in the 28 immunotherapy-treated patients. 
Following post-transplant immunotherapy, immune responses to the vaccine were 
detected in 100% of patients, including DTH reactions in 7 of 18 patients (39%), T-
cell responses (assessed by 7-day Elispot assay) in 15/17 and antibody responses 
to GVAX in 17/17 (100%). These results suggest that this immunotherapy 
approach may offer an interesting platform for post-remission maintenance 
therapy. 
 
I.7 THESIS AIMS 
 
I hypothesise that: 
- TKIs may have different immunomodulatory effects on T cells and B cells 
which may impact on humoral and cellular immune responses to vaccination 
against infectious agents and leukaemia-specific antigens 
 
- The mechanism for the altered immune responsiveness in patients with CML 
on TKI could be related to the CML disease itself of a consequence of TKI-
mediated inhibition of physiological ABL, SFKs or other off-target kinases activity. 
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Aims: The aims of this project are:  
1. Determine the in vivo cellular and humoral immune responses to 2009 H1N1 
vaccine in CML-CP patients on TKI, compared to patients with other 
haematological malignancies and healthy controls: I aimed to assess the extent of 
the underlying immunosuppression in patients with CML compared to patients with 
other haematological malignancies such as non-Hodgkin lymphoma (NHL), chronic 
lymphocytic leukaemia (CLL), allogeneic stem cell transplant (allo-SCT) recipients 
and healthy controls. I compared the B and T cell response to the first vaccine and 
the second booster injection in these patient groups. 
 
2. Determine T-cell and B-cell responses to vaccination against seasonal influenza 
virus and pneumococcus in CML patients treated with tyrosine kinase inhibitors: I 
carried a comprehensive immunological analysis following routine vaccination 
against seasonal influenza virus and streptococcal pneumonia in patients with CML 
on standard dose imatinib, dasatinib and nilotinib. The aim was to determine the 
potential impact of treatment with TKI on the efficacy of antigen-specific T-cell 
(against influenza) and polysaccharide-specific B-cell (against pneumococcus) 
responses. This comprehensive study will form the basis for an immunotherapy 
protocol to combine vaccination against LAA with TKI in patients with CML 
 
3. Exploring the immunomodulatory effect of TKIs through their impact on BCR 
downstream pathway. 
This study focused on evaluating the effect of TKI on BCR downstream signalling 
pathways and their impact on the B cell functions directly ex vivo. My goal was to 
explore the possible mechanisms underlying impaired B cell responses to 
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vaccination in CML patients on TKI. 
 
4. To investigate the possible impact of Ph+ B lymphopoesis on the vaccine-induced 
B cell responses in CML. The impaired B cell response to vaccination could be 
related to the CML disease itself or a consequence of TKI-mediated inhibition of 
multi tyrosine kinases activity. The aim of this work was to further explore the effect 
of TKI on different B-cell subsets and to look for the presence of, and implications 
of Philadelphia positive lymphopoiesis on the vaccine-induced humoral response. 
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CHAPTER 2  LABORATORY AND ANALYTICAL METHODS 
 
II.1 PATIENTS 
 
Informed consent for the use of patient material was obtained from all patients at 
Imperial NHS Trust, Hammersmith Hospital. The study was approved by the local 
ethics review board. 
TABLE II.1: inclusion of CML patients in studies reported in II.1.1 and II.1.2 
Patients 36 to 51 (cf Table IV.2 page 141) were vaccinated first with the seasonal influenza 
vaccine 2009/2010 
 
 
 
II.1.1 Patient selection for inclusion in the study ‘Immune response 
following vaccination against influenza A (H1N1) 2009 virus’ 
Individuals recruited in this study were CML patients, chronic lymphocytic 
leukaemia patients, Non-Hodgkin lymphoma patients, recipients of allogeneic stem 
cell transplantation (allo-SCT) and healthy volunteers. 
 
CML Patients Seasonal influenza
vaccine2008/2009
(CSL biotherapy)
Seasonal influenza
vaccine2009/2010
(CSL biotherapy)
H1N1 vaccine
2009/2010
(Pandemrix GSK)
Patient 1 to 35
(cf Table IV.2, page 142)
Yes
Patients 36 to 51 (n=16)
Dasatinib, n=4
Imatinib, n=12
Yes Yes
Patients included in 
H1N1 study only
N=16 
dasatinib, n=5
imatinib, n=11
Yes YesStudy ‘Immune response 
following vaccination against 
influenza A (H1N1) 2009 virus’, 
n=32
Study ‘T cell and B cell responses after 
vaccination against seasonal influenza 
and pneumococcus’, n=51
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Study design 
From 28th October until 18th December 2009,  97 adult patients with 
haematological malignancies and 25 adult controls were vaccinated in compliance 
with UK DoH guidelines (Department of Health, 2009). All patients and donors gave 
informed consent for collection of serum and PBMC and the study protocol was 
approved by the local research ethics committee. Of the 97 patients, 32 had 
chronic myeloid leukaemia (CML) in chronic phase (CP) in complete cytogenetic 
response (CCyR) on the tyrosine kinase inhibitors imatinib or dasatinib, 39 had a B-
cell malignancy in complete remission (CR) or untreated, including non-Hodgkin’s 
lymphoma (NHL), Hodgkin’s lymphoma (HL) or chronic lymphocytic leukaemia 
(CLL), and 26 were recipients of allogeneic hematopoietic stem cell transplantation 
in CR at least 6 months beyond transplant and without evidence of active graft 
versus host disease (GVHD). Healthy controls were recruited from hospital staff 
who were offered vaccination as front-line healthcare workers. Patients and 
controls with a previous exposure to 2009 H1N1 infection, as confirmed by RT-
PCR, were excluded from this study. 
 
Vaccine 
Consistent with UK DoH guidelines all patients received an inactivated split-virion 
preparation of the influenza A/California/2009 (H1N1)v-like strain  containing 
3.75µg of haemagglutinin and AS03 adjuvant (Pandemrix GSK, UK). The vaccine 
was administered by intramuscular injection into the deltoid muscle of the non-
dominant arm by the patient’s primary care physician, as per DoH guidelines. Over 
the same period, 89 of 97 patients and 15 of 25 controls also received one dose of 
a seasonal influenza vaccine containing 15 µg of haemagglutinin antigens of the 
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three following strains: A/Brisbane/59/2007 (H1N1)-, A/Brisbane/10/2007 (H3N2)- 
and B/Florida/30/2008-like strain; in the majority of patients and controls the 
vaccines were not given concomitantly. 
 
Safety assessments and assessment of influenza-like illness 
We solicited reports of local (pain, tenderness, redness, induration and 
ecchymosis) and systemic (fever, headache, malaise, myalgia, chills and nausea) 
adverse events by two-weekly phone calls performed by trained medical students, 
starting one week after the first injection. All solicited local and systemic adverse 
events within 7 days post vaccine were considered to be related to the vaccines. 
Symptoms were graded as follows: none, mild if they did not interfere with normal 
activities, moderate if they resulted in interference with normal activities, and 
severe if they prevented engagement in daily activities or necessitated medical 
attention. 
An influenza–like illness was defined as an oral temperature of more than 38°C or 
a history of fever or chills and at least one influenza-like symptom. 
 
Serum and peripheral blood mononuclear cells (PBMC) were collected before 
vaccination and on days 21 and 49 after the first vaccine dose, and cryopreserved. 
 
II.1.2 Patient selection for inclusion in the study ‘T cell and B cell 
responses after vaccination against seasonal influenza and pneumococcus’ 
Individuals recruited in this study were healthy volunteers and CML patients only. 
Fifty one patients with CML-CP patients in complete cytogenetic response (CCyR) 
on standard dose imatinib (n=26), dasatinib (n=13) or nilotinib (n=12) and 24 adult 
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controls were recruited in this study during two influenza seasons (2008 and 2009). 
Patient characteristics are summarized in Table IV.1. Healthy controls were 
recruited amongst hospital staff. The median age for CML patients was 52 years 
and for healthy controls 41 years (p=0.10). All patients and controls were 
vaccinated against influenza (Influenza vaccine Ph. Eur. 2008/2009, or Influenza 
vaccine Ph. Eur. 2009/2010, CSL biotherapies, Marburg Germany) and the 
pandemic influenza A(H1N1) in 2009 (de Lavallade H. et al, 2011). Forty five 
patients with CML and 12 healthy controls were concomitantly immunized with the 
23-valent polysaccharide pneumococcal vaccine (Pneumovax II; Sanofi Pasteur 
MSD, Maidenhead, UK). Only patients and controls who had not received a 
pneumococcal vaccine within the previous 5 years were re-immunized. 
Peripheral blood mononuclear cells (PBMCs) and serum samples were collected 
from all patients and donors prior to vaccination and responses were assessed at 4 
weeks and at 2–3 months post-immunization. All patients and adult controls gave 
informed written consent and the local institutional ethics board approved the study 
protocol. 
 
II.1.3 Patient selection for the study ‘effect of imatinib on B cell subsets 
in CML patients and impact of Philadelphia positive B cell subsets’ 
In this study the samples were directly requested from the John Goldman Centre 
for Cellular Therapy (JGCCT) in the department of Haematology at Hammersmith 
Hospital. The samples were apheresis-derived mononuclear cells (MNCs) obtained 
from newly diagnosed CML patients using a COBE® spectra Apheresis system. 
Patients were harvested before starting on imatinib and, where applicable, once 
they achieved CCyR on this treatment. 
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Selection of samples was done according to the following inclusion criteria: 
- All samples at diagnosis were from previously untreated CML patients in 
chronic phase 
- Samples harvested at the time of CCyR on imatinib were only requested if a 
paired diagnostic sample was available (‘responder group’) 
- Diagnostic sample from patients who did not respond to imatinib were 
selected only if they had not achieved a major cytogenetic response (MCyR) at 12 
months (‘non-responder’ group) 
- Diagnostic samples from CML patients in chronic phase whose disease 
secondarily transformed to lymphoid or myeloid blast crisis while on imatinib were 
also selected and included in the ‘non responder’ group 
 
Thirty nine chronic phase CML patients were included in this retrospective study. 
Paired samples from 25 CML patients who responded to imatinib (‘responder’ 
group) were studied. We also analysed samples collected at presentation from 14 
patients who subsequently failed imatinib therapy (‘non responder’ group, including 
10 patients who subsequently developed blast crisis). All 25 patients in the 
‘responder’ group achieved complete cytogenetic response and diagnostic samples 
were taken at presentation while remission samples were taken at a median time of 
25 months (range, 15 to 56 months) from presentation sample once patients had 
achieved CCyR. Samples used in this experiment were apheresis-derived MNCs 
obtained from leukapheresis products and subsequently frozen. 
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II.2 PROCESSING, FREEZING AND THAWING OF PBMC 
 
II.2.1 Isolation of PBMC 
A maximum of 20-30ml of whole blood was collected from patients and healthy 
controls. Peripheral blood mononuclear cells (PBMCs) were isolated using density 
gradient separation technique (Lymphoprep). Briefly, 15 ml heparinised whole 
blood was diluted 1:1 with RPMI 1640 media (GIBCO / Invitrogen) in a 50ml falcon 
tube and 10ml of lymphoprep (Axis Shield, UK) was gently layered under the 
diluted blood. After centrifugation at 1800 rpm for 30 min, the interface layer 
between plasma and lymphoprep, which contains mononuclear cells, was collected 
and re-suspended in fresh RPMI 1640. Cells were washed twice with RPMI 1640 
media at 1200 rpm for 10 min. PBMC were resuspended in 10% fetal calf serum 
(FCS)/ RPMI, counted using Trypan Blue (TB) for cell viability assessment. 
 
II.2.2 Cell Freezing 
PBMCs were suspended in freezing media (RPMI-CM with 20% foetal calf serum 
(FCS) and 20% DimethylSufoxide (DMSO) (Sigma-Aldrich, UK)) on ice and 
aliquoted into cryovials and stored in -80 (max 1 week) before transfer to liquid 
nitrogen. 
 
II.2.3 Cell Thawing 
Cryovials of PBMCs were transferred from liquid nitrogen on dry ice. Each vial was 
thawed in a water bath at 37 ºC. Once thawed,  PBMCs were  transferred 
immediately to a 15 ml falcon tube containing 10 ml thawing media (RPMI 20% 
FCS containing 50,000 unit DNase). PBMCs were centrifuged at 1200 rpm for 10 
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min. PBMCs were then re-suspended in 1 ml media and cell count and viability 
were assessed. 
Following freeze-thaw procedure, the average yield of live cells was 90% (range, 
80 to 95%). 
 
II.2.4 Cell count and viability 
Cell counts were performed by trypan blue exclusion. Cell volume was diluted 1:1 
with trypan blue and a viable cell count was performed on a standard 
haemocytometer. 
 
II.2.5 Apheresis-derived MNCs: freezing 
The MNCs obtained from patients’ apheresis were transferred to the JGCCT 
(Department of Haematology, Hammersmith Hospital), frozen and stored according 
to the Good Manufacturing Practice (GMP)’ and Human Tissue Authority (HTA) 
approved Standard Operating Procedures (SOPs) of the JGCCT. 
 
II.2.6 Apheresis-derived MNCs: thawing 
Thawing of apheresis-derived MNCs material was done using the following 
protocol: 
- Prepare 50 mL of 5x thawing solution (RPMI 1640 + 50% FCS + 50 000 U 
DNAse + 500 U preservative free heparin + 2% glutamine + 2 % pen/strep) 
- Prepare buffer for cell sorting using 500 mls CliniMACS® PBS/EDTA Buffer 
(Myltenyi Biotec GmbH, Germany) to which 50mls of Albumin 5% is added to 
obtain a 0.5% albumin MACS buffer 
- Thaw the cryovial in watherbath at 37º, transfer the cells in a universal tube 
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and add dropwise 10 mL of pre-warmed 5x thawing solution 
- Spin + discard supernatant and add 200 000 UI DNAse directly to the pellet 
for 2 minutes 
- Wash and resuspend in 10 mL RPMI 1640 
- Add 15 mL lymphoprep in a universal tube and layer the 10 mL cells in 
suspension; spin for 30 min 
- Take layer, resuspend in MACS buffer and count cells 
- Label cells with CD34+ beads (Mylteni) and incubate for 30 min 
- Wash and apply cells to an LS column; collect unlabelled cells that pass 
through 
- wash unlabelled cells in 10 ml MACS buffer and count cells 
- Take an aliquot of 10 x 106 cells for staining with the extended B cell panel 
(see II.9.5) and use the remains of the cells for B cell enrichment (see II.9.2). 
 
II-3 FLOW CYTOMETRY MATERIALS 
 
II-3.1 Antibodies 
Fluorescent-conjugated monoclonal antibodies (mAb) were used for phenotypic 
determination of cell subsets. A list of mAbs used in this project is shown in table II-
1. Antibodies were purchased from BD Biosciences UK, Beckmann Coulter UK, 
DakoCytomation, invitrogen and eBioscience. Fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), peridinin chlorophyll protein (PerCP) and allophycocyanin 
(APC) were used as fluorophores for intra-cellular staining experiments and some 
surface staining experiments, while phycoerythrin-Cyanine-7 (PE-Cy7), peridinin 
chlorophyll protein Cyanine 5.5 (PerCp Cy5.5), allophycocyanin H7 (APC-H7) 
69 
 
quantum dot 605 (Qdot605). 
 
TABLE II.2: The panel and clones of monoclonal antibodies used for surface 
staining and intra-cellular staining experiments. Figures in bold denote the antibody 
manufacturer (BD: BD Biosciences UK; BC: Beckmann Coulter UK,) 
Antibody Manufacturer (Clone) Description/function  
CD3  BD (SK7) Pan T cells marker 
CD4  BD (RPA-T4) T-helper marker 
CD8  BD (HIT8a) T-cytotoxic marker 
CD19  
Beckman Coulter /Immunotech  
(J3-119) Pan B-cell marker 
CD27 DakoCytomation (M-T271) Memory marker 
IgD SouthernBiotech (IADB6) Immunoglobulin D marker 
IgM Beckman Coulter (SA-DA4) Immunoglobulin M marker 
CD107a BD (H4A3) Degranulation marker 
CD154 BD (TRAP1) CD40 ligand 
IFN-γ BD (25723.11) Cytokine,Th1 marker 
TNF- BD (MAb11) Cytokine,Th1 marker 
IL-2 BD (5344.111) Cytokine,Th1 marker 
CD24 BD (ML5) B cell proliferation and maturation 
CD27 BD (M-T271) 
TNF-receptor super-family 
Regulation of B-cell activation and 
immunoglobulin synthesis 
CD38 eBioscience (HIT2) Ectoenzyme (calcium signalling) 
IgM BD (G20-127) Surface antibody 
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II-3.2 Other materials 
Brefeldin A and paraformaldehyde were purchased from Sigma. CD28/49d co-
stimulatory reagent, monensin, BD FACS Permeabilizing Solution 2 and BD FACS 
Lysing Solution were purchased from BD Biosciences UK. Two different live/dead 
markers were used: 
- LIVE/DEAD Fixable Aqua Dead cell stain Kit (invitrogen) 
- propidium iodide 1.0 mg⁄mL (invitrogen, P3566) 
 
II-3.3 Antibody titration 
The volume of monoclonal antibody (Mab) was determined in dose titration 
experiments. The volume which resulted in maximal mean fluorescence intensity 
(MFI) and maximal percentage of positively staining cells with minimal non-specific 
staining was selected. An example of antibody titration is shown in Figure II.4 (page 
84). 
 
Antibody Manufacturer (Clone) Description/function  
CD21 eBioscience (HB5) Complement component receptor 2 
CD19 BD (SJ25C1) Pan B-cell marker 
CD10 Invitrogen ( MEM-78) Membrane metallo-endopeptidase 
IgD BD (IA6-2) Surface antibody 
Btk (pY551) BD (24a) 
Tyrosine kinase 
BCR signal transduction molecule 
PLCγ2 (pY759) BD (K86-689.37) 
Superfamily of Phospholipase C 
Lipid signalling pathways 
BCR signal transduction molecule 
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II-3.4 Immunophenotyping 
Direct cell surface phenotyping was performed as follows; thawed cells were 
washed in 2 ml of PBS (pH 7.2). Samples were incubated at 4ºC for 20 minutes in 
the dark with directly conjugated surface antibodies (Table II-1). Cells were then 
washed in 2ml PBS buffer and re-suspended in 100μl prior to analysis. Data 
acquisition was performed with FACSCaliburTM (BD/Pharmingen, San Jose, CA). 
Data were analysed using CellQuestTM and FlowJoTM software (TreeStar, San 
Carlos, CA). 
 
II-4 DETECTION OF INFLUENZA-SPECIFIC CD8+ T CELLS USING 
PENTAMER 
 
II-4.1 HLA tissue typing 
High resolution HLA class I genotyping was performed by sequence-specific PCR 
using genomic DNA in the HLA Laboratory, Department of Immunology at 
Hammersmith Hospital. 
 
II-4.2 MHC class I pentamer staining 
To assess the percentage of Influenza specific CD8+ T cells, PBMCs from HLA 
A0201 patients were stained with HLA-A*0201/GILGFVFTL (FluMP) Pro5TM MHC I 
Pentamer (Pro-immune) conjugated to APC. PBMC were stained according to the 
manufacturer’s protocol. MHC Class I Pentamer was centrifuged at 14,000 × g for 5 
minutes in a chilled microcentrifuge to remove protein aggregates that contribute to 
non-specific staining; PBMC were washed and resuspended in 50 µL PBS at a 
concentration of 1 x 106 and incubated with 10µl of APC-labeled Class I Pentamer 
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for 10 minutes at room temperature (22ºC) in the dark. Cells were then washed and 
resuspended in ~ 50μl PBS and incubated on ice for 20 minutes with CD8-FITC 
(Pro-immune 1 μl), and CD3-PerCp (5 μl, BD). Cells were washed twice in PBS 
and processed on FACSCaliburTM immediately. Data were analysed using FlowJo 
software (TreeStar, San Carlos, CA). The volume of pentamer to be used in 
experiments was determined in dose titration experiments. The volume which 
resulted in maximal mean fluorescence intensity (MFI) and maximal percentage of 
positively staining cells with minimal non-specific staining was selected. 
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Figure II.1: Gating strategy to characterize HLA A0201 restricted Flu-specific CD8+ T cells 
Cells were first gated on lymphocytes (black round gate, left panel), of which CD3+ cells were 
selected (black round gate middle panel). CD8+ were finally gated from CD3+ cells (black square 
gate, right panel) 
 
 
 
 
 
 
 
When a new batch of pentamer was purchased, reproducibility of the assay was 
assessed by comparing the staining of the same sample, with the two different 
batches (Figure II-2). 
Figure II.2: example of reproducibility of results showing an identical sample (CML patient 
HLA -A0201, 4 months post influenza vaccination) thawed and stained on two different days, 
9 months apart, with two different batches of Pentamer. 
CD8+ cells were gated from CD8+ CD3+ lymphocytes, as shown in Figure II.1. 
 
 
 
 
 
 
 
 
 
74 
 
II-5 DETECTION OF POLYFUNCTIONAL CD8+ AND CD4+ ANTIGEN 
SPECIFIC T CELLS: OPTIMIZATION AND STANDARDISATION 
 
II.5.1 Intracellular cytokine assay and T cells cytotoxicity assay 
Frequency of antigen-specific CD8+ and CD4+ T cells was assessed by production 
of cytokines in response to antigenic stimulation. Production of TNF, INF and IL-
2 were assessed to study CD4+ Th1 and CD8+ cytotoxic T cell responses. T-cell 
cytotoxicity was studied after incubation with relevant antigens and measuring 
CD107a production, that is a sensitive surrogate marker for T cell degranulation 
(Lamoreaux et al, 2006). Surface expression of CD107a is found only in cells that 
have degranulated. Upon stimulation of PBMCs, cytotoxic granules that contain 
CD107a and CD107b in their membranes migrate toward the cell membrane and 
the CD107a and CD107b are transiently exposed on the cell surface. At this point, 
CD107a and CD107b are available for binding to fluorescence-tagged antibodies 
before being reinternalized into the endosomal spaces. 
 
PBMC were resuspended at a concentration of 1 x 106 PBMC/ 200 µL and plated in 
flat-bottom 96 well plates. PBMC were stimulated using 3 different conditions:  
1- No stimulation (negative control),  
2- PMA (50ng/ml)/Ionomycin (2ug/ml) (Sigma Aldrich), (positive control) 
3- Flu antigens (see II.5.2) 
The choice of cytokine secretion inhibitor was based on its potential to trap cytokine 
in the most effective manner. Monensin fails to optimally inhibit TNF secretion 
from the cell while Brefeldine A (BFA) (Sigma- Aldrich) successfully blocks it 
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(Lamoreaux et al, 2006;O'Neil-Andersen & Lawrence, 2002). 
BFA was therefore used for TNF detection. For CD107a degranulation assay 
monensin was used in addition to BFA because it is required to prevent 
acidification of lysosomes and endosomes when reinternalization of CD107a 
occurs during T-cell stimulation. 
 
Cells were incubated with either 10 µl Brefeldin A (BFA, 0.5mg/ml) alone (for TNF 
and IFN intracellular staining), or both BFA and 5µl monensin along with 10μl 
CD107a-FITC. For the study on immune responses to 2009 H1N1 vaccine, only 
TNF and IFN production were evaluated. Ten microlitres of 1ug/ml PMA (ie 
50ng/ml) and 8 μl of 50ug/ml ionomycin (ie 2ug/ml) were added as positive control 
at the same time as BFA or monensin. 
After 5 hours incubation, cells were washed and surface stained with 5 μl CD3-
PerCp and 5 μl CD8-PE (BD biosciences, UK) (as described in II.3.4). The cells 
were then fixed in  2 mL FACS lysing solution (BD biosciences, UK) for 10 minutes 
in the dark, centrifuged and then permeabilized using 0.5 mL FACS permeabilizing 
solution (BD biosciences, UK) for 10 minutes in t DECLARATION he dark. After a 
further wash, intracellular staining was performed using either 5 μl IFN-APC and 
0.5 μl TNF-FITC or 15 μl IL2-APC. For the study on immune responses to 2009 
H1N1 vaccine, 5 μl IFN-APC and 1 μl TNF-APC were used in order to capture T-
cells producing effector cytokines. 
Cells were incubated for 30 minutes in the dark, fixed in 1% paraformaldehye (PFA, 
Sigma) and refrigerated until acquisition. Data acquisition was performed using 
FACSCaliburTM and a minimum of 300 000 events were acquired. Data were 
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analysed using CellQuestTM and FlowJoTM software (TreeStar, San Carlos, CA). 
 
The gating strategy was performed as shown on Figure II-3; the threshold of 
positivity for cytokines and CD107a was set in order to minimize non-specific 
staining in non-stimulated cells (negative control) as shown on Figure II-3. The 
results were evaluated by subtracting the background positivity, and by comparing 
the fold increase in frequency of cytokine positive CD8+ and CD4+ T-cells (ie 
stimulated cells/non-stimulated cells). 
Protocol optimization included PMA titration, ionomycin titration, antibody titration 
(CD107a, IL2 and TNF), BFA titration, monensin titration and comparison 
between BFA alone versus monensin alone versus BFA + monensin. 
 
 
Figure II.3: Example of gating strategy for intracellular cytokine assay. The threshold was set 
based on the isotype and negative control (unstimulated). 
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II.5.2  Protocol optimization for antigenic stimulation 
Stimulation using seasonal influenza vaccine solution 
Protocol optimization was first performed on fresh PBMCs from adult controls that 
had been vaccinated with seasonal influenza vaccine. Briefly fresh PBMCs were 
plated at 2x106 cells/ 200 µL RPMI supplemented with 10% FCS per well of a 96-
well plate (BD FalconTM, Oxford, UK) and rested for 4 hours. To determine the 
optimal dose for the vaccine to induce CD8+ or CD4+ T-cells, PBMC were 
incubated with increasing dose of the seasonal influenza vaccine solution  (0.5 µl, 
1µl, 5µl, 10 µl or 50 µl) of the 0.5 ml (CSL Biotherapy) containing 15 µg of 
Haemagglutinin antigens of the three following strains: A/Brisbane/59/2007 (H1N1)-
, A/Brisbane/10/2007 (H3N2)- and B/Florida/30/2008-like strain and 1 µl CD28/49d 
co-stimulatory reagent (BD biosciences, UK) for 12 hours. The optimal CD8+ and 
CD4+ T-cell response to the influenza vaccine was achieved using 10µl of the 
vaccine solution, ie a concentration of 1.5 µg/ml of Haemagglutinin antigens 
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equivalent of each of the strains. 
Once the optimal dose of the vaccine was determined, I determined the optimal 
incubation time by stimulating PBMCs for 16, 24 or 48 hours with 1.5 µg/ml of 
Haemagglutinin antigens equivalent (10µl of the vaccine solution). The optimal time 
of incubation was found to be 24 hours, and was used for the subsequent 
experiments.  
 
The reproducibility of this protocol was confirmed by comparing fresh and frozen 
PBMC from the same donor. Briefly PBMCs were thawed and rested overnight at 
37 ºC, 5% CO2, to minimize background cytokine production secondary to 
lymphocyte manipulation. PBMCs were counted and plated at 1 to 2 x106 cells/ 200 
µL RPMI supplemented with 10% FCS per well of a 96-well plate (BD FalconTM, 
Oxford, UK). Cells were stimulated using 3 different conditions of antigen for 19 
hours at 37 ºC, 5% Co2:  
1- CD28/49d co-stimulatory reagent only (negative control), added at Hour (H) 0 
2- PMA (50ng/ml)/Ionomycin (2ug/ml) (Sigma Aldrich), (positive control) added 
at H+19 
3- CD28/49d co-stimulatory reagent and influenza antigens added at H0 
After 19 hours of stimulation, BFA or monensin + CD107a and PMA/ionomycin 
(where appropriate) were added for another 5 hours (see II.5.1) incubation at 37ºC, 
5% Co2 followed by intracellular staining (see II.5.1). PBMC were stimulated with 
influenza antigens for a total of 24 hours (19 + 5). 
Comparison with fresh cells was performed and the results were reproducible, as 
shown in figure II.4. 
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Figure II.4: Comparison between fresh and frozen cells (INF) 
 
Stimulation using 2009 H1N1 influenza vaccine solution 
The 2009 H1N1 influenza vaccine solution is a monovalent vaccine and contains 
one strain of A/California/07/2009(H1N1)v-like strain in various proportion. We 
tested two vaccines: 
- Pandemrix (GSK, UK) vaccine containing 3.75 µg A/California/07/2009(H1N1)v-
like strain Haemagglutinin antigen in 0.5 ml to be mixed with adjuvant SF03 
- Celvapan (Baxter, UK) containing 7.5 µg A/California/07/2009(H1N1)v-like strain 
Haemagglutinin antigen in 0.5 ml without adjuvant 
Protocol optimization was first performed on fresh PBMCs from adult controls at 
various time points from 4 weeks onward after vaccination with 2009 H1N1 
vaccine. Briefly cells were incubated for 24 hours with 5µl, 10 µl, 20 µl or 50 µl of 
both vaccine solutions. Importantly stimulation with Pandemrix was done using only 
the solution containing the antigens (separated from the one containing the 
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adjuvant). A quantity of 20 µl Celvapan was found optimal, which correspond to a 
final concentration of 1.5 µg/ml of Haemagglutinin antigens, equivalent to the 
titration obtained with the seasonal influenza vaccine (Figure II.5). Concentration of 
Haemagglutinin antigens were comparable to that described by others (Vogt et al, 
2008). Definition for a positive flu-specific cytokine immune response was 
comparable to that used by others (Vogt et al, 2008). 
 
Figure II.5: Optimisation of Celvapan concentration to induce optimal T cell stimulation 
 
 
II.5.3 Detection of H1N1-specific T cells in the study 
To assess T-cell responses to H1N1, PBMCs collected before vaccination and on 
day 49 were thawed and stimulated for 24 hours with or without H1N1 vaccine 
(A/California/07/2009(H1N1)v-like strain, Baxter, United Kingdom) or seasonal 
influenza vaccine (A/Brisbane 59/2007(H1N1), A/Brisbane/10/2007(H3N2)- and 
B/Florida/30/2008-like strain, CSL Biotherapies, Germany) (used as positive 
control) at a final concentration of 1.5 µg/ml of haemagglutinin antigens. 
Assessment of the effector function of antigen-specific CD8+ and CD4+ T-cells was 
performed by intracellular-cytokine staining for interferon-γ (INF-γ) and tumour 
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necrosis factor-α (TNF-α) as described in section II.5.1. Optimisation of antigen 
stimulation was performed as described in section II.5.2. Allophycocyanin (APC)-
conjugated antibodies to INF-γ and TNF-α were employed to detect the frequencies 
of INF-γ or TNF-α producing T-cells. A response was considered positive if the 
combined percentage of H1N1-specific TNF-α plus IFN-γ producing CD4+ or CD8+ 
T-cells was 2-fold or higher compared to background level (non-stimulated PBMC) 
and if there was a minimum of 0.05% H1N1-specific TNF-α plus IFN-γ producing 
CD4+ or CD8+ T-cells (after subtracting the background). 
 
II.5.4 Detection of seasonal influenza-specific T cells  
The immunological T-cell responses to seasonal influenza virus were analyzed 
both quantitatively and qualitatively using flow cytometry and intracellular cytokine 
assay for TNF-α, IFN-γ, IL-2 and the cytotoxicity marker CD107a as described in 
section II.5.1. PBMC collected before and 2-3 months post-vaccination were 
thawed and stimulated for 24 h with or without seasonal influenza vaccine at a final 
concentration of 1.5 µg/mL of hemagglutinin antigens or with PMA (50ng/ml) and 
ionomycin (2ug/ml, Sigma Aldrich) (positive control) for 19 h at 37°C. Brefeldin A 
(10 µg/mL) (Sigma Aldrich, Gillingham, UK) was added alone or with monensin 
(0.7µl/mL) (BD/Pharmingen, San Diego, CA) and the degranulation marker 
CD107a-FITC (BD/Pharmingen, San Diego, CA). Influenza vaccine Ph. Eur. 
2008/2009 was used to stimulate PBMC collected from subjects vaccinated in 2008 
and Influenza vaccine Ph. Eur. 2009/2010 in those who received the vaccine in 
2009. PBMCs were washed and stained with anti-CD3 (BD Biosciences, Oxford 
UK) and anti-CD8 antibodies (BD Biosciences, Oxford UK), fixed/permeablized (BD 
Biosciences, Oxford UK) and stained with anti–IFN-γ, anti–TNF-α anti-IL-2 
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antibodies (all BD/Pharmingen, San Diego, CA). Optimisation of antigen stimulation 
was performed as described in section II.5.2. 
 
The threshold of positivity for cytokines and CD107a was set in order to minimize 
non-specific staining in non-stimulated cells (negative control). The results were 
evaluated by subtracting the background positivity, and by comparing the fold 
increase in frequency of cytokine positive CD8+ and CD4+ T-cells. Following 
vaccination, a response was considered positive if there was a minimum of 0.10% 
Flu-specific TNF-α or INF-γ-producing T-cells and the percentage of antigen-
specific TNF-α or INF-γ-producing T-cells was 2-fold or higher compared to pre-
vaccination level. 
 
 
II.5.5 CD154 staining on CD4+ T cells 
CD154 expression has a fundamental role in the interactions between CD4+ T cells 
and B cells and antigen presenting cells. Indeed recently activated CD4+ T cells 
express    (CD40L), which provides costimulatory signals to activate B cells while 
resting CD4+ T cells do not express CD154 (Brines & Klaus, 1993;Kawabe et al, 
1994). By providing crucial costimulatory signals, the expression of CD154 by 
antigen-specific T cells identifies cells that may provide B-cell help. In addition 
stimulated CD4+ T cells expressing TNF, INF or Il-2 are predominantly CD154+ 
cells. CD154 expression is therefore a marker that represents multiple functional 
responses of CD4+ T cells. 
To determine the CD154 (CD40L) expression on CD4+ cells after vaccination with 
2009 H1N1 vaccine or seasonal influenza vaccine, protocol optimization was based 
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on previously publications (Chattopadhyay et al, 2005;Chattopadhyay et al, 2006); 
briefly fresh PBMCs from adult controls that had been vaccinated with both 2009 
H1N1 vaccine and seasonal influenza vaccines were incubated with different 
concentrations (1µl, 5 µl, 10 µl and 20 µl) of anti-CD154 (CD40L) PE-conjugated 
antibody to obtain the highest signal-to-noise ratio (see Figure II.4). 
PBMCs were thawed and rested overnight at 37°C in 96-well plate in 200 µl 
volume; after 18 hours stimulation with and without 1.5 µg/ml of the 2009 H1N1 
vaccine solution or 1.5 µg/ml of the 2009 seasonal influenza vaccine (CSL 
Biotherapy) cells were incubated for 6 hours with 0.7µL/mL monensin, 5 µl CD154 
(CD40L) PE-conjugated antibody and 10 µl CD107a FITC-conjugated antibody (all 
BD/Pharmingen, San Diego, CA). Finally cells were stained with 5 µl CD3 PerCP-
conjugated antibody and 10 µl CD4 APC-conjugated antibody for 20 minutes. 
CD154 expression was found to correlate with TNFα production and CD107a 
expression on CD4+ T cells as shown in Figure II.5. 
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Figure II.6: Antibody titration for CD154 staining: A dose of 5 µl CD154 was found to be optimal.  
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Figure II.7: Functional characterization of CD8+ and CD4+ T-cell responses to H1N1 and 
seasonal influenza in a multiple myeloma patient with confirmed H1N1 infection. 
A response was considered positive if the percentage of antigen-specific IFN-γ, TNF-α, or CD107a 
expressing T-cells was 2-fold or higher compared to background (unstimulated PBMC) and if there 
was a minimum of 0.05% antigen-specific T-cells (after subtracting the background). 
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II.6 FOUR-COLOUR MEMORY B CELL PHENOTYPING 
 
B cell phenotyping was adapted from a protocol kindly provided by Miss Melanie 
Hart in Dr William P Kelleher’s laboratory (Chelsea and Westminster Hospital, 
Department of Immunology). The mAbs used to define the human B cell subsets 
were: PE-cyanin 7 (PC7) conjugated anti-CD19 (Coulter Immunotech High 
Wycombe, UK), PE-conjugated anti-human IgD (Southern Biotechnology 
Associates, Birmingham, USA), APC-conjugated anti-human IgM (The Jackson 
Laboratory, Bar Harbor USA), FITC-conjugated anti-CD27 (DakoCytomation, 
Glostrup Denmark). 
Briefly frozen PBMCs were incubated for 30 minutes in the dark at room 
temperature with the antibodies shown on the panel (see Table II.2), and washed 
twice using PBS. A minimum of three thousand events were acquired on the B cell 
gate and the results are expressed as a percentage of CD19 events. FlowJo 
software (TreeStar, San Carlos, CA) was used for data analysis. Calibration was 
performed using cells alone and single labelled tubes, and acquired on a 
FACScalibur. Instrument settings were stored and used for subsequent 
experiments. Gating strategy was performed as shown in Figure II-6 and the 
threshold for CD27 FITC positivity was determined using the Fluorescence minus 
one (FMO) method (see Table II.3, tube 6). 
Since IgM memory B cells express both IgD and IgM, co-expression of either IgD 
or IgM together with CD27 was used to define this cell subset. IgM memory B cells 
(defined as CD19+ CD27+ IgMhigh IgD+/lo) and switched memory B cells (defined 
as CD19+ CD27+ IgM- IgD-) subsets were calculated according to a modified 
Piqueras classification,(Piqueras et al, 2003) where both IgM memory B cells and 
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switched memory B cells are calculated as a percentage of the total B cell 
population. 
 
 
Table II.3: Compensation tubes and FMO, B cell panel 
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Figure II.8: memory B-cell gating 
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II.7 DETERMINATION OF ANTIPNEUMOCOCCAL SERUM TITRES for IGM 
AND IGG 
 
This work was performed by Miss Melanie Hart (Chelsea and Westminster 
Hospital, Department of Immunology, Dr P. Kelleher, Imperial College London). 
Serum titres of IgM and IgG antipneumococcal were determined using ELISA 
technology. Briefly, 96-well plates (Maxisorp; Nunc; Fisher-Scientific) were coated 
with Pneumovax II 23-valent vaccine overnight at 4°C. Patient samples and 
reference standards were incubated with cell wall pneumococcal polysaccharide Ag 
(5 µg/ml; Statens Serum Institut) in PBS/0.1% Tween 20/1% BSA solution for 1 h at 
room temperature to remove nonspecific Abs which do not play a role in mediating 
protective immune responses. The 96-well plates were then washed three times 
with PBS/Tween 20 solution. Patient’ samples (duplicates at four different dilutions) 
were then added and incubated at room temperature for 1.5 h. Plates were washed 
and then the appropriate HRP-labeled IgG or IgM conjugate (Sigma-Aldrich) was 
added. After a second wash step, plates were developed using ο-
phenylenediamine substrate, with results calculated from a standard curve. 
Pneumococcal IgG standard, assigned a value of 70 U (Protein Reference Unit, 
Sheffield, U.K.), was used together with an in-house standard for pneumococcal 
IgM levels to set up the standard curve. 
A positive IgM Pneumovax II response was defined as a 4-fold rise in serum IgM 
titres or an IgM titre > 200 U/ml 4 weeks post-immunization irrespective of the pre-
immunization titre. A positive IgG response was defined as a 2-fold rise in serum 
IgG titre or an IgG titre >200 U/ml at 1 or 3 months (Hart et al, 2007). 
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II.8 HEMAGGLUTINATION-INHIBITION ASSAY TO DETECT 2009 H1N1 
ANTIBODY 
 
This work was performed by Dr Katja Hoschler (Centre for Infections, Health 
Protection Agency,London, U.K). Antibody responses were detected by means of 
hemagglutination-inhibition assays, according to standard methods (Miller et al, 
2010) and with the use of cell-culture X-179A H1N1 vaccine virus and egg-grown 
NIBRG-121 virus. Serum samples obtained from subjects were tested with the use 
of 1:2 serial dilutions; serum samples were tested in duplicates at an initial dilution 
of 1:8 and a final dilution of 1:1024. Haemagglutination-inhibition antibody titres 
were reported according to the criteria conventionally used to assess the 
immunogenicity of H1N1 influenza vaccines, i.e. geometric mean titres (GMT), 
geometric mean titre ratio, seroprotection rate (proportion with titres ≥1:32) and 
seroconversion rate (proportion with pre-vaccination titre <1:8 and a post-
vaccination titre ≥1:32, or a pre-vaccination titre ≥1:8 and an increase in the titre by 
a factor of four or more), (The European Agency for the Evaluation ofMedicinal 
Products (EMEA), 1997). 
Specific humoral responses to the seasonal flu vaccine were not measured as 
these have been extensively described previously (Kunisaki & Janoff, 
2009;Ljungman & Avetisyan, 2008;Pollyea et al, 2010;Ring et al, 2002). 
 
II.9 IDENTIFICATION OF BCR-ABL POSITIVE B-CELLS AND 8-COLOUR B 
CELL PANEL 
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II.9.1  Sample thawing and B-cell enrichment 
Samples used in this experiment were apheresis-derived MNCs cryopreserved and 
stored by the JGCCT. Sample identification, request, storage and thawing was 
jointly performed with Dr Alexandra Bazeos who used the CD34 positive fraction for 
her PhD work while the resulting CD34 negative fraction was used for the purposes 
of this work.  
Cell thawing was performed as described in II.2.6. CD34 positive selection was 
performed using a Miltenyi CD34 positive selection kit by Dr. Bazeos. The 
unlabelled, CD34 negative fraction was used for lymphocyte staining and selection. 
An aliquot of 10 x 106 cells was taken for staining with the extended B cell panel 
(see II.9.5) and the remaining cells were use for B cell enrichment and sorting. 
 
B cell enrichment was performed prior to cell sorting on the FACS ARIA II to 
increase cell yield. Enrichment using microbeads and magnetic separation was 
performed using either CD19 positive selection for panel #1 (see II.9.6: isolation of 
transitional T1 B-cells, naïve B-cells, IgM memory B-cells and Switched memory B-
cells) or negative B cell isolation (B cell isolation kit II’, Myltenyi) for panel #2 (see 
II.9.6: isolation of LSCs and progenitors). 
 
A buffer solution (containing PBS, pH 7.2, 0.5% BSA and 2 mM EDTA) was 
prepared by diluting MACS BSA Stock Solution (CN 130-091-376) 1:20 with 
autoMACS Rinsing solution (CN 130-091-222). 
Cells for B cell enrichment were filtered before selection using a 30 µm lylon mesh 
pre-separation filters (Myltenyi CN 130-041-407) in order to remove cell clumps. 
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B cell enrichment using the ‘CD 19 Microbeads’ positive selection (MACS, Myltenyi 
Biotech, CN 130-050-301) 
Cells were washed and resuspended in 80 μL of buffer per 10⁷ total cells. Magnetic 
labelling was performed by adding 20 μL of CD19 MicroBeads per 10⁷ total cells. 
After 15 minutes incubation in the refrigerator, cells were washed and resuspended 
at a maximum concentration of 109 cells per 5ml. 
 
Magnetic separation was then performed using LS Columns on a MACS Separator. 
After rinsing the column with 3mL of buffer, cells were applied to the LS column and 
the column was washed 3 times with 3ml of buffer. The column was then removed 
from the separator and placed into a collection tube. 5mL of buffer was placed onto 
the column to flush the magnetically labelled cells out, as shown in figure II.7 (left 
panel). Cells were then resuspended in PBS 200 μL and used for the sorting panel 
#1 (see II.9.3). 
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Figure II.9: B cell enrichment using microbeads (adapted from Miltelnyi Biotech, Bisely, UK). 
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B cell enrichment using the ‘B cell isolation kit II’ (MACS, Myltenyi Biotech, CN 130-
091-151) 
Cells were washed and resuspended in 40 μL of buffer per 10⁷ total cells. A 
labelling of the non-B cell fraction was performed by adding 10 μL of Biotin-
Antibody Cocktail per 10⁷ total cells. After 10 minutes incubation in the refrigerator 
cells were resuspended in 30 μL of buffer per 10⁷ total cells and 20 μL of Anti-Biotin 
MicroBeads per 10⁷ total cells was added. After an additional 15 minutes 
incubation in the refrigerator, cells were washed and resuspended at a maximum 
concentration of 108 cells per 5ml. 
 
Magnetic separation was then performed using LS Columns on a MACS Separator. 
After rinsing the column with 3mL of buffer, cells were applied to the LS column and 
the column was washed 3 times with 3ml of buffer. The unlabelled cells that passed 
through were collected and resuspended in PBS 200 μL as shown in Figure II.7. 
Cells were then used for the sorting panel #2 (see II.9.3). 
 
II.9.2  Panels for lymphocyte subset isolation 
 
Cells were stained before transfer to the Flow Cytometry Department of Respiratory 
Medicine (St. Mary's Medical School, Imperial College London) for cell separation 
using a BD FACS Aria2 cell sorter. 
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Panel #1: isolation of transitional T1 B-cells, naïve B-cells, IgM memory B-cells and 
Switched memory B-cells 
This panel was derived from the 4-colour B-cell panel that was used in the previous 
experiments (see II.6). Antibody titration for this panel was performed in order to 
optimise cell sorting on the BD FACS Aria2. 
 
The objective was to sort the following B-cell subsets: 
- Transitional T1 B-cells: CD27- CD10+ IgM+ 
- Naïve + transitional T2 and T3 B-cells: CD27- CD10- IgM+ 
- IgM memory B-cells: CD27+ CD10- IgM+ 
- Switched memory B-cells: CD27+ CD10- IgM- 
 
 
The antibodies used were: 
 
- CD27 FITC: DakoCytomation (clone M-T271, Catalog No. F7178) 
- CD19-PC7: BC/Immunotech (Catalog No.3628) 
- PerCP cy5.5 antihuman IgM (BD Cat # 561285) 
- CD10 APC (BD, catalog No. 332777) 
 
A Live/dead marker was included to optimise cell sorting. Propidium iodide (PI) 1.0 
mg⁄mL (invitrogen, P3566) was chosen as this dye can be added after staining and 
right before cell sorting at the St Mary’s facility with no need for further wash out; 
therefore the cells that would be apoptosing or dying during the transfer from the 
TIL (tumour immunology lab-Hammersmith Hospital campus) to the St. Mary's 
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campus would be stained and excluded through gating 
This dye was also compatible with the 4 colour panel as shown below: 
 
The panel below was used after titration for diagnostic CML samples and adapted 
to the cell count:  
Antibody R/ µl 
CD27 FITC 2µl 
CD19-PC7 10µl 
IgM PerCP cy 5.5 3µl 
CD10 APC 10µl 
 
Cells were incubated for 20 to 30 min at RT in the dark, washed and pelleted. PI 
1µl was added before cell sorting. 
 
Panel #2: isolation of leukaemia stem cell and progenitors 
The objective of this panel was to isolate CD34+CD38-cells (Leukaemia stem cell 
and multipotent progenitor), CD34+CD38+CD19- (common myeloid progenitor and 
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granulocyte-macrophage progenitor) and CD34+CD38+CD19+ (common lymphoid 
progenitors) from CD34 non depleted samples. 
The panel below was used after titration for diagnostic CML samples and adapted 
to the cell count:  
 
Antibody R/ µl 
CD34 FITC 5µl 
CD19-PE 10µl 
CD38 PE cy7 3µl 
 
Cells were incubated for 20 to 30 min at RT in the dark, washed and pelleted. 
 
Panel #3: isolation of T cells, NK cells and CD3+CD56+ cells 
The objective was to sort the following lymphocyte subsets: 
- T-cells: CD3+ cells 
- NK cells: CD3-CD56+ 
- CD3+CD56+ cells 
The panel below was used: 
 
Antibody R/ µl 
CD56 FITC 10µl 
CD3-PE 5µl 
 
Cells were incubated for 20 to 30 min at RT in the dark, washed and pelleted. 
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II.9.3  Lymphocytes isolation using BD FACS ARIA2 
 
Apheresis-derived MNCs materials were thawed as described in section II.2.6 
(‘Apheresis-derived MNCs: thawing’). In order to determine B cells subsets, an 8 
colour mAb panel was employed as detailed in section II.9.5 ‘B-cell extended 
panel’. The remainder of the sample underwent CD34+ positive selection (this cell 
fraction was used for a different project) and the negative fraction was used for 
positive B cell enrichment using the ‘CD 19 Microbeads’ positive selection (MACS, 
Myltenyi Biotech, CN 130-050-301), as detailed in section II.9.2 ‘Sample thawing 
and B-cell enrichment’. Stained cells were incubated for 20 to 30 min at RT and 
processed on a BD FACS Aria2 cell sorter. The sorted populations were collected 
in MACS buffer and stored on ice. 
The handling and management of the FACS Aria2 cell sorter was performed by Mr 
Robert Sampson, senior technician at the Flow Cytometry Department of 
Respiratory Medicine. 
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Gating strategy for B-cell subsets (panel 1): 
The purpose of this panel was to select transitional T1 B-cells (CD27- CD10+ 
IgM+), naïve B-cells + transitional T2 and T3 B-cells (CD27- CD10- IgM+), IgM 
memory B-cells (CD27+ CD10- IgM+) and switched memory B-cells (CD27+ CD10- 
IgM-). 
The B cells subsets were obtained by applying a gating strategy as shown below: 
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Gating strategy for leukaemia stem cell and  progenitors (panel 2): 
This second panel was standardised for isolation of CD34+CD38-cells (Leukaemia 
stem cell and progenitor), CD34+CD38+CD19- (common myeloid progenitor and 
granulocyte-macrophage progenitor) and CD34+CD38+CD19+ (common lymphoid 
progenitors) from CD34 non depleted samples. 
Only strongly positive cells for marker of interest were selected for cell sorting. Using 
this strategy the specificity of target cell sorted was very high although sensitivity for 
cells of interest was reduced. 
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Gating strategy for lymphocytes subsets (panel 3): 
 
 
A purity check was performed after cell sorting for each of the cell subset and on 
each occasion of cell sorting. 
The number of cell subsets obtained after each sorting was recorded. An example 
is listed below: 
Sample #5185 (CML leukapheresis sample at diagnosis): 
-  Transitional: 73494 
- Naive: 446546 
- Switched: 23540 
- IgM Memory: 40596 
- NKT: 18528 
- T cells: 101851 
- NK cells: 10158 
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II.9.4  BCR-ABL detection using FISH and DNA/RNA extraction. 
Stained cells were transferred in MACS buffer on ice shielded from light to the 
cytogenetic laboratory at the Hammersmith Hospital for Fluorescence In Situ 
Hybridization (FISH). 
 
Depending on the cell number for each subset, cells were also stored in RLT plus 
buffer for future DNA/RNA extraction. 
 
BCR-ABL1 detection using fluorescence In Situ Hybridization (FISH) 
Samples were fixed using a Methanol-Acetone solution, transferred into 1.5ml 
eppendorf tubes and stored at -20* for future FISH and analysis. 
 
FISH for BCR-ABL1 detection and its analysis was performed by Mrs Philippa May 
(Department of cytogenetics, Hammersmith Hospital) BCR/ABL1 t(9;22) Dual-
Color, Dual-Fusion Probe (Kreatech Diagnostics, KBI-10005) were used, were BCR 
is labelled in green and ABL1 is labelled in red (as shown below).  
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The ‘standard’ abnormal signal pattern is 1R1G2F, but other signal patterns are 
possible if the patient has deletions of 3’ BCR or 5’ ABL1. A classical example of a  
BCR/ABL1 positive signal is shown below (left hand side panel) together with a 
negative example (right hand side). 
 
 
1R1G2F : Ph+ cell 2R2G: normal 
BC   BCR-ABL BC   BCR 
BC   ABL 
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DNA/RNA lysis for future extraction 
Part of the cells of each subset were lysed in 350 µl RLT plus buffer (Quiagen) and 
stored for future DNA/RNA extraction using AllPrep kit (Quiagen). 
 
II.9.5  B-cell extended panel (8 colours). 
The following staining panel was used for extended B cell phenotyping: 
Reagents:  
- invitrogenTM  LIVE/DEAD Fixable Aqua Dead cell stain Kit (Cat # L34957) 
- BD PharmingenTM FITC mouse anti human CD24 (Cat # 555427) 
- BD PharmingenTM  PE Mouse Anti-Human CD27 (Cat # 555441) 
- eBioscience PE Cy7 mouse anti human CD38 (Cat # 25-0389-42) 
- BD PharmingenTM  PerCP cy5.5 antihuman IgM (Cat # 561285 
- eBioscience APC mouse anti human CD21 (Cat # 17-0219 -42) 
- BD PharmingenTM  APC H7 mouse anti human CD19 (Cat # 560177) 
- Invitrogen Qdot® 605 mouse anti-human CD10 (Cat # Q10153) 
- BD Horizon™ V450 Mouse Anti-Human IgD (Cat # 561309) 
 
Briefly, approximately 1 × 106 PBMCs were washed and stained with the viability 
marker; invitrogenTM LIVE/DEAD Fixable Aqua Dead cell stain Kit cat# L34957 
according the manufacturer’s protocol. Cells were then washed and incubated with 
the panel shown below in PBS in the dark for 30 min at room temperature. Cells 
were then washed once before analysis on BD FACSLSR2. 
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Antibody Full panel R/ µl 
CD24 FITC 5 
CD27 PE 5 
CD38 PE cy7 3 
IgM PerCP cy 5.5 3 
CD21 APC 3 
CD19 APC H7 5 
CD10 QDOT 2 
IgD PB 5 
Live/ dead  Boil cells for 60 sec 
mix with live cells 
 
Transitional B cells were defined as CD24high CD38high and naïve B cells as 
CD24int CD38int cells. 
 
 
II.10 DETECTON OF BTK AND PLCgamma2 PHOSPHORYLATION 
 
The purpose of this experiment was to detect the phosphorylated conformation of 
the kinase Btk and the phosphorylation of its downstream kinase PLCγ2 using the 
BD Phosflow antibody for flow cytometry. Ramos cell line was used as a positive 
control for this experiment. 
 
 
II.10.1  Ramos cell line subculture 
The Burkitt’s lymphoma-derived cell line Ramos (RA #1, ATCC, CN CRL-1596) 
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was thawed and cultured in 10%FCS RPMI complete media. It was used as a 
positive control to set up this experiment. 
 
II.10.2  PhosphoBtk and PhosphoPLCγ2 using BD Phosflow antibodies: 
detection in Ramos cell line 
107 ramos cells were stimulated with using 10 ml 50 mM H2O2 PBS and incubated 
for 15 minutes. Cells were then fixed with 5 ml of pre-warmed cytofix buffer (cat 
554655) and incubate for 10 min at 37°. After a wash cells were pelleted and 
permeabilized using 1 ml of BD Phosflow Perm buffer II (cat 558050) and incubate 
on ice for 30 min. After two washes 5 µl PE mouse anti-Btk(pY551) or 5 µl PE 
mouse anti-PLC- γ2 (pY759) (both from BD Biosciences, San Jose, CA) were 
added and cells were incubated at room temperature for 30 min in the dark. Cells 
were washed with BD Stain buffer and processed on a FACS Calibur. 
 
 
II.10.3  PhosphoBtk and PhosphoPLCγ2 staining with or without co-
incubation with tyrosine kinase in human B cells 
 
This work was performed by Miss Anushruti Sarvaria. 
To assess the impact of TKI on normal B cells, PBMC from healthy controls were 
isolated and cultured in the presence or absence of increasing concentrations of 
TKIs namely, 1-50 μM of imatinib (LC Laboratories, Woburn, MA), 1-25 μM of 
nilotinib (LC Laboratories, Woburn, MA) and 1-100 nM of dasatinib (LC 
Laboratories, Woburn, MA) for 72 hours. 
Following incubation, PBMC were stimulated with 5mL of 50 mM of H2O2 for 20 
minutes at 37˚C. The stimulation was terminated by the addition of 5 mL pre-
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warmed Cytofix Buffer (BD Biosciences, San Jose, CA) at 37°C for 12 minutes. 
Cells were then fixed and permabilized in Perm buffer II (BD Biosciences, San 
Jose, CA) and  resuspended in 200 μL of staining buffer (BD Pharmingen, Oxford 
UK). Cells were stained with PE-conjugated anti-phosphorylated Btk (pBtk-PE) or 
PE-conjugated anti-phosphorylated PLC-γ2 (pPLC-γ2-PE), PerCP-conjugated anti-
human IgM (BD Biosciences, Oxford UK), APC-conjugated anti-CD19 (BD 
Biosciences, San Jose, CA), and FITC-conjugated anti-CD27 (DakoCytomation, 
Glostrup Denmark). Data acquisition was performed on the FACSCaliburTM (BD 
Biosciences, Oxford UK). TKIs inhibited phosphorylation of Btk and PLC-γ2 in B 
cells in a dose and time-dependent manner. 
 
To assess the impact of physiological doses of imatinib, dasatinb and nilotinib on 
Btk phosphorylation in B cells, cyopreserved PBMCs from CML patients on TKI 
(imatinib, n=3, nilotinib n=4 and dasatinib n=3) were thawed, washed and co-
cultured with autologous plasma or RPMI/10%FCS overnight.  PBMCs were then 
stimulated with 5mL of 50 mM of H2O2 for 15 minutes at 37˚C. The stimulation was 
terminated by the addition of 5 mL pre-warmed Cytofix Buffer (BD Biosciences, 
San Jose, CA) at 37°C for 12 minutes. Cells were fixed and permabilized in Perm 
buffer II (BD Biosciences, San Jose, CA) and resuspended in 200 μL of staining 
buffer (BD Pharmingen, Oxford UK). Cells were stained with PE-conjugated anti-
phosphorylated Btk (pBtk-PE) (BD Biosciences, San Jose, CA) and APC-
conjugated anti-CD19 (BD Biosciences, San Jose, CA). Data acquisition was 
performed on the FACSCaliburTM (BD Biosciences, Oxford UK) and FlowJo 
software (TreeStar, San Carlos, CA) was used for analysis. 
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II.11 STATISTICAL ANALYSIS 
 
II.11.1 Study ‘Immune response following vaccination against influenza A 
(H1N1) 2009 virus’ 
Groups were compared using Fisher’s exact test for categorical data and the 
Mann-Whitney test for continuous variables. To evaluate the effect of a second 
vaccine dose, paired sample analysis was performed using a Mc-Nemar test. GMT 
values, with 95% confidence intervals (CIs), were calculated by use of the mean, 
and lower and upper limits of the 95% CIs of log-transformed titres. The influence 
of variables on the rates of seroprotection or seroconversion was studied using a 
logistic regression model. All reported p values are two-sided and without 
adjustment for multiple testing. Analyses were done for the full-analysis set using 
the software package SPSS (version 17). 
 
II.11.2 Study ‘T cell and B cell responses after vaccination against 
seasonal influenza and pneumococcus’ 
Fisher’s exact test was used to compare proportions. Continuous variables were 
compared using the Mann-Whitney test or the Kruskal Wallis test. Paired samples 
were compared using the Wilcoxon signed rank. Multivariate analysis was 
performed using a logistic regression model. All reported p values are two-sided. 
Samples were correlated using Spearman rank correlation test. Analyses were 
performed using the software package SPSS version 17 
 
 
  
109 
 
CHAPTER 3 COMPARISON OF HUMORAL AND CELLULAR IMMUNE 
RESPONSES TO 2009 H1N1 VACCINE IN CML PATIENTS, PATIENTS WITH 
OTHER HAEMATOLOGICAL MALIGNANCIES AND HEALTHY CONTROLS 
 
III-1 INTRODUCTION 
 
In 2009 the spread of influenza A (H1N1) satisfied the World Health Organization 
(WHO) criteria of a global-pandemic and led to the initiation of a vaccination 
campaign to ensure protection for the most vulnerable patients, including those with 
haematological malignancies. However, the immunogenicity of the 2009 H1N1 
vaccine in immunocompromised patients has not been specifically tested. 
Furthermore, the number of doses of vaccine required for effective immunization 
against novel influenza A (H1N1) has not been established. Whereas the European 
Medicines Agency (EMEA) (The European Agency for the Evaluation ofMedicinal 
Products (EMEA), ) and the UK Department of Health (DoH) (Department of 
Health, 2009) recommend the injection of two doses of inactivated H1N1 vaccine 
with a minimum of three weeks between doses for immunocompromised 
individuals, the Centers for Disease Control and Prevention (CDC) recommend 
immunization with one dose of inactivated H1N1 vaccine for patients with cancer 
receiving chemotherapy, followed by a booster vaccine 3 months after completion 
of treatment if the pandemic continues (Pollyea et al, 2010). 
 
The vaccination against a novel H1N1 influenza virus strain has created a unique 
opportunity to study the immune response in CML patients compared to other 
subgroups of patients with haematological malignancies. In order to gain further 
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understanding on the capability of such patients to develop an immune response to 
novel leukaemia associated antigen vaccine, I decided to compare the immune 
response to the novel pandemic 2009 H1N1 influenza vaccine between CML 
patients and adult controls as well as patients with other haematological 
malignancies; the assumption being that most patients would not have been 
previously exposed to the pandemic H1N1 virus. To that end I conducted a 
prospective study to determine the safety and immunogenicity of the vaccination 
program against the 2009 pandemic H1N1 in chronic phase CML patients on 
tyrosine kinase inhibitor (TKI) as well as in patients with other haematological 
malignancies and healthy controls; I also characterized the different components of 
the immune response to H1N1. 
 
III-2 AIM 
The aims of this study were 
- to determine the humoral and cellular immune responses to 2009 H1N1 
vaccine in CML patients on TKI, and the role of a booster injection 
- to compare the humoral and cellular immune responses to the vaccine in CML 
patients and healthy controls 
- to evaluate the humoral and cellular immune responses to the vaccine in CML 
patients in CCyR on TKI compared to other groups of patients with haematological 
malignancies such as non-Hodgkin lymphoma (NHL), chronic lymphocytic 
leukaemia (CLL) or allogeneic stem cell transplant (allo-SCT) recipients 
- to provide a more complete picture of the host response to 2009 H1N1 
vaccination, and facilitate the development of improved vaccination strategies for 
immunosuppressed individuals 
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III-3 RESULTS 
 
III.3.1  Patients characteristics 
Clinical characteristics of patients and healthy controls are summarized in Table 
III.1. Of the 97 patients, 89 received the recommended booster at a median of 27 
days (range, 18-57) after the first vaccine dose. Eight patients failed to receive a 
booster dose, either due to patient refusal (n=3) or limited access to their primary 
health care physician (n=5). Twenty five healthy controls received one dose of the 
vaccine only as per UK DoH guidelines. 
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Table III.1: Patient and healthy control characteristics. 
Abbreviations: M: Male; F: Female; Allo-SCT: allogeneic stem cell transplantation; CML: 
chronic myeloid leukaemia; CML CP: CML in chronic phase; RIC: reduced intensity 
conditioning; MAC: myeloablative conditioning; SIB: identical sibling donor; MUD: matched 
unrelated donor; GVHD: graft-versus-host disease; CLL: chronic lymphocytic leukaemia; 
SLL: small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; CCyR: 
complete cytogenetic response; Y: yes; N: no. 
 
Characteristics Patients 
N=97 
Healthy  
controls 
N=25 
P value 
Age, median ( range) 57.0 (22.8-88.1) 37.9 (25.6-61.8) 0.001 
Allo-SCT 38.6 (22.8-63.4)   
B-cell malignancies 66.0 (29.9-82.1)   
CML 53.9 (25.0-88.1)   
    
Gender (M/F) 58/39 10/15  
  
Disease 
Allo-SCT 26   
Underlying disease:     
CML CP  11   
Other myeloid malignancies  5   
Lymphoid malignancies  5   
Other  5   
Month from allo-SCT, median 
(range) 
 39 (6-127)   
RIC/MAC  11/15   
SIB/MUD  11/15   
Acute GVHD (Y/N)  10/16   
Chronic GVHD (Y/N)  7/19   
     
B-cell malignancies 39   
CLL/SLL  19   
Follicular lymphoma  7   
DLBCL  4   
Hodgkin’s lymphoma  2   
Others  7   
     
Chronic phase CML in CCyR on 32   
Imatinib  23   
Dasatinib  9   
     
Seasonal influenza vaccination in 2008 (Y/N) 57/35 10/15  
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III.3.2 Toxicity profile following vaccination with 2009 H1N1 and seasonal 
influenza vaccines  
In general the vaccines were well tolerated. Table III.2 shows the adverse events 
during the first 7 days after the first dose. Overall 86/95 evaluable patients (90.5%) 
reported adverse reactions after the first vaccine dose, including local reactions in 
84/95 (88.4%) and systemic adverse events in 41/95 (43.2%), of which 2.1% and 
3.2% respectively were reported as severe adverse events. We solicited side 
effects after the second vaccine dose in 72 patients: 9/72 (12.5%) reported 
worsening side effects, including exacerbation of local reactions (pain or 
tenderness) in 6 and systemic adverse events (fever, nausea or malaise) in 3 
patients. No patient required hospital admission as a consequence of vaccine-
related adverse events. 
In comparison 22/25 healthy controls (88%) reported adverse events, of whom 
22/25 had local reactions (88%) and 10/25 (40%) had systemic adverse events. 
There were no obvious difference in the side effect profiles or frequencies of 
adverse events between patients and controls (data not shown). 
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Table III.2: Injection-site and systemic adverse effects within 7 days after the first 
dose of vaccine among patients. 
 
 
 
III.3.3 Clinical efficacy of vaccination 
Five patients reported influenza-like illness by the end of the influenza season on 
31st March 2010, of whom one required admission to hospital. None of these 5 
patients had a RT-PCR-confirmed H1N1 influenza illness or received antiviral 
therapy, and all had achieved seroconversion after vaccination. Similarly, H1N1 
infection was not diagnosed in any of the vaccinated controls during follow-up. 
 
Adverse event Mild Moderate Severe All grades 
  percent (95% confidence interval) 
local event     
Any 64.2 (54.6-73.9) 22.1 (13.8-30.4) 2.1 (0-5.0) 88.4 (82.0-94.9) 
Pain 54.7 (44.7-64.7) 18.9 (11.1-26.8) 1.0 (0-3.1) 74.7 (66.0-83.5) 
Tenderness 57.9 (48.0-67.8) 20.0 (12.0-28.0) 2.1 (0-5.0) 80.0 (72.0-88.0) 
Redness 13.7 (6.8-20.6) 4.2 (0.2-8.2) 0 17.9 (10.2-25.6) 
Induration 15.8 (8.5-23.1) 3.2 (0.4-6.7) 0 18.9 (11.1-26.8) 
Ecchymosis 4.2 (0.2-8.2) 0 0 4.2 (0.2-8.2) 
     
systemic event     
Any 28.4 (19.4-37.5) 11.6 (5.1-18.0) 3.2 (0-6.7) 43.2 (33.2-53.1) 
Fever 5.3 (0.8-9.8) 3.2 (0-6.7) 1.1 (0-3.1) 9.5 (3.6-15.4) 
Headache 14.7 (7.6-21.9) 3.2 (0-6.7) 0 17.9 (10.2-25.6) 
Malaise 17.9 (10.2-25.6) 10.5 (4.4-16.7) 1.1 (0-3.1) 29.5 (20.3-38.6) 
Myalgia 11.6 (5.1-18.0) 6.3 (1.4-11.2) 0 17.9 (10.2-25.6) 
Chills 6.3 (1.4-11.2) 3.2 (0-6.7) 0 9.5 (3.6-15.4) 
Nausea 7.4 (2.1-12.6) 1.1 (0-3.1) 1.1 (0-3.1) 9.5 (3.6-15.4) 
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III.3.4 Seroprotection rates to 2009 H1N1 in controls and patients 
We evaluated the humoral response in 70 patients and 24 healthy controls in whom 
antibody titres were available at all study time points (before vaccination and at 
days 21 and 49); patients who failed to receive a second dose were also excluded 
from this analysis. Before vaccination protective antibody titres of 1:32 or more 
were seen in 8/24 (33.3%) controls compared to 1/28 (3.6%) patients with B-cell 
malignancies (p=0.008), 1/22 (4.5%) allo-SCT recipients (p = 0.023) and 3/20 
(15.0%) CML patients (p=0.29) as shown in Table III.3 and Figure III.1. 
On day 21 after vaccination, protective antibody titres of 1:32 or more were seen in 
24/24 (100%) controls compared to only 11/28 (39.3%) patients with B-cell 
malignancies (p<0.001), 10/22 (45.5%) of allo-SCT recipients (p<0.001) and 17/20 
(85.0%) CML patients (p=0.086), Table III.3 and Figure III.1. The GMT was also 
significantly higher in healthy controls compared to all patients groups, namely 362 
vs. 18 (p=0.001) in patients with B-cell malignancies, 362 vs. 42 (p=0.001) in allo-
SCT recipients and 362 vs. 100 (p=0.004) in CML patients (Table III.3). The 
seroprotection rates achieved in CML patients were significantly higher than those 
in patients with B-cell malignancies (p=0.003) and recipients of allo-SCT (p=0.011). 
Similar results were obtained when looking at the rate of seroconversion after the 
first injection (Table III.3). 
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Table III.3: Antibody response to the first (day 21) and second dose (day 49, patients only) of vaccine as measured with the 
haemagglutination-inhibition assay, according to patient group. Geometric mean ratios are calculated by comparing the ratios between the 
geometric mean titre (GMT) after vaccination to the GMT before vaccination. Seroprotection was defined as an antibody titre of 1:32 or more. 
Seroconversion was defined as a pre-vaccination antibody titre of 1:8 or less and a post-vaccination titre of 1:32 or more, or a pre-vaccination titre 
greater than 1:8 and an increase in the antibody titre by a factor of four or more. P values correspond to the comparison between controls and each 
patient subgroup. 
 
 
 
 
 
 
 
 
 
 
 
 
Value B-cell malignancies 
(n=28) 
Allo-SCT 
(n=22) 
CML (n=20) 
Imatinib, n=15 
Dasatinib n=5 
Controls 
(n=24) 
Pre- H1N1 vaccination     
Geometric mean titre (95%  CI) 
5.5 (3.8-7.8) 
p=0.010 
5.1 (3.8-6.9) 
p=0.016 
6.6 (4.3-10.3) 
p=0.11 
10.7 (6.5-17.4) 
 
Seroprotection -% (95% CI) 
3.6 (0-10.4) 
p=0.008 
4.5 (0-13.2) 
p=0.023 
15.0 (0-30.6) 
p=0.29 
33.3 (14.5-52.2) 
Day 21     
Geometric mean titre (95%  CI) 
17.7 (8.7-35.7) 
p<0.001 
41.8 (14.5-120.3) 
p=0.001 
100.4 (54.2-186.0) 
p=0.004 
362.0 (216.4-605.5) 
Geometric mean ratio (95% CI) 3.2 (1.7-6.0) 8.1 (3.0-22.2) 15.2 (8.2-28.0) 33.9 (21.4-53.6) 
Seroconversion -% (95% CI) 
35.7 (18.0-53.5) 
p<0.001 
45.5 (24.6-66.3) 
p<0.001 
80.0 (62.5-97.5) 
p=0.036 
100 
Seroprotection -% (95% CI) 
39.3 (21.2-57.4) 
 p<0.001 
45.5 (24.6-66.3) 
p<0.001 
85.0 (69.4-100) 
p=0.086 
100 
Day 49     
Geometric mean titre (95%  CI) 
57.2 (24.2-135.2) 
p=0.012 
130.0 (43.8-386.4) 
p=0.67 
130.2 (67.6-251.0) 
p=0.17 
248.7 (144.1-429.2) 
Geometric mean ratio (95% CI) 10.5 (4.6-24.2) 25.3 (8.3-76.8) 19.7 (9.9-39.0) 23.3 (14.3-37.7) 
Seroconversion -% (95% CI) 
64.3 (46.5-82.0) 
p=0.001 
72.7 (54.1-91.3) 
p=0.008 
90.0 (76.9-100) 
p=0.20 
100 
Seroprotection -% (95% CI) 
67.9 (50.6-85.2) 
p=0.002 
72.7 (54.1-91.3) 
p=0.008 
95.0 (85.4-100) 
p=0.46 
100 
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Figure III.1: Frequency of seroprotected individuals after one dose (patients and controls) 
and two doses (patients only) of vaccine. 
 
 
 
III.3.5 Humoral response to the second dose of vaccine  
When I analyzed the antibody response to H1N1 at day 49 post-vaccination the 
seroprotection rates were significantly lower in patients with B-cell malignancies 
(p=0.002) and in allo-SCT recipients (p=0.008) than in healthy controls (Table III.3). 
The seroprotection rates achieved in CML patients at day 49 were significantly 
higher than those achieved in patients with B-cell malignancies (19/20 vs. 19/28 
respectively; p=0.031) but not significantly different to recipients of allo-SCT 
controls (19/20 vs. 16/22; p=0.096) or healthy controls (p=0.46). 
In order to assess the effect of the second booster dose, I performed a paired 
sample analysis using a Mc-Nemar test. The second vaccine dose induced a 
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significant increase in the seroprotection rates from 39% to 68% (11/28 vs. 19/28; 
p=0.008) in patients with B-cell malignancies and from 45% to 73% (10/22 vs. 
16/22; p=0.031) in allo-SCT recipients. However, after the second booster dose, 
the seroprotection rate for CML patients did not change significantly (17/20 after the 
1st dose and 19/20 after 2nd dose; p=0.5). The seroconversion rates followed the 
same pattern (data not shown). 
 
III.3.6 Impact of age on the level of seroprotection and seroconversion 
The median age of controls was 37.9 years (range, 25.6-61.8) compared to 66.0 
years (range, 29.9-82.1) in patients with B-cell malignancies, 38.6 years (range, 
22.8-63.4) in allo-SCT recipients and 53.9 years (range, 25.0-88.1) in CML 
patients. We studied the relationship between age and the rate of seroconversion 
or seroprotection by constructing a logistic regression model for each outcome in 
which we entered the baseline disease (B-cell malignancies, CML, allograft or 
control) and the age of the patient or control. Age, either as continous variable or as 
a categorical variable (quartiles) did not influence the seroconversion or 
seroprotection rates as measured on day 21 or day 49 (data not shown). 
 
III.3.7 Effect of chemotherapy and rituximab on the humoral response to 
vaccination 
Among the 28 evaluable patients with B-cell malignancies, 9 patients had not 
received chemotherapy. Of the 19 treated patients 12 patients had received 
rituximab-based treatment or were on maintenance rituximab (Table III.4). The 
period of time between chemotherapy and vaccination was significantly longer in 
patients who were seroprotected at day 49 compared to those who were not (4.7 
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vs. 17.5 months, p=0.001). Of the 19 patients who had received prior 
chemotherapy, 8/8 (100%) patients vaccinated more than 12 months after 
chemotherapy achieved seroprotection after two doses of the vaccine, compared to 
3/6 (50%) vaccinated between 6-12 months and 0/5 (0%) vaccinated within 6 
months of chemotherapy (p=0.001, Chi-squared trend test). There were no 
significant differences in the seroprotection rates of the 8 patients who were 
vaccinated more than 12 months following chemotherapy compared to the 9 
patients who had not been previously treated (100% versus 89%, p = 0.99), Table 
4. Importantly, when restricting the analysis to the 17 patients with B-cell 
malignancies who were vaccinated more than 12 months after receiving 
chemotherapy (n=8) or those who had never been treated with chemotherapy 
(n=9), 16/17 (94%) achieved a level compatible with seroprotection after a second 
dose, which was not statistically significantly different from the healthy controls 
(p=0.415). However, it appears that 2 doses of vaccine are still necessary to induce 
a significant antibody titre in these patients as only 10 of the 17 seroconverted after 
the 1st dose (p = 0.031). 
 
120 
 
Table III.4: Comparison of antibody response to 2009 H1N1 vaccination in patients with B-cell malignancies according to time from 
chemotherapy 
Only patients in whom antibody titres were available at all time points and who received two vaccine doses were included in this table. 
Abbreviation: HI: haemagglutination-inhibition; DLBCL: diffuse large B-cell lymphoma; SLL: small lymphocytic lymphoma; FL: follicular lymphoma; 
CLL: chronic lymphocytic leukaemia; HL: Hodgkin’s lymphoma; MCL: mantle cell lymphoma; NHL: non-Hodgkin’s lymphoma; LPL: 
lymphoplasmacytoid lymphoma; R: rituximab; Chl: chloraminophen; Fluda: fludarabine; Cycl: cyclophosphamide; CHOP: cyclophosphamide, 
doxorubicin, vincristine, prednisone; R-CHOP: rituximab-CHOP; R-CVP: rituximab, cyclophosphamide, vincristine, prednisone; ABVD: doxorubicin, 
bleomycin, vinblastine, dacarbazine; DHAP: dexamethasone, cytarabine, cisplatin; Codox M: cyclophosphamide, vincristine, doxorubicin, 
methotrexate; IVAC: ifosfamide, etoposide, cytarabine; NA: not available. 
 
Patient # 
 
Disease type 
 
Chemotherapy received 
 
Maintenance 
Rituximab 
Time from 
chemotherapy or 
maintenance 
rituximab(months) 
HI assay 
Day 0 Day 21 Day 49 
1 DLBCL 3*R-CVP, 4*R-CHOP N 1.7 <1:8 <1:8 <1:8 
2 SLL 6*R-Chl Y 1.8 <1:8 <1:8 <1:8 
3 FL 6*R-CVP Y 2.4 <1:8 <1:8 <1:8 
4 FL 3*R-CVP, 3 * R-CHOP Y 3.6 <1:8 <1:8 <1:8 
5 CLL 3*Fluda-Cycl, 6*R-Cycl N 5.9 <1:8 <1:8 <1:8 
6 HL 6*AVBD N 6.2 <1:8 <1:8 1:32 
7 FL 6*R-CHOP Y 6.4 <1:8 <1:8 <1:8 
8 CLL 5*Fluda-Cycl N 6.6 <1:8 <1:8 1:8 
9 MCL 5*R-CHOP, 1*R-CVP N 6.8 <1:8 1:23 1:64 
10 FL 6*Chl, 2 * DHAP, 2*R-CVP Y 6.9 <1:8 <1:8 <1:8 
11 DLBCL 6* R-CVP N 10.5 16 1:256 1:256 
12 CLL 1*Fluda-Cycl N 16.7 <1:8 <1:8 1:32 
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Patient # 
 
Disease type 
 
Chemotherapy received 
 
Maintenance 
Rituximab 
Time from 
chemotherapy or 
maintenance 
rituximab(months) HI assay 
Patient # 
 
Disease 
type 
 
13 CLL 
5*Chl, 4*Fluda, 6*Fluda-Cycl, 
Campath N 16.9 <1:8 <1:8 1:362 
14 CLL Campath N 17.6 <1:8 1:256 1:4096 
15 DLBCL 6 * R-CHOP N 31.9 <1:8 1:32 1:512 
16 
Hairy cell 
leukaemia Cladribine N 58.7 <1:8 1:64 1:5792 
17 CLL 6*Fluda-Cycl, Campath N 58.9 1:16 1:512 1:512 
18 FL 6*R-CVP N 66.7 <1:8 1:64 1:32 
19 Splenic NHL 8*R-CHOP N 82.9 <1:8 1:16 1:256 
20 LPL None     <1:8 1:512 1:512 
21 CLL None (Binet stage A)     <1:8 <1:8 1:64 
22 CLL None (Binet stage A)     1:8 1:64 1:128 
23 CLL None (Binet stage A)     1:362 1:128 1:362 
24 CLL None (Binet stage A)     1:8 1:362 1:256 
25 CLL None (Binet stage A)     <1:8 <1:8 1:256 
26 CLL None (Binet stage A)     <1:8 1:32 1:32 
27 CLL None (Binet stage A)     <1:8 <1:8 1:33 
28 CLL None (Binet stage B)     <1:8 <1:8 <1:8 
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III.3.8  Impact of time from transplant on humoral response to vaccination 
In the allo-SCT recipient group, we studied the impact of a number of factors 
including conditioning regimen (myeloablative versus reduced-intensity), donor type 
(sibling or matched unrelated donor- MUD), time from transplant, previous history 
of acute GVHD or chronic GVHD, and underlying disease on seroconversion and 
seroprotection rates following H1N1 vaccination (Table III.1). The time from 
transplantation was the only significant predictive variable: patients who achieved 
seroprotection had a significantly longer transplant-to-vaccination interval 
compared to patients who failed to achieve seroprotection (6.5 vs. 48 months; 
p=0.015). Of note only 2 patients were on low dose immunosuppressive therapy 
with cyclosporin A, neither of whom developed a seroprotective humoral response 
to vaccination. 
 
III.3.9  H1N1-specific T-cell response to vaccination 
The induction of virus-specific T-cell responses by H1N1 vaccination was assessed 
directly ex-vivo by flow cytometric enumeration of antigen-specific CD8+ and CD4+ 
T lymphocytes using an intracellular cytokine assay for IFN-γ and TNF-α (Th1 
effector cytokines) production. PBMC were available for analysis at baseline and at 
day 49 in 23 controls and 81 patients. Prior to H1N1 vaccination, pre-existing T-cell 
responses against 2009 H1N1 influenza could be detected in 10/23 (43%) controls 
compared to 2/25 (8%) allo-SCT recipients (p=0.007), 2/28 (7%) patients with B-
cell malignancies (p=0.003) and 6/28 (21%) of CML patients (p=0.131). 
Following vaccination, H1N1-specific T-cells were induced in a significant 
proportion of allo-SCT recipient, (2/25 pre-vaccine vs. 10/25 post-vaccine; p=0.008, 
Mc-Nemar test) and patients with B-cell malignancies (2/28 pre-vaccine vs. 10/28 
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post-vaccine; p=0.008). There appeared to be no effect of prior chemotherapy or 
time from transplant on the induction of H1N1-specific T-cells after two doses of 
vaccine. In contrast, there was no significant increase in the proportion of 
individuals with H1N1 specific T-cell response following H1N1 vaccination in CML 
patients (6/28 pre-vaccine vs.9/28 post-vaccine; p=0.51) and healthy controls 
(10/23 pre-vaccine vs. 11/23 post-vaccine; p = 0.51), table III.5. Figure III.2 depicts 
the Fluorescent Activated Cell Sorting (FACS) plots from 3 representative patients 
and a control with robust T-cell responses to H1N1 vaccines. 
Furthermore, I did not find an association between vaccine-induced T and B-cell 
responses following H1N1 vaccination in the 81 patients for whom both day 49 
PBMC and sera were available; 19/81 patients mounted both cellular and humoral 
responses to H1N1 vaccination, 10/81 patients had only T-cell responses, and 
41/81 patients had only antibody responses. (p=0.32). 
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Table III.5: T-cell responses against 2009 influenza A H1N1. 
Frequencies of CD4+ and CD8+ T-cells expressing either TNF-α or IFN-γ in PBMC stimulated with H1N1 vaccine are presented. Values are shown 
with the background (unstimulated cells- negative control) subtracted. A response was considered positive if the percentage of antigen-specific IFN-γ 
or TNF-α expressing T-cells was 2-fold or higher compared to background (unstimulated PBMC) and if there was a minimum of 0.05% antigen-
specific T-cells (after subtracting the background). 
*Median and range are calculated on samples with a positive T-cell response. 
 
Value B-cell 
malignancies  
(n=28) 
Allo-SCT 
(n=25) 
CML 
(n=28) 
Controls 
(n=23) 
Pre- H1N1 vaccination     
Number of patients with T- cell 
responses against H1N1 influenza - (% ) 
2/28 (7.1) 2/25 (8.0) 6/28 (21.4) 10/23 (43.5) 
Median CD8+ T-cells against H1N1 
influenza, % (range)* 
0.07 (0.03-0.12) 0.03 (0.03-0.03) 0 (0-0.09) 0.05 (0-0.08) 
Median CD4+ T-cells against H1N1 
influenza. % (range)* 
0.09 (0.08-0.11) 0.11 (0.07-0.16) 0.08 (0.06-0.27) 0.08 (0-0.15) 
Day 49     
Number of patients with T- cell 
responses against H1N1 influenza - (% ) 
10/28 (35.7) 10/25 (40.0) 9/28 (32.1) 11/23 (47.8) 
Median CD8+ T-cells against H1N1 
influenza, % (range)* 
0.02 (0-0.14) 0.04 (0.01-0.19) 0.05 (0-0.08) 0.05 (0-0.12) 
Median CD4+ T-cells against H1N1 
influenza, % (range)* 
0.10 (0.05-0.34) 0.09 (0.06-0.55) 0.08 (0-0.30) 0.10 (0.06-0.27) 
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Figure III.2: Fluorescent Activated Cell Sorting (FACS) plots from 3 patients (one from each 
group- Allo-SCT, B-cell malignancy and CML) and a control with robust T-cell responses to 
H1N1 vaccine.  
Cells were gated on CD3 positive lymphocytes. The Y axis represents CD8 expression and X axis 
TNFα + INFγ production. The allo-SCT patient (upper left panel), CLL patient (lower left panel) and 
the healthy control (lower right panel ) received both the 2009 H1N1 vaccine and the 2009/2010 
seasonal influenza vaccine, while the CML patient (upper right panel) was only vaccinated with the 
2009 H1N1 vaccine. 
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III.4 DISCUSSION 
 
A number of publications have studied the efficacy of vaccination with seasonal 
influenza in protecting against influenza like illnesses (Kunisaki & Janoff, 
2009;Pollyea et al, 2010). Although the incidence of proven influenza infection in 
the vaccinated population is the preferred clinical endpoint, the low incidence of 
influenza like illnesses (ILI) in these studies makes the seroprotection rate an 
acceptable surrogate endpoint in normal controls (Clark et al, 2009;Greenberg et 
al, 2009;Liang et al, 2010;Plennevaux et al, 2010) and in the immunocompromised 
population (Kunisaki & Janoff, 2009;Ljungman et al, 2005;Ljungman & Avetisyan, 
2008;Pollyea et al, 2010). In contrast T-cell protection against influenza remains 
poorly understood. In a study performed in elderly patients, the antibody response 
to influenza was reported not to be reliable at predicting risk for laboratory 
diagnosed influenza (LDI) while the T cell response –as assessed by cytokine and 
granzyme B production- was predictive for LDI (McElhaney et al, 2006). The same 
group recently suggested a link between cell-mediated immunity and influenza 
A/H3N2 illness severity in vaccinated older adults (Shahid et al, 2010). 
 
The benefit of a seasonal influenza booster vaccine in patients with haematological 
malignancies remains controversial despite a number of well designed studies 
(Smithson et al, 1978;Ljungman et al, 2005;Lo et al, 1993). Even less is known 
about the safety,  immunogenicity and optimal dosing regimen of 2009 H1N1 
vaccine in this group of patients, although several investigators have reported 
efficacy of single dosing in healthy adults and children (Clark et al, 2009;Greenberg 
et al, 2009;Liang et al, 2010;Plennevaux et al, 2010). 
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Our data demonstrate that vaccination against 2009 pandemic H1N1 is associated 
with an acceptable safety profile in patients with treated and untreated 
haematological malignancies. As previously reported (Clark et al, 2009;Greenberg 
et al, 2009;Liang et al, 2010;Plennevaux et al, 2010), 100% of healthy controls in 
our study seroconverted after one vaccine dose. In contrast the level of humoral 
immunity induced by the vaccine in patients appears to be influenced by both the 
underlying malignancy and the time from last chemotherapy or transplantation. The 
seroprotection rates were significantly higher in patients with CML, patients with B-
cell malignancies who had never received chemotherapy or who were vaccinated 
more than 12 months after chemo-immunotherapy and in intermediate to long-term 
survivors of transplant, compared to all other groups. 
 
The recovery of peripheral blood B-lymphocytes following rituximab-induced B-cell 
depletion begins 6 months after treatment(Maloney et al, 1997;van der Kolk et al, 
2002) and does not return to pre-treatment levels for up to 1 year (McLaughlin et al, 
1998). Although the effect of rituximab on the immunogenicity of seasonal influenza 
vaccination remains unclear (Ljungman et al, 2005;Takata et al, 2009), it has been 
suggested that rituximab negatively impacts the ability to respond to novel influenza 
antigens (Takata et al, 2009). Indeed, we recently showed that patients treated with 
rituximab with confirmed H1N1 infection fail to mount  an antibody response to 
H1N1 (Garland et al, 2011). In our current study none of the patients treated with 
rituximab within 6 months of vaccination achieved detectable antibody titres to 
H1N1. However our results show that the immune responses in untreated patients 
with B-cell malignancies, those who are more than 6 months from treatment and 
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allo-SCT recipients can be substantially improved by a second dose of vaccine 
confirming the need for a booster in these patient groups. In view of the limited 
efficacy, the advisability of vaccination in recently treated patients remains unclear 
and must be balanced against the high degree of mortality associated with H1N1 
infection in the immunocompromised. Reassuringly the incidence and severity of 
side effects were no greater in this group than in any other cohort. 
 
I evaluated the immunogenicity of H1N1 vaccine in CML-CP patients stably treated 
with the tyrosine kinase inhibitors (TKI), imatinib and dasatinib and compared the 
humoral and cellular immune responses to the vaccine in CML patients to other 
groups of patients with haematological malignancies and to healthy controls. 
Indeed some of the tyrosine kinase targets of these drugs play a role in immune 
responses such that there are theoretical reasons to postulate altered immune 
reactivity. A number of reports have documented seemingly contradictory 
immunomodulatory effects of TKI, ranging from impaired T-cell responses (Fraser 
et al, 2009b;Mumprecht et al, 2006;Seggewiss et al, 2005) to enhanced responses 
to vaccination (Larmonier et al, 2008). Also, little is known on the potential effect of 
TKI on humoral responses and few studies have examined the impact of TKIs on B 
cells (Kawamata et al, 2012;Paniagua et al, 2006). 
Our results show that patients with CML treated on TKI can mount effective 
humoral immune responses to H1N1 vaccination that is not significantly different 
from that achieved in healthy controls. Moreover the humoral response to H1N1 is 
significantly better in patients with CML compared to patients with B-cell 
malignancies and recipients of allo-SCT. Those data would suggest that TKI do not 
impair humoral responses in CML patients with a good remission status and are 
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seemingly in contradiction with the study by Paniuga and colleagues which shows 
that imatinib inhibits murine B cell proliferation and immunoglobulin production by 
naive B cells. However the method used in our study to evaluate humoral 
response, namely the haemagglutination-inhibition antibody titres, cannot 
distinguish an IgM from an IgG response. A haemagglutination-inhibition assay 
detects the presence of an antibody to a virus (in this case antibodies to H1N1 
virus) that will interfere with viral attachment to red blood cells. The presence of 
antibody will therefore inhibit hemagglutination and red cell lysis, irrespectively of 
the isotype of antibody. A haemaglutination-assay cannot distinguish selective 
impairments in IgM or IgG responses and more detailed analysis is therefore 
needed to study the impact of TKI on B cell responses to vaccination. 
 
Of note this study was not designed to look at differences in vaccine-induced 
immune responses between imatinib and dasatinib treated patients and we cannot 
determine whether dasatinib may be more immunosuppressive than imatinib as 
suggested in a number of in vitro studies (Schade et al, 2008;Weichsel et al, 2008). 
 
Seasonal influenza vaccine fails to produce cross-reactive antibodies to pandemic 
H1N1(Hancock et al, 2009) because H1N1 virus and conventional influenza strains 
differ in their haemagglutinin and neuraminidase sequences, the two surface 
proteins that are the primary targets of neutralizing antibodies (Greenbaum et al, 
2009). In contrast, recent in vitro data show up to 69% cross-reactivity in CD8+ T-
cell epitopes derived from pandemic H1N1 and other seasonal influenza strains 
(Greenbaum et al, 2009). Prior to vaccination, pre-existing T-cell responses to 
H1N1 could be detected in a significant proportion of healthy controls and CML 
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patients, possibly related to previous exposure to 2009 H1N1 virus but more likely 
due to the presence of cross-reactive seasonal and pandemic H1N1 specific T-cells 
(Greenbaum et al, 2009). This possibility is supported further by a recent study 
demonstrating the existence of cross-reactive seasonal and 2009 H1N1 specific T-
cells of similar avidity with a memory phenotype in healthy controls (Ge et al, 2010). 
Following vaccination, H1N1-specific T-cells were induced in a significantly greater 
proportion of allo-SCT recipient and patients with B-cell malignancies than in CML 
patients or healthy controls. The limited ability of vaccination to significantly 
increase pre-existing influenza-specific T-cells has been previously reported 
although the mechanism for this phenomenon has not yet been fully elucidated (He 
et al, 2008;Keynan et al, 2010). A potential mechanism could be the exhaustion of 
influenza-specific T-cells upon repeated stimulation with the same influenza 
antigens (McElhaney et al, 2005). 
 
Combining cellular and humoral measures of vaccine efficacy may increase the 
ability to predict the risk of influenza illness. Indeed cellular immune responses to 
influenza have been shown to correlate with protection against influenza in the 
absence of strong serum antibody responses among the elderly (McElhaney et al, 
2006). Moreover studies in patients vaccinated against other viruses such as 
Hepatitis B have demonstrated persistence of HBsAg-specific memory T cells in 
the circulation for a long time after vaccination, even when serum anti-HBs 
antibodies were no longer detectable (Wang et al, 2004). This phenomenon may 
also apply to rituximab treated patients in whom no antibody responses were 
detected, yet cellular responses were present. It is possible that the effector 
cytotoxic T cells seen in this group can provide protection against H1N1 infection, 
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supporting vaccination for this subgroup of patients. I found no significant 
correlation between the H1N1 vaccine-induced humoral and cellular immune 
responses. Furthermore, none of the vaccinated patients in our study contracted 
H1N1 infection; therefore we are unable to evaluate the relationship between the 
development of influenza illness, serum antibody titres and ex vivo cellular immune 
responses to 2009 H1N1. 
 
In summary, these data suggest that following vaccination with 2009 H1N1 vaccine, 
the humoral response to H1N1 in CML patients and healthy controls is significantly 
better than that achieved in patients with B-cell malignancies and recipients of allo-
SCT. However, due to the inherent limitations of the haemagglutination-inhibition 
assay, we cannot confidently surmise that the B cell response in CML patients is 
not affected by TKI. Following vaccination, healthy controls and CML responded in 
a similar manner to H1N1 vaccination, probably due to the presence of pre-existing 
T-cell immunity which most likely had been lost in the all-SCT and B-cell 
malingnancies patient groups. I could not find a statistically significant difference in 
T cell responses in CML compared to healthy controls. It is possible that with a 
larger study, and greater power, small differences in T cell response to vaccination 
can be detected between CML patients on TKI and healthy controls. Finally our 
results unequivocally support the EMEA and the UK DoH guidelines for the 
administration of 2 vaccine doses in patients with B-cell malignancies and stem cell 
transplant recipients to induce protective immune response against 2009 H1N1 
influenza and may contribute towards the development of evidence-based 
guidelines for influenza vaccination in patients with haematological malignancies or 
other immunocompromised hosts. 
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CHAPTER 4 TYROSINE KINASE INHIBITORS IMPAIR B-CELL IMMUNE 
RESPONSES IN CML THROUGH OFF-TARGET INHIBITION OF KINASES 
IMPORTANT FOR B-CELL SIGNALLING 
 
IV-1 INTRODUCTION 
The tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib are remarkably 
effective as single-agent therapy for chronic myeloid leukaemia (CML) in chronic 
phase (CP) (de Lavallade H. et al, 2008;Kantarjian et al, 2010;Saglio et al, 2010). 
To date very few in vivo human studies have addressed the long-term impact of 
these molecular-targeted drugs on the immune function. Data from in vitro and 
animal studies have documented seemingly contradictory effects of imatinib on the 
immune response, ranging from impaired antigen-specific T-cell 
responses(Cwynarski et al, 2004;Mumprecht et al, 2006;Seggewiss et al, 2005) to 
reversal of T cell tolerance (Wang et al, 2005) and potentiation of anti-tumor 
immune responses (Larmonier et al, 2008;Balachandran et al, 2011). The limited in 
vitro data available with second-generation TKIs nilotinib (Tasigna; Novartis) and 
dasatinib (Sprycel; Bristol-Myers Squibb) all report impaired antigen-specific T-cell 
responses (Blake et al, 2008a;Blake et al, 2009;Chen et al, 2008;Fei et al, 
2008;Fraser et al, 2009a;Weichsel et al, 2008). Few studies have examined the 
impact of TKIs on B cells (Paniagua et al, 2006), although 
hypogammaglobulinaemia has been reported in CML patients treated with imatinib 
(Steegmann et al, 2003). A recent murine study reported that imatinib may directly 
impair class switch recombination following B cell activation through 
downregulation of activation-induced cytidine deaminase (AID) (Kawamata et al, 
2012). 
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In our previous study we have shown that patients with CML treated on TKI can 
mount effective humoral immune responses to H1N1 vaccination. However due to 
the limitation of the haemagglutination-inhibition assay, we could not confidently 
exclude possible impairments in IgM or IgG response to vaccination in patients with 
CML on TKI, as previously suggested by murine studies (Paniagua et al, 2006). It is 
however important to note that clinically significant antibody deficiency requiring 
IgG therapy is not a recognised complication of imatinib. 
 
In our previous study on immune responses to H1N1 vaccination, we did not find a 
significant difference in the proportion of individuals with H1N1 specific T-cell 
response in CML patients and healthy controls. However, I did not compare the 
quality of the T cell response between CML patients and healthy controls. 
Assessment of the polyfunctionality of the T cell response to vaccination would 
represent a better model to assess any possible impairment in cellular immune 
response in CML patients on TKI. 
 
ABL- and SRC-dependent intracellular signalling molecules are also involved in 
normal T- and B-cell activation (Blake et al, 2009;Lee et al, 2010;Rix et al, 2007), 
as well as other kinases such as Btk or Syk (Atwell et al, 2004;Hantschel et al, 
2007). I hypothesise that TKI may interfere with vaccine-induced cellular and 
humoral immune responses in patients with CML on TKI through their off-target 
multi-kinase inhibitory effects. To investigate this, I characterized T and B cell 
responses to vaccination against seasonal influenza and pneumococcus in CML-
CP patients receiving imatinib, dasatinib and nilotinib and healthy controls. I found 
that the B cell response to pneumococcal vaccine is significantly impaired in CML 
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patients, associated with loss of memory B cell subsets. Furthermore, I showed that 
all 3 TKIs suppress an important kinase in B cell receptor signalling and survival, 
namely Bruton's tyrosine kinase (Btk) and its downstream substrate phospholipase 
C (PLC)-γ2 in a dose-dependent manner. Our findings suggest that TKIs may 
interfere with B-cell activation and induction of humoral immune responses in vivo 
through their off-target multi-kinase inhibitory effects. 
 
IV-2 AIM 
The aims of this study were  
- to evaluate the cellular immune response both qualitatively and qualitatively, 
including analysis of the cytokine profile and effector function of vaccine-induced T 
cell responses 
- to determine if TKI have a differential effect on IgM and IgG humoral responses to 
antigen 
- to understand the potential mechanisms responsible for the immunomodulatory 
effect of TKIs on B cells 
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IV-3  RESULTS: T CELL RESPONSES TO INFLUENZA 
Patient characteristics are shown in table IV.1. 
Table IV.1: Patient characteristics: The characteristics of 51 CML-CP patients on TKI 
and 24 healthy controls in this study are presented 
Characteristics Patients 
N=51 
Healthy controls 
N=24 
Age, median ( range) 52 (27-75) 41 (29-70) 
Gender (M/F) 33/18 13/11 
   
Tyrosine kinase inhibitor  N/A 
Imatinib 26  
Dasatinib 13  
Nilotinib 12  
 
The induction of virus-specific T-cell responses by Flu vaccination was assessed 
directly ex vivo by flow cytometric enumeration of antigen-specific CD8+ and CD4+ 
T lymphocytes using an intracellular cytokine assay for IFN-γ and TNF-α. Specific 
T-cell responses to Flu were based on the detection of at least one intracellular 
cytokine above levels seen in unstimulated cells (as defined in the materials and 
Methods section). 
 
IV.3.1 T cell responses to Influenza A are detectable in patients with CML 
on TKI prior to vaccination 
The induction of virus-specific T-cell responses to Flu vaccination was assessed 
directly ex vivo by flow cytometric enumeration of antigen-specific CD8+ and CD4+ 
T lymphocytes using an intracellular cytokine assay for IFN-γ and TNF-α. A T cell 
response was defined to be Flu-specific if at least one cytokine was detected 
following in vitro antigen-stimulation as defined in Materials and Methods. Prior to 
vaccination, T cell responses against Flu could be detected in 21/51 (41.2%) 
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patients on TKI and 12/24 (50%) healthy controls (p=0.15), indicating the presence 
of pre-existing memory T cell responses to Flu in patients with CML on TKI and in 
healthy controls (Figure IV.1). 
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Figure IV.1: Examples of pre-existing CD8+ and CD4+ T cell responses to Influenza before 
vaccination in patients on TKI and one healthy control 
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IV.3.2 Vaccination with influenza A induces CD8+ and CD4+ T cell 
responses in patients on TKI and healthy controls 
A response was considered positive if there was a minimum of 0.10% Flu-specific 
TNF-α or INF-γ-producing T-cells and the percentage of antigen-specific TNF-α or 
INF-γ-producing T-cells was 2-fold or higher compared to pre-vaccination level. 
Following vaccination, flu-specific T-cells were induced in 24/51 (47.0%) patients 
on TKI (median 0.15% TNF-α+ CD3+ T cells, range 0.05–0.64%) and 15/24 
(62.5%) healthy controls (median 0.40% TNF-α+ CD3+ T cells, range 0.12–2.0%), 
p=0.16 (Table IV.2). FACS plots showing examples of T cell response to influenza 
vaccine in patients on TKI are shown in Figure IV.2. 
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Table IV.2. T cell responses in 51 CML patients and 24 healthy controls.  
ND: not detected; NA: not available 
   
pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
1 CML, imatinib pre-vaccine Yes No 0.24 ND NA NA 
 
  4 weeks     0.13 ND NA NA 
2 CML, imatinib pre-vaccine Yes Yes 0.05 0.06 0.19 0.22 
 
  4 weeks 
 
  0.05 0.06 ND ND 
 
  3 months     0.42 ND ND ND 
3 CML, imatinib pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months 
 
  ND ND ND ND 
4 CML, imatinib pre-vaccine Yes Yes 0.1 ND ND ND 
 
  4 weeks     0.1 ND ND ND 
 
  3 months     0.2 0.05 ND ND 
5 CML, imatinib pre-vaccine Yes Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.1 ND ND ND 
6 CML, imatinib pre-vaccine Yes No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
7 CML, imatinib pre-vaccine Yes Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
142 
 
   
pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
8 CML, imatinib pre-vaccine Yes No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
9 CML, imatinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks     0.15 ND ND ND 
10 CML, imatinib pre-vaccine No No ND ND ND ND 
 
  3 months     ND ND ND ND 
11 CML, imatinib pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
12 CML, imatinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  0.15 ND ND ND 
 
  3 months     NA NA NA NA 
13 CML, imatinib pre-vaccine Yes Yes 0.14 ND ND ND 
 
  4 weeks 
 
  0.05 ND ND ND 
 
  3 months     0.36 ND ND ND 
14 CML, imatinib pre-vaccine Yes Yes 0.14 ND ND ND 
 
  4 weeks 
 
  NA NA ND ND 
 
  3 months     0.36 ND ND ND 
15 CML, nilotinib pre-vaccine Yes No 0.14 ND ND ND 
 
  4 weeks 
 
  0.05 ND ND ND 
 
  3 months     0.06 ND ND ND 
16 CML, nilotinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND 0.1 ND 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
 
  3 months     0.1 ND ND ND 
17 CML, nilotinib pre-vaccine No Yes ND ND 0.13 ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months 
 
  0.1 ND ND ND 
18 CML, nilotinib pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
19 CML, nilotinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND 0.1 ND ND 
20 CML, nilotinib pre-vaccine Yes No 0.36 ND ND ND 
 
  3 months     0.08 ND ND ND 
21 CML, nilotinib pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
22 CML, nilotinib pre-vaccine No Yes ND ND ND ND 
 
  3 months     0.49 ND ND ND 
23 CML, nilotinib pre-vaccine Yes No 0.07 ND 0.09 0.09 
 
  3 months     ND ND ND ND 
24 CML, nilotinib pre-vaccine No No ND ND ND ND 
 
  3 months     ND ND ND ND 
25 CML, nilotinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  0.1 ND ND ND 
 
  3 months     0.05 ND ND ND 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
26 CML, nilotinib pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND 0.14 ND 
27 CML, dasatinib pre-vaccine Yes No 0.1 ND 0.08 ND 
 
  4 weeks 
 
  0.09 ND ND ND 
 
  3 months     ND ND ND ND 
28 CML, dasatinib pre-vaccine No No ND ND ND ND 
 
  3 months     ND ND ND ND 
29 CML, dasatinib pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.05 ND ND ND 
30 CML, dasatinib pre-vaccine Yes Yes ND ND 0.22 ND 
 
  4 weeks 
 
  0.07 ND 0.16 ND 
 
  3 months     NA NA NA NA 
31 CML, dasatinib pre-vaccine No Yes 0.05 NA NA NA 
 
  4 weeks 
 
  0.13 NA NA NA 
 
  3 months     0.64 NA NA NA 
32 CML, dasatinib pre-vaccine No No ND ND 0.07 ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
33 CML, dasatinib pre-vaccine Yes No 0.36 ND ND ND 
 
  4 weeks 
 
  0.1 ND ND ND 
 
  3 months     0.3 ND ND ND 
34 CML, dasatinib pre-vaccine No No ND ND ND ND 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
35 CML, dasatinib pre-vaccine No Yes ND ND ND ND 
 
  3 months     0.28 ND ND ND 
36 CML, dasatinib pre-vaccine Yes No 0.07 0.11 NA NA 
 
  3 months     0.1 0.13 NA NA 
37 CML, imatinib pre-vaccine No No 0.08 0 NA NA 
 
  3 months     0.12 0 NA NA 
38 CML, dasatinib pre-vaccine No No 0.07 0.05 NA NA 
 
  3 months     ND 0.07 NA NA 
39 CML, dasatinib pre-vaccine Yes Yes 0.16 0 NA NA 
 
  3 months     0.33 0.06 NA NA 
40 CML, imatinib pre-vaccine No Yes 0 0 NA NA 
 
  3 months     0.18 0.09 NA NA 
41 CML, imatinib pre-vaccine No   0.08 0 NA NA 
 
  3 months     0.1 0.05 NA NA 
42 CML, imatinib pre-vaccine No Yes 0.08 0 NA NA 
 
  3 months     0.17 0.07 NA NA 
43 CML, imatinib pre-vaccine No Yes 0.07 0 NA NA 
 
  3 months     0.15 0 NA NA 
44 CML, imatinib pre-vaccine No Yes 0 0 NA NA 
 
  3 months     0.1 0 NA NA 
45 CML, dasatinib pre-vaccine Yes No 0.12 0 NA NA 
 
  3 months     0 0.05 NA NA 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
46 CML, imatinib pre-vaccine Yes No 0.18 0 NA NA 
 
  3 months     0 0 NA NA 
47 CML, imatinib pre-vaccine Yes No 0.16 0 NA NA 
 
  3 months     0.06 0 NA NA 
48 CML, imatinib pre-vaccine No Yes 0.08 0 NA NA 
 
  3 months     0.17 0.07 NA NA 
49 CML, imatinib pre-vaccine Yes No 0.12 0 NA NA 
 
  3 months     0.2 0.08 NA NA 
50 CML, imatinib pre-vaccine No Yes 0.06 0 NA NA 
 
  3 months     0.12 0 NA NA 
51 CML, imatinib pre-vaccine No No 0 0 NA NA 
 
  3 months     0.08 0.06 NA NA 
1 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.18 0.09 ND ND 
2 Healthy control pre-vaccine Yes No 0.36 0.1 0.25 0.08 
 
  4 weeks 
 
  0.4 ND ND ND 
 
  3 months     0.39 ND 0.3 0.16 
3 Healthy control pre-vaccine No No ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND 0.14 0.11 
4 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  0.21 ND ND ND 
 
  3 months 
 
  0.22 ND ND ND 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
5 Healthy control pre-vaccine No Yes ND ND 0.1 ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.5 ND ND ND 
6 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.17 ND ND ND 
7 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.49 ND ND ND 
8 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  0.16 ND ND ND 
 
  3 months     ND ND ND ND 
9 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  0.1 0.01 ND ND 
 
  3 months     0.4 0.05 ND ND 
10 Healthy control pre-vaccine Yes No 0.16 0.1 0.12 0.08 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     ND ND ND ND 
11 Healthy control pre-vaccine No Yes ND ND ND ND 
 
  4 weeks 
 
  ND ND ND ND 
 
  3 months     0.15 ND ND ND 
12 Healthy control pre-vaccine Yes No 0.4 0.11 
 
  3 months     0.28 0.2 
13 Healthy control pre-vaccine Yes No 0.1 0.07 
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pre-vaccine 
Response 
TNFa gammaINF 
Patient Time point  memory T-cells CD4+ CD8+ CD4+ CD8+ 
 
  3 months     0.12 0.05 
14 Healthy control pre-vaccine No Yes ND ND 
 
  3 months     0.42 0.24 
15 Healthy control pre-vaccine Yes Yes 0.18 0 
 
  3 months     0.7 1.3 
16 Healthy control pre-vaccine No Yes ND ND 
 
  3 months     0.22 0.09 
17 Healthy control pre-vaccine Yes Yes 0.14 0.06 
 
  3 months     0.21 0.47 
18 Healthy control pre-vaccine Yes Yes 0.15 0 
 
  3 months     0.52 0.54 
19 Healthy control pre-vaccine Yes No 0.76 0 
 
  3 months     0.27 0.08 
20 Healthy control pre-vaccine Yes No 0.13 0 
 
  3 months     0.11 0.02 
21 Healthy control pre-vaccine No No 0 0 
 
  3 months     0.09 0.07 
22 Healthy control pre-vaccine Yes Yes 0.16 0.07 
 
  3 months     0.22 0.2 
23 Healthy control pre-vaccine Yes Yes 0.28 0.11 
 
  3 months     0.45 0.24 
24 Healthy control pre-vaccine Yes No 0.11 0.06 
 
  3 months     0.1 0.11 
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Figure IV.2: Examples of T cell responses to influenza A vaccination in patients on TKI using 
intracellular cytokine assay. 
 
 
IV.3.3  Detection of Influenza-specific CD8+ T cells using HLA-A2 
restricted GILGFVFTL (FluMP) pentamers. 
In 12 HLA-A*0201+ patients with CML (including 3 imatinib, 6 dasatinib and 3 
nilotinib treated patients), and 4 HLA-A*0201+ healthy donors I also confirmed the 
presence of circulating Flu-specific memory CD8+ T cells using the HLA-A2 
restricted GILGFVFTL (FluMP) pentamer. An increase of at least 2 fold in the 
frequencies of Flu-specific CD8+ T cells was detected in 2/4 controls and 5/12 
patients (median 0.44% of total CD8+ T cells, range 0.1 to 1.51%) as shown in 
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Table IV.3. All patients and donors with detectable Flu-specific CD8+ T-cell 
responses by pentamer analysis also had detectable responses by intracellular 
cytokine assay, indicating that HLA-A2/FluMP CD8+ T cells are functional (data not 
shown). An example of a patient on dasatinib with a robust CD8+ T cell response 
(Patient 33) to influenza vaccination is presented in Figure IV.3. 
Table IV.3: influenza-specfic CD8+ T-cells responses in 4 patients and two healthy 
controls using an HLA-A2 restricted GILGFVFTL (FluMP) pentamer. 
 
 
Figure IV.3: Detection of influenza-specific CD8+ T-cells using an HLA-A2 restricted 
GILGFVFTL (FluMP) pentamer: the FACS plot from a CML patient on dasatinib showing a 
robust CD8+ T cell response to influenza vaccination is presented. 
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27 CML, dasatinib 0.07 0.15 0.14
28 CML, dasatinib 0.05 0.1 NA
31 CML, dasatinib 0.03 0.44 0.09
33 CML, dasatinib 0.04 0.06 1.51
39 CML, dasatinib 0.16 0.46 NA
7 Healthy control 0.07 0.08 0.22
11 Healthy control 0.11 0.26 0.3
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IV.3.4 Vaccination with influenza A induces polyfunctional CD8 and CD4 T 
cell responses in patients on TKI. 
 
I next evaluated the functional quality of the influenza vaccine-induced T-cell 
response by flow-cytometric analysis of markers related to T-helper cell-1 (TNF-α, 
IFN-γ and IL-2) and degranulation/cytotoxicity (CD107a) in individuals with a 
positive vaccine-induced T cell response (responders) and in whom sufficient 
numbers of cells were available for the analysis, i.e. 9 of 24 ‘responders’ in the 
CML and 7 of 15 ‘responders’ in the healthy control groups. 
A polyfunctional response was defined by the production of 2 or more cytokines or 
one cytokine and the cytotoxic marker CD107a. Such polyfunctional responses 
were detected at baseline in 2/9 CML patients (two functions, n=1; three functions, 
n=1) and 2/7 controls (two functions, n=2). Following vaccination, polyfunctional 
responses were induced in 6/9 evaluable patients (2 functions, n=3, three 
functions, n=3) and 3/7 normal controls (two function, n=2; three function, n=1). 
I found no significant differences in the quality of the T cell response to influenza 
vaccine in the two groups as summarized in Table IV.4. 
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Table IV.4: Polyfunctional T cell responses in 9 evaluable CML patients and 7 evaluable healthy controls 
ND: not detected; NA: not available 
   
pre-vaccine 
Response 
TNFa gammaINF CD107a IL2 
Patient 
Time 
point 
 memory T 
cells CD4+ CD8+ CD4+ CD8+ CD4+ CD8+ CD3+ CD4+ CD8+ 
2 
CML, 
imatinib 
pre-
vaccine Yes Yes 0.05 0.06 0.19 0.22 0.2 0.25 0.68 ND ND 
    4 weeks     0.05 0.06 ND ND 0.21 0.23 0.81 ND ND 
    3 months     0.42 ND ND ND 0.17 0.17 0.77 ND ND 
4 
CML, 
imatinib 
pre-
vaccine Yes Yes 0.1 ND ND ND NA NA NA ND ND 
    4 weeks     0.1 ND ND ND NA NA NA ND ND 
    3 months     0.2 0.05 ND ND NA NA NA NA NA 
5 
CML, 
imatinib 
pre-
vaccine Yes Yes ND ND ND ND 0.2 0.08 0.44 ND ND 
    4 weeks     ND ND ND ND 0.3 0.15 0.62 ND ND 
    3 months     0.1 ND ND ND 0.53 0.17 0.57 ND ND 
7 
CML, 
imatinib 
pre-
vaccine Yes Yes ND ND ND ND 0.2 0.09 0.38 ND ND 
    4 weeks     ND ND ND ND 0.42 0.18 0.48 ND ND 
    3 months     ND ND ND ND 0.38 0.14 0.2 ND ND 
13 
CML, 
imatinib 
pre-
vaccine Yes Yes 0.14 ND ND ND NA 0.72 0.49 ND ND 
    4 weeks     0.05 ND ND ND NA 0.29 0.28 0.08 ND 
    3 months     0.36 ND ND ND NA NA 0.67 0.08 ND 
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pre-vaccine 
Response 
TNFa gammaINF CD107a IL2 
Patient 
Time 
point 
 memory T 
cells CD4+ CD8+ CD4+ CD8+ CD4+ CD8+ CD3+ CD4+ CD8+ 
14 
CML, 
imatinib 
pre-
vaccine Yes Yes 0.14 ND ND ND NA ND ND ND ND 
    4 weeks     NA NA ND ND NA ND ND ND ND 
    3 months     0.36 ND ND ND NA NA NA NA NA 
16 
CML, 
nilotinib 
pre-
vaccine No Yes ND ND ND ND 0.26 0.27 0.67 ND ND 
    4 weeks     ND ND 0.1 ND NA NA NA 0.06 0.06 
    3 months     0.1 ND ND ND 0.53 0.21 0.73 NA NA 
26 
CML, 
nilotinib 
pre-
vaccine No Yes ND ND ND ND ND ND 0.32 ND ND 
    4 weeks     ND ND ND ND 0.31 0.13 0.21 ND ND 
    3 months     ND ND 0.14 ND 0.99 0.37 0.59 ND ND 
30 
CML, 
dasatinib 
pre-
vaccine Yes Yes ND ND 0.22 ND ND ND ND NA NA 
    4 weeks     0.07 ND 0.16 ND 0.58 0.11 0.78 ND ND 
    3 months     NA NA NA NA NA NA 0.58 NA NA 
1 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND ND ND ND ND ND 
    4 weeks     ND ND ND ND ND ND ND ND ND 
    3 months     0.18 0.09 ND ND ND ND ND ND ND 
4 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND ND ND ND ND ND 
    4 weeks     0.21 ND ND ND NA NA 0.88 ND ND 
    3 months     0.22 ND ND ND NA NA 1.37 ND ND 
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pre-vaccine 
Response 
TNFa gammaINF CD107a IL2 
Patient 
Time 
point 
 memory T 
cells CD4+ CD8+ CD4+ CD8+ CD4+ CD8+ CD3+ CD4+ CD8+ 
5 
Healthy 
control 
pre-
vaccine No Yes ND ND 0.1 ND NA NA NA 0.11 ND 
    4 weeks     ND ND ND ND NA NA NA ND ND 
    3 months     0.5 ND ND ND NA NA NA NA NA 
6 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND ND ND ND ND ND 
    4 weeks     ND ND ND ND ND ND ND ND ND 
    3 months     0.17 ND ND ND NA NA NA NA NA 
7 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND NA NA NA ND ND 
    4 weeks     ND ND ND ND NA NA NA ND ND 
    3 months     0.49 ND ND ND NA NA NA NA NA 
8 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND NA NA ND ND ND 
    4 weeks     0.16 ND ND ND NA NA 0.1 NA NA 
    3 months     ND ND ND ND NA NA ND ND ND 
9 
Healthy 
control 
pre-
vaccine No Yes ND ND ND ND 0.19 0.11 0.27 0.05 0.05 
    4 weeks     0.1 0.01 ND ND 0.38 0.17 0.32 ND ND 
    3 months     0.4 0.05 ND ND NA NA NA NA NA 
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IV-4  RESULTS: B CELL RESPONSES TO PPS VACCINE 
 
IV.4.1 CML patients on TKI have lower pneumococcal IgM titres after 
vaccination 
Forty five patients with CML on TKI and 12 healthy controls were vaccinated 
against the PPS vaccine (Pneumovax II) and all could be evaluated for response. 
Prior to vaccination, the median pneumococcal IgG levels were 123 U/ml in CML 
patients compared to 71.5 U/ml in controls (p=0.3); 16/45 patients and 3/12 
controls had a pre-vaccination pneumococcal IgG levels >200 U/ml (p=0.7). In 
contrast, the pre-vaccine pneumococcal IgM levels were significantly lower in CML 
patients on TKI (median 15, range 3 to 72 U/ml) compared to healthy controls 
(median 38, range 13 to 78 U/ml), p=0.002. 
 
We assessed the humoral response to PPS vaccine by measuring pneumococcal 
IgM levels 4 weeks following vaccination. Eleven of 12 (92%) of controls had a 
positive IgM humoral response (defined as a 4-fold rise in serum IgM titre or IgM > 
200 U/ml post-vaccination) compared to only 18 of 45 (40%) of CML patients on 
TKI (p=0.002). Moreover, pneumococcal IgM titres achieved at 4 weeks were 
significantly lower in patients with CML on TKI compared to healthy controls 
(median, 79 U/ml, range 5-200 vs. 200 U/ml, range 58-200, p=0.0006; Figures IV.4 
and IV.5), supporting the notion that CML patients on TKI have an impaired IgM 
response to vaccination. Of note we only found a weak correlation between the pre- 
and post-vaccination IgM levels in CML patients on TKI (R2=0.17). 
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Figure IV.4: Pneumococcal IgM response following vaccination: pneumococcal IgM titres are 
presented before and 4 weeks following vaccination in healthy controls and CML patients on TKI. A 
positive IgM pneumococcal response was defined as a 4-fold rise in serum IgM titres or an IgM titre 
> 200 U/ml 4 weeks post-immunization irrespective of the pre-immunization titre. 
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Figure IV-5: Pneumococcal IgM response following vaccination: The pneumococcal IgM 
response is presented before and 4 weeks after vaccination in responders (black lines) and non-
responders (dashed lines) for healthy controls and CML patients on TKI 
 
CML patientsHealthy controls
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We also assessed humoral responses to the vaccine in patients and controls 
without prior evidence of pneumococcal infection or immunization (defined as IgG 
<200 U/ml prior to vaccination). Of 24/45 evaluable patients, 6/24 (25%) failed to 
mount both an IgM and IgG response compared to 0/9 healthy controls (p=0.15), 
suggesting the presence of global B cell memory impairment in a proportion of CML 
patient on TKI. The characteristics of the 6 CML patients who failed to mount an 
IgM and IgG response to PPS vaccine is presented in Table IV.5. We found no 
significant differences in the underlying characteristics (including age, Sokal risk 
score and spleen size) between the 6/24 patients who failed to mount a humoral 
response compared to the 18/24 responders. 
Table IV.5: Patient characteristics: The characteristics of the 6 patients who failed to 
mount an appropriate IgM and IgG response to pneumococcal vaccination are 
presented. 
Patient Age/ 
gender 
TKI IgM titres 
U/ml 
IgG titres 
U/ml 
IgM memory B 
cell frequencies 
[%] 
Class switched 
memory B cell 
frequencies 
[%] 
  Pre Post Pre Post 
5 M/68 Imatinib 4 5 23 37 4.7 9.0 
7 F/38 Imatinib 23 72 198 270 8.1 3.2 
8 F/65 Imatinib 19 17 176 172 4.1 3.5 
24 F/42 Nilotinib 8 30 49 171 4.0 11.6 
28 F/60 Dasatinib 14 12 106 110 4.5 3.8 
29 F/43 Dasatinib 14 46 32 170 14.9 8.8 
 
 
Although this study was not specifically designed to look at differences in the 
vaccine response in patients treated with different TKIs, I did not find significant 
differences in the post-vaccine humoral response rates (7/19, 4/12 and 7/14, 
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p=0.87) or pneumococcal IgM serum titres (median, 75, 80 and 69 U/ml, p=0.7) in 
patients treated with imatinib, nilotinib or dasatinib, respectively (Figure IV.6). 
 
Figure IV.6: Pneumococcal IgM response following vaccination: the post-immunization 
pneumococcal IgM titres are presented for CML patients on imatinib, nilotinib and dasatinib. Bars 
represent medians with interquartile range. 
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IV.4.2 IgM memory B cell subsets are markedly reduced in CML patients 
who do not mount an anti-pneumococcal IgM response after vaccination 
 
To further elucidate the mechanisms underlying the impaired humoral immune 
response to Pneumovax II in patients with CML on TKI, I determined the 
159 
 
percentages of IgM memory B cells (CD19+ CD27+ IgMhigh IgD+/lo) and switched 
memory B cells (CD19+ CD27+ IgM- IgD-) before and 4 weeks following 
immunization and correlated these with pneumococcal IgM and IgG levels 
respectively. We had sufficient samples to perform this analysis in 39 patients and 
10 healthy controls. Of note the percentage of IgM memory and switched memory 
B cells did not differ significantly before and after immunization. 
 
CML patients were stratified based on their 4 week pneumococcal IgM response 
into 2 groups of ‘vaccine responders’ and ‘vaccine non-responders’ (Figure IV.5). A 
positive IgM Pneumovax II response was defined as a 4-fold rise in serum IgM 
titres or an IgM titre > 200 U/ml 4 weeks post-immunization irrespective of the pre-
immunization titre (Hart et al, 2007). CML patients who failed to mount a 
pneumococcal IgM response had significantly lower IgM memory B cell frequencies 
at vaccination compared to patients who mounted a positive pneumococcal IgM 
response (median, 6.5% vs 17.6%, p=0.005) and compared to healthy controls 
(median, 6.5% vs 12.8%, p=0.02) (Figure IV.7).  
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Figure IV.7: Relationship between memory B-cell subsets and pneumococcal humoral 
response. Patients who fail to mount a pneumococcal IgM response have significantly lower 
frequencies of IgM memory B cells compared to responders and healthy controls 
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Furthermore, in patients with CML, I found a significant correlation between IgM 
memory B cell frequencies at vaccination and the post-vaccine pneumococcal IgM 
titre (R2=0.36, p<0.0001), Figure IV.8. Interestingly, the IgM memory B cell 
frequency for the one healthy donor who failed to mount a positive IgM 
pneumococcal vaccine response was within the normal range (14.6%). 
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Figure IV.8: Relationship between memory B-cell subsets and pneumococcal humoral 
response. Scatter plot evaluating the association between pneumococcal IgM titres and IgM 
memory B cell frequencies in CML patients. 
 
 
 
Impaired IgM responses to vaccination with PPS vaccines have been reported in 
the elderly population (Shi et al, 2005).To exclude an impact of age on the 
pneumococcal humoral response in our slightly older CML patient population 
compared to controls, we performed univariate and multivariate analyses including 
age, Sokal score, spleen size and IgM memory B cell frequencies. On univariate 
and multivariate analyses the IgM memory B cell frequency at vaccination was the 
only independent predictor for a positive IgM humoral response (p=0.006). 
 
The gating strategy employed for the analysis of the B cell phenotype in vaccine 
responders and non-responders is shown in sectionII.6. Of note we found no 
significant difference in the CD19+ B frequencies between responders and non-
responders (p= 0.92). 
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In line with the normal pre-vaccine pneumococcal IgG titres in CML, I found no 
significant differences in the frequencies of switched memory B cells between CML 
patients on TKI and controls before vaccination (median, 13.2% vs 8.9%, p=0.30 
data not shown); however, the frequencies of switched memory B cells were 
significantly lower in the 6 patients who failed to mount an appropriate IgM and IgG 
response compared to the 33 patients who had an appropriate IgM or IgG response 
to the pneumococcal vaccine (median, 6.3% vs 13.7%, p=0.0031, Figure IV.9 and 
Table IV.5). 
 
Figure IV.9: Relationship between memory B-cell subsets and pneumococcal humoral 
response. Frequencies of class switched memory B-cells in the 33 patients who achieved a 
post-immunization IgG > 200 U/ml compared to the 6 patients who failed to mount a positive 
pneumococcal IgM and IgG response 
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IV.4.3 Treatment with imatinib is associated with a significant decrease in 
the frequencies of IgM memory and class switched memory B cells 
To investigate whether the loss of IgM memory B cell subset in CML patients is 
related to CML itself or to treatment with TKIs, I studied B cell subsets in paired 
samples collected from 15 CML-CP patients at diagnosis (i.e. prior to initiating 
imatinib therapy) and once CCyR was achieved on imatinib. The patient 
characteristics are summarized in Table IV.6. Only patients on imatinib were 
studied, as paired samples from diagnosis and following therapy were not available 
for patients on dasatinib and nilotinib. 
Table IV.6: Characteristics of the 15 CML-CP patients whose B cell subsets were 
analyzed at diagnosis (i.e. prior to initiating imatinib therapy) and once CCyR was 
achieved on imatinib are presented. *Duration of treatment with imatinib when 
remission sample was collected. 
 
Patient Age gender Duration of imatinib therapy* (months) BCR-ABL/ABL (%)* 
A 50.4 F 34 0.017 
B 54.8 F 42 0.014 
C 37.1 M 23 0.104 
D 53.6 M 32 0.338 
E 44.2 M 20 0.115 
F 38.0 F 18 0.619 
G 35.1 M 41 0.08 
H 41.5 F 54 0.003 
I 46.7 F 25 0.365 
J 55.9 M 21 0.003 
K 59.2 M 21 0.231 
L 58.1 F 30 0.017 
M 56.5 F 35 0.578 
N 49.6 F 33 0.005 
O 27.9 M 19 0.004 
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 No significant differences were found in the frequencies of IgM memory and 
switched memory B cells in CML patients at diagnosis (i.e. prior to initiation of 
imatinib) (n=15) compared to healthy controls (n=10) (median 12.6% vs 12.8%, 
p=0.85, and 14.1% vs 8.9%, p= 0.21 respectively). However, we found a significant 
reduction in the frequencies of IgM memory B cells in CML-CP patients following 
treatment with imatinib compared to diagnosis (median 6.5%, range 2.5-21.0% at 
CCyR, vs. 12.6%, range 3.9-33.5% at diagnosis, p=0.003), Figure IV.10. 
 
 
Figure IV.10: IgM memory B-cell frequencies at diagnosis and following CCyR 
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7.48%, range 2.3- 22.3% at CCyR, vs. 14.1% range 6.1-28.0% at diagnosis, p= 
0.001), Figure IV.11, indicating that TKI are responsible for the lower frequencies of 
memory B cells in CML. FACS plots from two representative patients are presented 
in Figure IV.12. 
Figure IV.11: Class-switched memory B-cell frequencies at diagnosis and following CCyR 
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Figure IV.12: B-cell phenotype of a CML patient who developed a positive pneumococcal IgM 
response (Patient A) compared to a non-responder (Patient B).
 
 
IV.4.4 Plasma from CML patients on TKI co-incubated with autologous B 
cells inhibits Btk phosphorylation 
To understand the molecular basis through which TKIs inhibit B cell activation, we 
co-incubated plasma from 3 vaccinated CML patients on imatinib (Patients 5, 8 and 
12), 4 on nilotinib (Patients 15, 17 and 20) and 3 on dasatinib (Patients 27, 28 and 
29) with autologous B cells overnight, and assessed their impact on Btk 
phosphorylation by phosphoflow analysis on gated CD19+ B cells. We noted 
significant inhibition in Btk phosphorylation in B cells of patients treated with 
imatinib (median inhibition 50%, range 35- 53%), nilotinib (median inhibition 65%, 
range 61-68%) and dasatinib (median inhibition 83%, range 81-86%), (Figure 
IV.13). 
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Figure IV.13: Inhibition of Btk phosphorylation in CD19+ B cells from CML patients on TKI co-
incubated with autologous plasma. PBMC from CML patients were co-incubated with autologous 
CML plasma and stimulated with 50mM of H2O2 for 15 minutes. Phosphorylation of Btk was 
assessed in gated CD19+B cells. Negative controls include PBMC from healthy donors and CML 
patients co-incubated overnight with RPMI/10% FCS. 
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IV.4.5 Imatinib, dasatinib and nilotinib inhibit Btk and PLC-γ2 
phosphorylation in a dose-dependent manner 
 
We also assessed the impact of increasing doses of imatinib, dasatinib and nilotinib 
on the phosphorylation of Btk, and its downstream signalling molecule PLC-γ2, in 
healthy donor B cells. Untreated normal B cells showed little evidence of 
phosphorylated PLC-γ2 (0.51%, range 0.01-2.07%) and phosphorylated Btk 
(0.33%, range 0.00-1.15%) (Figure IV.14, top panel). Upon stimulation with H2O2, 
CD19+ B cells responded by expressing increased levels of p-Btk (97.36%, range 
93.10-99.83%) and p-PLC-γ2 (96.73%, range 90.83-100.00%) (Figure IV.14, 
bottom panel). 
Figure IV.14: Btk and PLC-γ2 phosphorylation inhibition by imatinib, dasatinib and nilotinib: 
Cells were gated on lymphocytes: the panels on the top depict the unstimulated negative control 
and on the bottom H202-induced phosphorylation of Btk (left) and PLC-Y2 (right). 
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We then investigated the impact of imatinib on Btk and PLC-γ2 phosphorylation in 
gated CD19+ B cells derived from healthy donors. Imatinib inhibited 
phosphorylation of Btk (IC50 = 6.81µM) and PLC-γ2 (IC50 = 10.46 µM) in gated 
CD19+ B cells in a dose-dependent manner (Figure IV.15). We next determined 
the impact of nilotinib and dasatinib on the kinase activity of Btk and PLC-γ2. 
Similarly, we found that both nilotinib and dasatinib dose-dependently inhibit p-Btk 
(IC50 = 4.63 µM and IC50 = 27.25 nM respectively) and pPLC-γ2 (IC50 = 3.59 µM 
and IC50 = 25.95 nM respectively) (Figure IV.15). Each experiment was performed 
a minimum of 3 times. 
Collectively, our data provide clear evidence that all 3 TKIs can suppress B cell 
activation through their off-target kinase inhibition. 
 
Figure IV.15: Curve fit (nonlinear regression) of log transformed TKI doses plotted against 
the percentage of Btk phosphorylation inhibition induced by each of the three TKI; imatinib, 
nilotinib and dasatinib 
Each experiment was performed a minimum of 3 times; IC50 was calculated using nonlinear 
regression. The Y bar represents the percentage of gated population in which phosphorylated Btk or 
PLC-γ2 are detected. 
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Btk IC50 (CI 95%) Plc γ2 IC50 (CI 95%)
Imatinib (μM) 6.81 (5.5-8.4) 10.46 (8.04-13.62)
Nilotinib (μM) 4.63 (2.86-7.44) 3.59 (1.99-6.45)
Dasatinib (nM) 27.25 (12.8-58.03) 25.95 (6.7-99.33)
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IV.4.6 Imatinib, dasatinib and nilotinib inhibit Btk and PLC-γ2 within the 
memory B cell subset 
 
To assess if TKIs can inhibit B cell activation in memory B cell subsets, we 
examined the impact of these drugs on phosphorylation of Btk and PLC-γ2 by 
phosphoflow analysis on gated naïve B cells (CD19+CD27-), IgM memory B cells 
(CD19+ CD27+ IgMhigh IgD+/lo) and switched memory B cells (CD19+ CD27+ 
IgM- IgD-); (each experiment was performed a minimum of 3 times). With all 3 TKIs 
tested, inhibition of phosphorylation could be demonstrated in the memory B cell 
subsets as well as in naive and transitional B cells as shown in Figure IV.16. 
 
 
Figure IV.16: Btk and PLC-γ2 phosphorylation inhibition in B-cell subsets 
Btk phosphorylation in B cell subsets cultured in the presence or absence of Imatinib, Dasatinib or 
Nilotinib and stimulated with 50mM of H2O2 for 15 minutes. Effect of the TKI on pBtk inhibition is 
shown in gated IgM Memory B cell, Switched Memory B cell and Naive B cell subsets. 
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IV-5
  DISCUSSION 
 
A number of in vitro human as well as experimental models studies have 
investigated the potential immunomodulatory effects of TKIs on the phenotype and 
function of APCs and T cells. Whereas some in vitro data suggested a possible 
immunosuppressive effect of TKI on T cell responses (Cwynarski et al, 
2004;Mumprecht et al, 2006;Seggewiss et al, 2005), in vivo animal models suggest 
a positive immunomodulatory effect of imatinib on T and APC function 
(Balachandran et al, 2011;Larmonier et al, 2008;Wang et al, 2005). Furthermore 
little data are available on the impact of TKIs on B cell function (Paniagua et al, 
2006). In this study I show that CML-CP patients treated with imatinib, dasatinib or 
nilotinib have significant impairment in their B cell response to pneumococcal 
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polysaccharide vaccine. The impaired humoral response to the vaccine was 
associated with loss of memory B cell subsets following treatment with TKIs. 
Furthermore, imatinib, dasatinib and nilotinib are capable of dose-dependently 
suppressing one or more kinases important in BCR signalling, survival and memory 
formation, as demonstrated by reduced phosphorylation of Btk and indirectly its 
substrate PLC-γ2, providing a possible mechanism for TKI-induced B cell 
impairment. 
 
In contrast, I did not find a significant difference in the T cell response to influenza 
vaccine in patients with CML on TKI and healthy controls. Furthermore, vaccine-
induced T cells in patients with CML-CP on TKIs were functional and capable of 
producing effector cytokines as well as cytotoxicity, as assessed by CD107a 
degranulation when stimulated with the relevant antigen in vitro. Further evidence 
supporting the notion that prolonged TKI use may not interfere significantly with the 
successful induction of T cell responses in vivo has been provided by a number of 
clinical trials of tumor vaccination in CML patients on imatinib. Patients with CML on 
prolonged treatment with imatinib who were vaccinated with BCR-ABL peptides or 
engineered tumor cells could mount successful T cell responses against the 
vaccine, associated with improved cytogenetic and molecular responses (Bocchia 
et al, 2005;Cathcart et al, 2004;Pinilla-Ibarz et al, 2000;Rojas et al, 2007;Smith et 
al, 2010;Li et al, 2005). Our study is however limited by the small sample size and it 
is possible that with a larger cohort of patients and healthy controls, small 
differences in the T cell response to vaccination could be detected.  
 
I found a strong correlation between pneumococcal IgM vaccine response and IgM 
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memory B cell frequencies; 60% of patients with CML-CP on TKI (27 of 45) had 
significantly impaired pneumococcal IgM antibody responses to vaccination, 
associated in almost all cases with a significant loss of IgM memory B cells. In 
comparison effective pneumococcal IgM responses following vaccination were 
seen in nearly all healthy controls (11/12) and in 18 of 45 CML patients on TKI, 
associated with normal IgM memory B cell frequencies. Impaired IgM responses to 
vaccination in association with significant reduction in IgM memory B cells has 
been reported in a number of conditions including common variable 
immunodeficiency (CVID), HIV, congenital asplenia, as well as in the elderly and 
children under the age of 2 years. The importance of IgM memory B cell subset in 
host protection against pneumococcal infection has been studied most extensively 
in CVID patients; in these patients a strong correlation was shown between IgM 
memory B cell frequencies and the incidence of encapsulated bacterial infection 
(Carsetti et al, 2005;Kruetzmann et al, 2003). Similarly, a number of studies 
analyzed the peripheral blood B lymphocyte population in HIV-positive individuals; 
loss of memory B cells correlated with a decrease in the pneumococcal IgM 
response (Hart et al, 2007). It is however not clear whether CML patients on TKI 
have more pneumococcal infection compared to the normal population. Whereas 
earlier studies suggested an increased infection rate in dasatinib treated CML 
patients,(Garcia-Munoz et al, 2007;Sillaber et al, 2009) larger prospective studies 
have failed to confirm these results (Kantarjian et al, 2010). Patients with CML-CP 
with low IgM memory B cell frequencies may derive some protection against 
infections from prior immune memory or cross-protection from other immune 
subsets. It is possible that patients with CML-CP on TKI who do not mount 
adequate responses to polysaccharide pneumococcal vaccine may respond to 
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vaccination with the conjugated pneumococcal vaccine, which obviously would 
need testing in similar settings (French et al, 2010). In our study we also 
investigated the impact of other factors including age, gender, spleen size and 
Sokal score on the pneumococcal humoral response. On univariate and 
multivariate analyses, IgM memory B cell frequency remained the only significant 
predictive factor for a vaccine-induced pneumococcal IgM response. 
 
IgM memory B cells are believed to recognize T-independent (TI) antigens such as 
pneumococcal polysaccharide by virtue of a prediversified surface IgM and can 
respond immediately to antigen without T cell help. (Shi et al, 2003) These 
antibodies are of key importance in the initial phase of infection because they 
opsonize the pathogen and favor its phagocytosis by macrophages (Vos et al, 
2000). Although an IgM response is believed to be the hallmark for PPS vaccine, 
there is evidence that switched memory B lymphocytes are also involved in the 
anti-PPS Ab response. Recent studies performed in SCID mice transplanted with 
human B lymphocytes elegantly showed that both IgM memory and switched 
memory B lymphocytes are involved in the anti-polysaccharide immune response 
(Moens et al, 2008). In our study a small number of CML patients (6/24 evaluable, 
25%) failed to mount both an IgM and IgG response to the vaccine; the poor 
humoral response was associated with significantly lower switched and IgM 
memory B cell frequencies (Table IV.5) supporting a role for switched memory B 
cells in the anti-PPS humoral response. These data suggest that TKIs may affect 
both T-dependent and T-independent B cell activation signals in vivo, resulting in 
global B cell dysfunction in these patients.  
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The impaired humoral response and loss of B cell subsets seen in our study could 
be a consequence of CML itself or could be a direct effect of treatment with TKI. B 
cell progenitors are part of the leukaemic clone in a subset of CML patients 
(Takahashi et al, 1998) and it is therefore possible that TKIs may block BCR-ABL in 
Ph+ B cell lymphoid cells, thereby inducing B cell immune deficiency. Conversely, it 
is conceivable that Ph+ B cells may be hypo- or dysfunctional and as a result fail to 
mount an effective humoral response to a pathogenic antigen. However, our data 
do not support these scenarios as we observed a significant decrease in the 
frequencies of memory B cell subsets at CCyR, when a state of minimal residual 
disease was achieved, compared to diagnosis. Instead, our results favor a direct 
quantitative and qualitative effect of TKI on B cells. I found a significant reduction in 
IgM memory and switched memory B cell subsets following treatment with imatinib, 
suggesting that TKIs might interfere with the production and maintenance of B cell 
memory. These data may provide a possible explanation for recent reports of 
disease response to imatinib, despite a lack of correlation with PDGF receptor 
phosphorylation (Chen et al, 2011) and further support the use of TKI in B cell 
mediated immune disorders such as rheumatoid arthritis or chronic graft-versus-
host disease (Olivieri et al, 2009;Paniagua et al, 2006;Chen et al, 2011). 
 
Polysaccharides stimulate B cells via cross-linking of multiple antigen receptors, 
resulting in activation of Btk, a critical enzyme in the TI-2 signalling cascade (Vos et 
al, 2000). Btk and its downstream substrate PLC-γ2 are involved in B cell 
signalling, survival and memory formation and maintenance (Breitkopf et al, 
2010;Hantschel et al, 2007;Kurosaki & Hikida, 2009;Rix et al, 2007;Hikida et al, 
2009). I hypothesized that through their off-target kinase inhibition, TKIs may impair 
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the intracellular phosphorylation of Btk and indirectly inhibit its downstream 
substrate PLC-γ2, resulting in impaired IgM responses to vaccination and a 
decrease in the memory B cell compartment. We found that co-incubation of 
plasma from CML patients on TKI with autologous B cells resulted in significant 
inhibition of Btk phosphorylation. Plasma from CML patients on dasatinib induced 
more profound suppression of Btk kinase activity compared to plasma derived from 
patients on imatinib or nilotinib, suggesting that dasatinib may have more potent 
off-target Btk inhibitory activity compared to the more specific BCR-ABL inhibitors 
such as imatinib or nilotinib. These findings are further supported by previous work 
showing dasatinib to be a strong inhibitor of Btk phosphotylation (Hantschel et al, 
2007). Physiological concentrations of imatinib, dasatinib and nilotinib were also 
shown to inhibit Btk phosphorylation in activated B cells from healthy controls. 
Finally, we showed that all 3 TKI suppress Btk activity in memory B cell subsets, 
known to be critical to B cell memory development. Btk has also been shown to 
play an important role in class switching of B cells,(Halcomb et al, 2008) providing a 
possible explanation for our observation that a subset of CML patients on TKI fail to 
mount IgG responses to vaccination. These data are in keeping with a recent study 
in mice, reporting that imatinib impairs activation-induced class switching 
(Kawamata et al, 2012). Our study was not designed to address the underlying 
reasons for differential responses to pneumococcal vaccine in CML patients on 
TKI. A possible explanation could be variations in serum TKI levels due to inter-
individual differences in drug metabolism(Di et al, 2011) or variations in adherence 
rates that may in turn impact on the in vivo B cell response to the vaccine (Marin et 
al, 2010). 
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In conclusion, treatment with TKIs is associated with loss of memory B cell subsets 
and impaired humoral immune responses to pneumococcal polysaccharide 
vaccine, likely driven by the off-target kinase inhibitory activity of these drugs. Our 
results call for close monitoring of patients on TKI to assess the long-term impact of 
impaired B cell function on immune surveillance and susceptibility to infection and 
cancer. The inhibitory effect of imatinib, dasatinib and nilotinib on memory B-cell 
expansion and antibody production provides further rationale for studies of 
selective tyrosine kinase inhibitors in the treatment of autoimmune diseases and 
cGVHD. 
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CHAPTER 5 IMPACT OF PHILADELPHIA-POSITIVE LYMPHOPOIESIS ON 
RESPONSE TO IMATINIB AND OUTCOME 
 
V-1 INTRODUCTION 
I demonstrated in the study outlined in the previous chapter that treatment with 
TKIs is associated with loss of memory B cell subsets and impaired humoral 
immune responses to pneumococcal polysaccharide vaccine, likely mediated by 
the off-target kinase inhibitory activity of these drugs. I next investigated if TKI 
could also impact on the function of other B cell subsets such as transitional and 
naive B cells.  
 
To that end I performed a comprehensive analysis of B cell subsets in paired 
frozen samples obtained from CML-CP patients at diagnosis and after the 
achievement of a CCyR on imatinib, as well as in presentation samples from CML 
patients who did not respond to imatinib. The aim of this work was to further 
explore the effect of TKI on different B-cell subsets and to look for the presence of, 
and implications of Philadelphia positive lymphopoiesis on B cell function. 
 
It is also possible that the impaired humoral response and loss of B cell subsets 
seen in our study is a consequence of CML itself, through BCR-ABL involvement in 
the B cell lineage. Indeed it has been shown that B cell progenitors are part of the 
leukaemic clone in a subset of CML patients. In the pre-imatinib era, Takahashi 
and collaborators reported the presence of the Philadelphia chromosome in B cell 
progenitors from CML patients at diagnosis or while on INF-alpha or 
hydroxycarbamide therapy (Takahashi et al, 1998), as shown in Figure V.1. It is 
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therefore possible that Ph+ B cells may be hypo- or dysfunctional and as a result 
fail to mount an effective humoral response to a pathogenic antigen. To investigate 
this possibility, I looked for the presence of BCR-ABL fusion gene in flow sorted B 
cell subsets. 
 
 
Figure V.1: Cells with the BCR/ABL fusion signals inCD34+ subpopulations (Takahashi et al, 
1998) 
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V-2 AIMS 
The aims of this study were: 
- to study changes in the phenotype of B cells (transitional, naïve, IgM memory 
and switched memory) in CML patients at diagnosis and following achievement of 
CCyR on imatinib  
- to evaluate if the phenotype of B cells, and specifically involvement of B cell 
subsets by Ph+, predicts response to imatinib therapy 
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V-3 RESULTS 
Patient characteristics are shown in Table V.1. Among the 39 chronic phase CML 
patients included in this study, extended B cell phenotyping were available in 18/25 
in the responder group and in 12/14 in the non-responder group due to limitations 
in sample availability. Among the 14 non-responders, 9/14 transformed to blast 
crisis at a median time of 24 months (range, 5 to 57 months) following diagnosis. 
 
Table V.1: Patient characteristics. CCyR: complete cytogenetic response; NA: not 
applicable 
Patient’s group Responders (n=25) Non responders (n=14) 
Age (median, range) 46 (24 to 65) 40 (21 to 68) 
Sokal risk score at diagnosis 
-Low 
-Intermediate 
-High 
-unknown 
 
12 
9 
3 
1 
 
2 
6 
6 
0 
Time to CCyR, months (median, range) 7 (3 to 17) NA 
Interval diagnostic-remission samples, 
months (median, range) 
25 (15 to 56) NA 
Best CCyR response on imatinib 0.002% (0 to 
0.184%) 
NA 
Time to transformation into blast crisis, 
Months (median, range) 
NA 23 (5 to 57) 
Blastic transformation 
(Lymphoid/Myeloid/Unknown) 
NA 3/1/5 
Transcript type (e14a2/e13a2) 14/11 7/7 
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V.3.1 Transitional B cells are reduced at diagnosis both in responders 
and non-responders compared to healthy controls 
Among the 18/25 evaluable ‘responder’ group, the median percentage of 
transitional (T1 and T2) B cells at diagnosis (defined as CD24high CD38high) was 
significantly lower compared to healthy controls (0.39% vs 3.2% respectively, 
p<0.0001). Similarly the median percentage of transitional B cells at diagnosis was 
reduced among non-responders compared to the control group (0.28% vs. 3.2% 
respectively, p<0.0001) and was not different to the responder group (0.28% vs. 
0.38%, p=0.55), Figure V.3.  
 
Figure V.2: Transitional (T1 and T2) B cells in 18 CML responders and 12 non-responders at 
diagnosis compared to 8 healthy controls 
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I found no significant difference in the frequencies of naive B cells (defined as 
CD24int CD38int cells), when comparing CML responders, non responders and 
healthy controls (median, 57.7%, 67,8% and 63.1% respectively, means 60.5%, 
65.0% and 63.7% respectively), suggesting that this subset may not be directly 
affected in CML patients (Figure V.4). 
 
 
Figure V.3.: Naive B cells in 18 CML responders and 12 non responders at diagnosis 
compared to 8 healthy controls 
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V.3.2 Transitional B cell frequencies partially normalise in CML patients 
who achieve CCyR on imatinib 
 
In paired samples taken from CML patients at diagnosis and following CCyR on 
imatinib, the percentage of transitional (T1 and T2) B cells increased while on 
treatment, suggesting that imatinib may restore normal transitional B cell 
frequencies in CML patients who achieve CCyR. Figure V.5 shows FACS plot 
examples of 3 representative patients at diagnosis and at CCyR. 
 
Figure V.4: FACS plot examples of 3 representative patients at diagnosis and while in CCyR 
(paired samples) 
t: transitional B-cells; n: naive B-cells; m: memory B-cells; p: plasmablasts 
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Analysis of 18 paired samples from diagnosis and at CCyR demonstrated 
significant increases in the frequencies of transitional B cells (median, 0.38% vs 
1.62%, mean vs 0.54%, vs.1.91% p<0.001 paired t test) as shown in Figure V.6.  
 
Figure V.5: Transitional B cell frequencies in paired samples from CML responders at 
diagnosis and while in CCyR 
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When comparing the transitional B cells between the paired samples and samples 
taken from 8 healthy controls, we found a statistically significant difference between 
diagnostic CML samples and healthy controls (median 0.38% vs 3.18% 
respectively, mean 0.53% vs 3.06%, p<0.0001) as shown in figure V.4.5. When 
comparing the transitional B cell frequencies in CML patients in CCyR with 
controls, there was still a statistically significant difference, although less 
pronounced than at diagnosis (median 1.62% vs 3.18% respectively, mean 1.91% 
vs 3.06%, p=0.013), suggesting that, although treatment with imatinib restores 
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transitional B cell frequencies, the recovery of this subset might not be complete 
(Figure V.7). 
 
Figure V.6: Transitional B cells in paired samples from CML patients at diagnosis, following 
CCyR and compared to controls 
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We next investigated if this difference could be attributed to the effect of G-CSF 
since the leukapheresis products from patients at CCyR were collected following 
G-CSF mobilisation. We compared the frequencies of B cell subsets in G-CSF 
mobilised leukapheresis products from 2 patients at CCyR and paired peripheral 
blood samples collected from the same patients a minimum of 12 months (12-36 
months) following G-CSF therapy.  
We found no significant impact of GCSF on the frequencies of transitional, 
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suggesting that the G-CSF may not be the underlying reason for the higher 
frequencies of transitional B cells observed at CCyR. Examples of FACS plots from 
two patients whose B cells were collected in the absence or presence of G-CSF 
are shown in Figure V.8. 
 
Figure V.7: B cell subsets with or without G-CSF mobilisation in two patients in CCyR 
(PBMCs) 
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We next compared the frequencies of naive B cells in paired samples collected 
from CML patients at diagnosis and following achievement of CCyR. Interestingly, 
we observed a small but significant increase in the percentage of naive B cells 
before and after imatinib (median 57.7% vs 69.7%, p=0.007 paired t test), Figure 
V.9. Of note there was a trend towards higher percentage of naive B cells in 
remission samples from CML patients compared to healthy controls (median 69.7% 
vs 63.1% respectively, mean 70.1% vs 63.7%, p=0.067), as shown on Figure V.9. 
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Figure V.8: Naive B cell subsets in paired samples from responders at diagnosis and in 
CCyR 
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V.3.3 Purity of B cell subsets after FACS sorting 
 
I next evaluated the purity of the B cell subsets after cell sorting on the FACS ARIA 
and before performing FISH analysis to look for the presence of BCR-ABL1 fusion 
gene. The median purity for CD19+ total B cells (out of live cells) was 99.4% (range 
97% to 100%), while the median purity for IgM memory B cells, switched memory B 
cells, naive B cells and transitional B cells were 97.7% (range 86%-100%), 96.8% 
(range 96.6%-100%), 93.9% (range, 92.8%-96.8%) and 94.1% (range, 84.2%-
100%) respectively. Examples of representative purity checks in 3 samples are 
shown in Figure V.10. 
  
Figure V.9: Examples of representative purity checks in 3 samples 
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V.3.4 The presence of BCR-ABL positive B cells at diagnosis predicts for 
poor response to imatinib 
Among the 39 chronic phase CML patients, FISH for BCR-ABL was performed in 
26/39 patients, including paired samples from 12/25 patients in the responder 
group and in 14/14 samples in the non responder group. 
 
The presence of BCR-ABL fusion gene was found in B cell subsets from 13/26 
(50%) diagnostic samples. Approximately 5.5% (range, 1% to 27%) of B cells had 
evidence of BCR-ABL fusion gene by FISH, Table V.2. Among these13 cases, 
transitional B cells were involved in all (10/10) evaluable samples (median 53.5% 
of BCR-ABL+/ total transitional B cells, range 21% to 89%), Naive B cells in 9/12 
(75%) evaluable samples (median 11%, range 4% to 29%), IgM memory B cells in 
4/12 (33%) evaluable samples (median 11.5%, range 7% to 23%) and switched 
memory B cells in 5/13 (38%) evaluable patients (median 14%, range 4% to 25%), 
as shown in table V.2.  
I then investigated if there was a correlation between BCR-ABL involvement of B 
cell subset and the B cell subsets frequencies. I found no significant difference in 
the frequencies of transitional B cells at diagnosis between patients with or without 
evidence of Ph+ lymphopoiesis (median 0.34% vs 0.34% respectively, mean 
0.69% vs 0.50%, p=0.49, unpaired t test). Similarly there was no significant 
difference in the frequencies of naive B cells in the two groups (median 72% vs 
60% respectively, mean 65% vs 60%, p=0.37, unpaired t test) 
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Table V.2: Percentage of BCR-ABL positivity in sorted B cell subsets from 
diagnostic samples collected from 13 CML patients with BCR-ABL positive B 
lymphopoiesis (3 responders and 10 non responders) 
NA: not available 
Patients Total 
B cells 
Transitional 
B cells 
Switched 
memory B 
cells 
Naive 
B cells 
IgM 
memory B 
cells 
Blastic 
transformation 
from diagnosis, 
Months, type 
Responder, 
Sample 5450 
6% 39% 20% 0% 0% No 
Responder, 
Sample 5086 
NA 21% 25% 5% 23% No 
Responder 
Sample 4997 
2% 42% 0% 0% 
 
0% No 
Non responder 
Sample 6021 
20% NA 0% 29% 7% No 
Non responder 
Sample 4902 
5% 69% 0% 11% 0% 24 
Myeloid 
Non responder 
Sample 6950 
3% NA 4% 7% NA No 
Non responder 
Sample 5887 
2% 80% 0% 4% 0% 8 
Unknown 
Non responder 
Sample 6144 
6% 77% 0% 8% 0% No 
Non responder 
Sample 5337 
13% NA 
 
14% 12% 13% No 
Non responder 
Sample 5394 
27% 50% 0% 13% 0% 5 
Lymphoid 
Non responder 
Sample 3958 
1% 57% 0% NA 0% 35 
Lymphoid 
Non responder 
Sample 3298 
1% 36% 0% 0% 0% 57 
Unknown 
Non responder 
Sample 4980 
14% 89% 9% 16% 10% 22 
Unknown 
 
I next investigated the impact of BCR-ABL positive B cells at diagnosis on 
response to imatinib. Significantly higher proportion of non-responders had 
evidence of BCR-ABL positive B lymphopoiesis compared to responders (10/14 vs 
3/12 respectively, p= 0.047, Fisher exact test), suggesting that the presence of 
BCR-ABL positive B cells at diagnosis may be a maker of poor response to 
imatinib. Among the 14 non-responders, 9/14 had secondary transformation to 
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blast crisis and 5/14 had primary resistance to imatinib but did not transform to 
accelerated phase. Of note 6/9 patients with secondary blast crisis and 2/5 patients 
with primary resistance had evidence of BCR-ABL positive B lymphopoiesis at 
diagnosis. 
 
V.3.5 Imatinib eradicates BCR-ABL positive B cell clones in CML patients 
who achieve CCyR 
Among the 3 patients who had BCR-ABL positive B cells at diagnosis and who 
subsequently achieved CCyR (samples 5450, 5086 and 4997, Table V.4.4), FISH 
for BCR-ABL at remission (CCyR) was available in 2/3 (paired samples from 
samples 5450 and 4997). There was no detectable BCR-ABL fusion gene in the B 
cells in the remission samples, suggesting that imatinib is capable of eradicating 
the BCR-ABL positive B cell clone. 
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V.3.6 BCR-ABL positive CD34+CD38+CD19+ and CD34+CD38+CD19- 
cells are detected in a patient with BCR-ABL positive B cells subsets 
An additional panel was performed in one of the patients with BCR-ABL positive B 
cells (sample 5394, see Table V.3). This panel was designed to sort CD34+CD38-
leukaemia stem cell and multipotent progenitor (MPP), CD34+CD38+CD19- 
common myeloid progenitor (CMP) and granulocyte-macrophage progenitor 
(GMP), and CD34+CD38+CD19+ common lymphoid progenitors (CLP), Figure 
V.11. The gating strategy is shown in Figure V.4.7. CD34+CD38- represented 
1.7% of the MNCs while the CD34+CD38+CD19- and CD34+CD38+CD19+ 
subsets were 4.6% and 4% respectively. 
Figure V.10: hierarchy of haematopoiesis 
 
BCR-ABL by FISH was present in 100% of the CD34+CD38+CD19+ (CLP) and 
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CD34+CD38+CD19- (CMP and GMP) subsets, as shown in table V.12. 
Unfortunately the number of CD34+CD38- sorted cells was not sufficient to perform 
FISH analysis. 
 
Figure V.11: Gating strategy for myeloid and lymphoid progenitors 
 
 
Table V.3: Frequencies of BCR-ABL positive cells (by FISH analysis) in B cell 
subsets in the diagnostic sample 5394 
 
Total  
B cells 
CD34+CD38+CD19- CD34+CD38+CD19+ Transitional 
B cells 
Switched 
memory B 
cells 
Naive 
B 
cells 
IgM memory B 
cells 
27% 100% 100% 50% 0% 13% 0% 
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V-4 DISCUSSION 
The first aim of this study was to perform a comprehensive analysis of B cell 
subsets in CML patients at presentation and, where possible, following 
achievement of CCyR on imatinib treatment. I found that transitional B cells are 
significantly lower in CML patients at diagnosis compared to healthy donors. There 
was no significant difference in the frequencies of transitional B cells in patients 
who failed to subsequently respond to imatinib (non-responders) compared to 
those who achieved CCyR (responders). Interestingly, I observed a partial 
normalisation of transitional B cell frequencies in patients who had a complete 
cytogenetic response to imatinib (median, 1.62% vs 0.38% at diagnosis, p<0.001). 
 
In the setting of allogeneic haematopoietic stem cell transplantation (allo-SCT), 
transitional B cells have been shown to be a necessary developmental 
intermediate for mature B cell generation in humans. Indeed, after allo-SCT 
transitional B cells are the first B cell subset to reconstitute (Marie-Cardine et al, 
2008). Similarly, it is possible that B cell lymphopoiesis is suppressed or restrained 
by the expansion of the myeloid CML clone and that eradication of the CML clone 
by TKI therapy may facilitate B cell reconstitution, including transitional B cell 
recovery. It is also possible that the increase in the transitional B cell frequencies at 
CCyR could be attributed to a direct effect of imatinib, although my previous study 
does not support this hypothesis, since I showed that TKIs, through their off target 
kinase inhibition, impair Btk activity and memory B cell response. Analysis of B cell 
subsets in paired samples from non responders (i.e. CML patients with significant 
residual disease after treatment with imatinib) might have provided further insights 
into the possible role of the CML clone in suppressing B lymphopoiesis; 
206 
 
unfortunately this study was not possible as paired samples from non-responders 
were not available. 
 
Transitional B cell frequencies restored only partially following therapy and 
continued to remain significantly lower than normal levels, even in patients who 
achieved CCyR (median 1.62% vs 3.18% in healthy controls respectively, 
p=0.013). The failure of transitional B cell normalisation may at least be partly 
related to the off target inhibition of Btk in this subset. This supposition is further 
supported by my observation, summarised in Chapter 4, that imatinib inhibits Btk 
phosphorylation not only in IgM and switched memory B cells but also in 
CD27+IgM+ B cells (naive and transitional B cells), as shown in Figure IV.16 
(Chapter IV), although I did not specifically investigate the effect of imatinib on Btk 
in transitional (CD10+CD27+IgM+) compared to naïve B cells (CD10-CD27+IgM+). 
Finally I also found a small but significant increase in the percentage of naive B 
cells after imatinib therapy (median 69.7%, vs. 57.7% prior to therapy p=0.007 
paired t test). One possible explanation could be that B cell reconstitution in CML 
patients on TKI therapy mirrors B cell recovery after allo-SCT, where transitional B 
cell frequencies decrease secondarily, while the mature naive B cell compartment 
expands at around 9 months post allo-SCT (Marie-Cardine et al, 2008). In our 
study the median interval between collection of the diagnostic samples and the 
remission samples was 25 months (range, 15 to 56 months). It is therefore possible 
that by 25 months post TKI therapy, transitional B cells have already started 
declining in numbers while the naive B cell compartment is recovering. It is 
however also possible that imatinib may exert differential effect on transitional and 
naive B cell recovery. 
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I next looked for the presence of Philadelphia positive B lymphopoiesis at diagnosis 
and its implications on disease response. Although in all patients with Ph+ B cells, 
transitional B cells were involved, I found no difference in the frequencies of 
transitional B cells in patients with or without Ph+ B lymphopoiesis. Interestingly in 
patients with Ph+ B lymphopoiesis, transitional and naive B cell were BCR-ABL+ 
cells by FISH in 10/10 and 9/12 evaluable samples respectively compared to only 
4/12 and 5/13 evaluable samples for IgM memory and switched memory B cell 
subsets. This indicates that BCR-ABL is present in the most immature B cell 
subsets, with possibly a maturation arrest. Although other groups have looked into 
the presence of a Philadelphia chromosome in B cell progenitors (Takahashi et al, 
1998) or total B cells (Primo et al, 2006), my study is the first to selectively look at 
the presence of the Philadelphia chromosome in the different B cell subsets. Primo 
reported the presence of BCR-ABL positive B cells in 43% of CML patients, which 
is comparable to the 50% I found in my study (Table V.4.shows the clinical 
characteristics of patients reported in the study by Primo and colleagues). 
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Table V.4: patients characteristics of the study reported by Primo and colleagues 
(Primo et al, 2006) 
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Notably, the presence of Ph+ B lymphopoiesis was a poor prognostic marker. A 
significantly higher proportion of patients who failed to respond to imatinib (non-
responders) had Ph+ B cell involvement compared to the responder group (10/14 
vs 3/12 respectively, p= 0.047, Fisher exact test). To my knowledge, this is the first 
study demonstrating that the presence of BCR-ABL positive B lymphopoiesis at 
diagnosis predicts for poor response to imatinib. Although this study was not 
originally designed to look at the B cell progenitors, BCR-ABL was found by FISH 
in 100% of the CD34+CD38+CD19+ common lymphoid progenitors (CLP) and 
CD34+CD38+CD19- (common myeloid progenitor, CMP and granulocyte-
macrophage progenitor, GMP) subsets in one evaluable patient. One possible 
explanation for the observation that patients with Ph+ B lymphopoiesis have a 
worse prognosis may be related to a relative insensitivity of the BCR-ABL positive 
B cell clone to imatinib. However, my data do not support this hypothesis as in the 
two patients with Ph+ B cells who subsequently responded to imatinib, BCR-ABL 
positive B cell subsets were no longer detectable at CCyR. However it is still 
possible that B cell subsets may have different levels of sensitivity to imatinib 
depending on the disease biology. 
  
Another possible explanation may be that the presence of BCR-ABL positive B-
cells could be a marker of a downstream progenitor with self-renewal capacity. 
Although haematopoietic stem cells (HSC) are the only normal progenitors that 
renew themselves and are therefore considered to be the only cells in the marrow 
in which preleukaemic changes can accumulate, it is also possible that a 
downstream progenitor can acquire self-renewal capacity. There is growing 
evidence that whereas leukaemic progression could occur in self-renewing clones 
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in the HSC compartment, frank AML and blast crisis CML occur also in their clonal 
progeny at a non-HSC stage. Indeed it has been shown that the leukaemic stem 
cells (LSCs) giving rise to blast crisis CML are granulocyte-macrophage progenitor 
(GMP)-like (Jamieson et al, 2004), challenging the notion that LSCs reside solely in 
the CD34+CD38- compartment. More recently Goardon and colleagues have 
added another candidate LSC, a lymphoid-primed multipotential progenitor 
(LMPP)-like LSC coexisting with a GMP-like LSC (Goardon et al, 2011). Building 
on previous models of normal HSC development, they found that the LMPP-like 
and GMP-like LSCs were hierarchically organised, whereby the LMPP-like cells 
gave rise to the GMP-like cells. Alternative models for normal HSC are shown in 
Figure V.13. 
Figure V.12: current and alternative models for HSC commitment (Adolfsson et al, 2005) 
LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; MPP, 
multipotent progenitor; LMPP, lymphoid-primed multipotent progenitor; CLP, common lymphoid 
progenitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage pronenitor; MkEP, 
megakaryocyte-erythroid progenitor; B, B cell; T, T cell. 
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The authors, through the investigation of a large number of AML patient samples 
found two predominant populations within CD34+ cells, a Lin-CD34+CD38-CD90-
CD45RA+ LMPP-like population (CD38-CD45RA+) and a Lin-
CD34+CD38+CD123+CD110-CD45RA+ GMP-like population. Both of these 
populations possessed LSC activity (Figure V.14). This previously uncharacterised 
LMPP-like population was shown to be able to produce in vitro granulocytes, 
monocytes/macrophages and lymphocytes, but not erythroid cells or 
megakaryocytes. LMPP-like cells gave rise to GMP-like cells but not vice versa. 
Figure V.15 shows the phenotype of the different populations and their ontogeny 
based on Goardon’s findings. These results implicate normal hematopoietic 
progenitors, LMPP, and/or GMP as the cell of origin for AML LSC in the majority of 
cases. Our data would be consistent with a similar hypothesis in CML whereby a 
LMPP-like LSC would be the candidate LSC giving rise to both a GMP-like LSC (as 
reported by Jamiesson and colleagues (Jamieson et al, 2004)) and B cell subsets 
(through a common lymphoid progenitor). Our data suggest that the presence of 
BCR-ABL positive B cells may be a marker for the presence of an LMPP-like LSC 
in CML, from which a GMP-like and blast crisis CML could derive. 
 
In keeping with this hypothesis, work on acute lymphoblastic leukaemia (ALL) 
using NOD/SCID mice have demonstrated that the CD34+/CD38-/CD19+ as well 
as CD34+/CD38+/CD19+ cells are leukaemia-initiating cells in human B-precursor 
ALL (Kong et al, 2008). Moreover le Viseur and colleagues described that the 
leukaemia-initiating ability of standard-risk ALL was found in both the 
CD34+CD19+ and CD34-CD19+ populations, and that the CD34-CD19+ 
population was able to serially transplant leukaemia in high-risk ALL (le et al, 
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2008). These data raise the intriguing possibility that a more lineage-committed B 
cell subset could give rise to a LSC in CML, as also suggested in a recent study in 
philadelphia positive ALL or blast crisis CML (Tanizaki et al, 2010). 
 
Figure V.13: Coexistence of LMPP-like and GMP-like Leukaemia Stem Cells in Acute Myeloid 
Leukaemia (Goardon et al, 2011) 
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Figure V.14: Model for LSC commitment in AML and CML 
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CHAPTER 6 CONCLUSIONS AND FUTURE WORK 
 
VI.1 CONCLUSIONS 
Because of their lower toxicity and impressive efficacy, tyrosine kinase inhibitors 
(TKIs), notably imatinib, have replaced allo-SCT as first-line therapy for CML. 
Although over 85% of imatinib-treated patients with chronic phase CML (CML-CP) 
achieve a complete cytogenetic response (CCyR), the majority of patients have 
persisting molecular disease as assessed by q-PCR for BCR-ABL transcripts. 
Functional leukaemic CD34+ progenitor cells have been identified in such patients 
in CCyR, suggesting the presence of a reservoir of leukaemic cells resistant to 
TKIs. Therefore future developments in CML therapy seem likely to combine 
different approaches to integrate and reinforce the patient’s immune response 
against residual leukaemic stem cells. The immunological GVL effect seen after 
allo-SCT suggests that an approach based on the amplification of the patient’s own 
immune response to the disease might increase the depth of the responses seen 
after treatment with TKIs. One such approach would be to vaccinate the patient 
with leukaemia derived antigens. I hypothesised that vaccination against leukaemia 
antigens will be most effective once a state of minimal disease is achieved on 
imatinib. 
Because previous studies have documented conflicting effects of TKIs on the 
immune response, ranging from impaired antigen-specific T-cell responses to 
enhanced stimulation of tolerant T cells, I aimed to determine the in vivo 
immunomodulatory effects of TKIs on T and B cell immune responses to antigens. 
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The specific aims of this thesis were: 
1. To determine the in vivo effect of TKI on T and B cell responses in patients 
with CML on TKI. To address this question, I assessed the cellular and humoral 
immune response to a novel pandemic 2009 H1N1 vaccine in CML-CP patients on 
TKI, compared to patients with other haematological malignancies and healthy 
controls 
2. To determine if TKI have a differential effect on IgM and IgG humoral 
responses to antigen. This goal was achieved by assessing T-cell and B-cell 
responses to vaccination against seasonal influenza virus and a polysaccharide 
pneumococcal vaccine in CML patients treated with tyrosine kinase inhibitors 
compared to healthy controls 
3. To understand the potential mechanisms responsible for the 
immunomodulatory effect of TKIs on B cells by examining their impact on B cell 
receptor downstream pathway 
4. To investigate any possible impact of Ph+ B lymphopoiesis on normal B cell 
function by comparing B cell responses to vaccination in CML patients with or 
without leukaemic B cell clones and to determine the effect of TKI on different B cell 
subsets 
 
The achievements of this thesis can be summarised as follows. The purpose of 
chapter 3 was to determine the in vivo cellular and humoral immune responses to 
H1N1 influenza vaccination in CML-CP patients on TKI, compared to patients with 
other haematological malignancies and healthy controls. I found that the B cell 
responses to H1N1 vaccine was significantly better in patients with CML compared 
to patients with other haematological malignancies and was not significantly 
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different from healthy controls. We did not find a significant difference in the 
proportion of individuals with H1N1 specific T-cell response in CML patients and 
healthy controls. However this study did not address differences in the quality of the 
T cell response between CML patients and healthy controls and the differential 
impact of TKI on IgM and IgG humoral responses. 
 
In chapter 4 I performed a more comprehensive analysis of T and B cell responses 
to vaccination with influenza and Pneumococcus in 51 CML-CP on imatinib, 
dasatinib or nilotinib compared to 24 healthy controls. The T cell response to 
influenza was defined both quantitatively and qualitatively, including analysis of the 
cytokine profile and effector function of vaccine-induced T cells responses. I did not 
find a significant difference in the T cell response to influenza vaccine in patients 
with CML on TKI and healthy controls. Furthermore, vaccine-induced T cells in 
patients with CML-CP on TKIs were functional and capable of producing effector 
cytokines as well as cytotoxicity, as assessed by CD107a degranulation when 
stimulated with the relevant antigen in vitro. 
I also studied the B cell response to vaccination with Pneumococcus in more 
details, including titres of pneumococcal IgM and IgG antibodies and frequencies of 
IgM memory and switched memory B cells. I found that following vaccination, CML 
patients on TKI had significant impairment in their IgM humoral response to 
pneumococcus compared to controls. The impairment in IgM humoral response 
was associated with significantly lower frequencies of peripheral blood IgM memory 
B cells. To elucidate whether CML itself or treatment with TKI was responsible for 
the impaired humoral response, I assessed memory B-cell subsets in paired 
samples collected before and after imatinib therapy. Treatment with imatinib was 
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associated with significant reductions in IgM memory B-cells. To further elucidate 
the underlying mechanism for this observation, I studied the off target effect of TKI 
on kinases important in B cell activation and survival. In vitro co-incubation of B-
cells with plasma from CML patients on TKI or with imatinib, dasatinib or nilotinib 
induced significant and dose-dependent inhibition of Bruton's tyrosine kinase and 
indirectly its downstream substrate, phospholipase-C-γ2, both important in B cell 
signalling and survival. I concluded that treatment with TKIs is associated with loss 
of memory B cell subsets and impaired humoral immune responses to 
pneumococcal polysaccharide vaccine, likely driven by the off-target kinase 
inhibitory activity of these drugs. 
 
The impaired humoral response to vaccination and loss of memory B cell subsets 
observed in patients on TKI may also be a consequence of CML itself, through 
BCR-ABL involvement in the B cell lineage. In chapter 5, I further explored the 
effect of TKI on different B-cell subsets and the implications of Philadelphia positive 
lymphopoiesis on B cell function. I performed a comprehensive analysis of B cell 
subsets in paired frozen samples obtained from CML-CP patients at diagnosis and 
after the achievement of a CCyR on imatinib, as well as in samples collected from 
CML patients at diagnosis who subsequently failed to respond to imatinib. I found 
that CML patients at diagnosis have significantly lower frequencies of transitional B 
cells compared to healthy donors, and that following achievement of CCyR, there is 
a partial normalisation of transitional B cell frequencies. These data suggest that B 
cell lymphopoiesis may be suppressed or restrained by the expansion of the 
myeloid CML clone and that eradication of the CML clone by TKI therapy may 
facilitate B cell reconstitution, including transitional B cell recovery. The failure of 
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complete normalisation of transitional B cells at CCyR may be partly related to the 
off target inhibition of Btk in transitional B cells, as shown in chapter 4. Next, I 
looked for the presence of Philadelphia positive B lymphopoiesis in samples from 
CML patients at diagnosis. I found evidence of Ph+ B lymphopoiesis in 43% of 
CML patients at diagnosis. I then sort purified different B cell subsets and evaluated 
for evidence of BCR-ABL involvement by FISH analysis. I observed that nearly all 
patients with Ph+ B lymphopoiesis had BCR-ABL+ transitional and naive B cells. In 
contrast, only a minority of patients exhibited BCR-ABL+ IgM memory and switched 
memory B cells. These results suggest that Ph+ involvement of the B lymphoid 
lineage may result in maturation arrest. I found no difference in the frequencies of 
transitional B cells in patients with or without Ph+ B lymphopoiesis.  
Overall BCR-ABL positive B cells were present in 43% of CML patients at 
diagnosis. Notably, the presence of Ph+ B lymphopoiesis was a poor prognostic 
marker as a significantly higher proportion of patients who failed to respond to 
imatinib (non-responders) had Ph+ B cell involvement compared to the responder 
group. In the two patients with Ph+ B cells who subsequently responded to 
imatinib, BCR-ABL positive B cell subsets were no longer detectable at CCyR, 
suggesting that the BCR-ABL positive B cell clone is sensitive to imatinib. The 
observation that patients with Ph+ B lymphopoiesis appear to have a worse 
prognosis is intriguing. BCR-ABL positive B cell involvement may indicate the 
presence of a downstream progenitor with self-renewal capacity, such as a 
lymphoid-primed multipotential progenitor (LMPP)-like subset that was recently 
described in acute myeloid leukaemia (Goardon et al, 2011). Our data support a 
similar hypothesis in CML, whereby a LMPP-like BCR-ABL+ LSC may give rise to 
both a GMP-like LSC (as reported by Jamiesson and colleagues (Jamieson et al, 
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2004)) and a common lymphoid progenitor resulting in Ph+ B lymphopoiesis. These 
data suggest that BCR-ABL positive B cells may be a surrogate for the presence of 
an LMPP-like LSC, which could potentially result in a GMP-like driven disease 
progression and blast crisis CML (Jamieson et al, 2004). 
 
In summary these results indicate that CML patients in CCyR on TKIs can mount a 
normal T-cell response to vaccination, suggesting that in these patients, 
concomitant treatment with TKI may not hamper a T-cell response to LAA 
vaccination. Therefore the combined application of vaccination with LAA with TKI in 
chronic myeloid leukaemia may be a successful immunotherapeutic approach to 
improve the rate of CCyR. However TKIs induce significant functional alterations in 
B cell subsets in a subset of CML patients on TKI, likely related to their off-target 
tyrosine kinase inhibition. While the presence of Ph+ B cells at diagnosis predicts 
for worse prognosis, Ph+ B lymphopoiesis does not appear to correlate with 
impaired humoral immunity. Our finding that BCR-ABL positive B cell involvement 
is predictive for poor response to imatinib may indicate the presence of an LMPP-
like LSC in these patients and warrants further studies. 
 
 
VI.2 FUTURE WORK 
 
To further confirm my hypothesis that BCR-ABL+ B cells may indicate the presence 
of a LMPP-like LSC, I propose to perform a comprehensive analysis of myeloid and 
lymphoid B cell progenitors and stem cells in samples from patients with and 
without Ph+ B cell involvement. 
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To that end, I will sort purify the following progenitors, based on the surface 
markers outlined below, for BCR-ABL FISH, DNA and RNA analysis: 
- LSC: Lin-CD34+CD38-CD90+CD45RA- 
- MPP: Lin-CD34+CD38-CD90-CD45RA- 
- LMPP: Lin-CD34+CD38-CD90-CD45RA+ 
- CMP: Lin-CD34+CD38+CD123+CD110-CD45RA- 
- GMP: Lin-CD34+CD38+CD123+CD110-CD45RA+ 
- CLP: CD34+CD38+CD19+ 
 
The hierarchy of LSC and progenitors are shown in Figure V.15 ‘Model for LSC 
commitment in AML and CML. 
I will first enrich for CD34+ progenitors using CD34 Microbead kit and MACS 
separation columns (Miltenyi Biotec, Bisley UK), followed by cell sorting on a FACS 
ARIA cell sorter using a panel of surface antibodies consisting of CD38, CD45RA, 
CD90, CD110 and CD19. Cells will be gated on CD38, and the following subsets 
will be sort purified: 
- LSC: CD38neg, CD45RAneg, CD90 pos 
- MPP: CD38neg, CD45RAneg, CD90 neg 
- LMPP: CD38neg, CD45RApos 
- CMP: CD38pos CD45RAneg, CD110 neg 
- GMP: CD38pos CD45RApos 
- CLP: CD38pos, CD19pos 
 
An example of cell sorting strategy employed by Goardon and colleagues to study 
LSCs and progeny cells is shown in Figure VI.1. 
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Figure VI.1: example of cell sorting of LSC, MPP, LMPP, CMP and GMP is AML patients 
(Goardon et al, 2011) 
 
 
Finally, I will perform gene expression profiling and/or whole exome sequencing on 
the sort purified LSC and progenitors cells and B cell subsets collected from 
patients both with or without BCR-ABL positive B cells as outlined in Chapter V. 
Cryopreserved mononuclear cells, as well as DNA and RNA from sort purified B 
cells subsets are stored and available for these analyses. 
Candidate genes such as deletion of IKZF1 (encoding the transcription factor 
Ikaros) will be of particular interest, since Ikaros was recently shown to be deleted 
in 83% of patients with Ph+ ALL but not in chronic phase CML (Mullighan et al, 
2008). Expression of the B cell mutator AID, reported to be overexpressed in CML 
lymphoid blast crisis, will also be investigated (Klemm et al, 2009). 
  
LSC
MPP LMPP LMPP MPP
GMP
CMP
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